Growth hormone-releasing hormone analog linked to extended length polypeptides and methods of using same

Conjugating GHRH analogs with ELNN polypeptides addresses the short half-life issue and improves weight gain and reduces IUGR and mortality in offspring by enhancing serum IGF-1 levels.

WO2026236649A1PCT designated stage Publication Date: 2026-11-12ELANCO US INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027340
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing growth hormone-releasing hormone (GHRH) analogs have a short half-life, limiting their effectiveness in promoting growth and weight gain in animals, and there is a need to address intra-uterine growth restriction (IUGR) and pre-weaning mortality in offspring.

Method used

Conjugation of GHRH analogs with extended length polypeptides (ELNN) via linkers, such as maleimido-methylcyclohexane carboxylate activation, to create conjugated proteins that enhance serum IGF-1 levels and improve weight gain and reduce IUGR and mortality in offspring.

Benefits of technology

The conjugated proteins increase serum IGF-1 concentration, enhance weight gain, and reduce pre-weaning mortality and IUGR in offspring by providing sustained GHRH activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000017_0001_TABLE
    Figure IMGF000017_0001_TABLE
  • Figure IMGF000034_0001_TABLE
    Figure IMGF000034_0001_TABLE
  • Figure IMGF000036_0001_TABLE
    Figure IMGF000036_0001_TABLE
Patent Text Reader

Abstract

A conjugated protein comprising growth hormone-releasing hormone or hormone analog linked to a pharmacokinetic extender molecule, optionally extended length polypeptides (ELNN) and methods of decreasing pre-weaning mortality and / or incidence of intrauterine growth restriction (IUGR) in an offspring from a mammal comprising administering to the female animal an effective amount of the conjugated protein.
Need to check novelty before this filing date? Find Prior Art

Description

International Patent Application Attorney Docket No. 2920951-238977 GROWTH HORMONE-RELEASING HORMONE ANALOG LINKED TO EXTENDED LENGTH POLYPEPTIDES AND METHODS OF USING SAMEREFERENCE TO RELATED PATENT APPLICATIONS

[0001] This U.S. Patent Application claims priority to U.S. Provisional Patent Application No.63 / 802,294, filed May 8, 2025, the disclosures of which is herein incorporated by reference in their entireties.FIELD OF THE INVENTION

[0002] The present disclosure relates to a conjugated protein comprising growth hormone-releasing hormone (GHRH) analog linked to a pharmacokinetic extender molecule, optionally to an extended length polypeptide.INCORPORATION-BY-REFERENCE OF COMPUTER READABLE FORM

[0003] Pursuant to the Patent Center legal framework and 37 C.F.R. § 1.831 - 1.834 (see M.P.E.P. § 2412), a Sequence Listing in the form of an XML file entitled “2920951-238977_Sequence_Listing_ST26.xml” created on May 6, 2026 (25,590 bytes in size), and is submitted concurrently with the instant application, and the entire contents of the Sequence Listing are incorporated herein by reference.BACKGROUND

[0004] Growth hormone-releasing hormone (GHRH) and somatostatin are released by the hypothalamus. Human GHRH is a 44-amino acid protein with a short half-life. GHRH regulates growth hormone expression and secretion by the anterior pituitary. Growth hormone binds to liver cell surface receptors and stimulates expression of insulin growth factor- 1 (IGF-1). IGF-1 stimulates systemic body growth and has growth-promoting effects on almost every cell in the body, especially skeletal muscle, cartilage, skin, hematopoietic, bone, liver, and lung cells.BRIEF SUMMARY

[0005] The present disclosure is directed to conjugated proteins, compositions comprising the conjugated proteins, and methods of using such conjugated proteins or compositions to treat an animal. In embodiments, a composition can comprise the conjugated protein described herein. In embodiments, in a method of using the conjugated protein described herein and composition comprising the same, the conjugated protein or composition can be administered to an animal,International Patent Application Attorney Docket No. 2920951-238977 optionally a pregnant animal, to alter or enhance a characteristic in an offspring or litter from the animal. In embodiments, a method for increasing the rate of weight gain and / or feed conversion efficiency is provided, the method comprising administering a conjugated protein described herein or a composition comprising the same to an animal, optionally a cow.

[0006] In embodiments, a conjugated protein comprises a growth hormone-releasing hormone (GHRH) analog linked to a pharmacokinetic extender molecule, wherein the GHRH analog sequence comprises an amino acid sequence comprising at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In embodiments, the GHRH analog can comprise an amino acid sequence comprising at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In embodiments, the GHRH analog can comprise an amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 9, 10, 11, or 12. In embodiments, the GHRH analog can comprise at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 6.

[0007] In embodiments, the pharmacokinetic extender molecule can comprise an extended length polypeptide (ELNN) comprising between about 400 to 3000 amino acids residues. The ELNN can comprise an amino acid sequence comprising at least 90% sequence identity to an amino acid sequence of SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21, or 22. In embodiments, the ELNN can comprise an amino acid sequence comprising at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to an amino acid sequence of SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21, or 22. In embodiments, the ELNN can comprise an amino acid sequence comprising at least about 95% sequence identity to an amino acid sequence of SEQ ID NO: 15.

[0008] In embodiments, the GHRH analog is linked to the ELNN via a linker. In embodiments, the linker can be a lysine molecule, cysteine molecule, threonine molecule, serine molecule, ornithine molecule, or any combination thereof. In embodiments, the linker can be a lysine molecule. In embodiments, the GHRH analog can be linked to the ELNN via a terminal lysine residue, optionally linked to a cysteine residue in the ELNN.

[0009] In embodiments, the conjugated protein comprises a D-alanine substitution at position 2 of the GHRH, optionally comprises the amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 5 or 6.International Patent Application Attorney Docket No. 2920951-238977

[0010] In embodiments, the conjugated protein comprises a D-isoleucine substitution at position 2 of the GHRH, optionally comprises the amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 7 or 8.

[0011] In embodiments, the conjugated protein comprises a valine at position 2 of the GHRH, optionally comprises the amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 9 or 10.

[0012] In embodiments, the conjugated protein comprises a threonine at position 2 of the GHRH, optionally comprises the amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO: 11 or 12.

[0013] In embodiments, the conjugated protein comprises D-Ala2-GHRH-ELNN864, wherein D-Ala2-GHRH-ELNN864 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 6 conjugated to the ELNN864 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 15, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to the cysteine at position 854 of the ELNN sequence. In an embodiment, the ELNN864 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0014] In embodiments, the conjugated protein comprises D-Ile2-GHRH-ELNN864, wherein D-Ile2-GHRH-ELNN864 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 8 conjugated to the ELNN864 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 15, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to the cysteine at position 854 of the ELNN sequence. In an embodiment, the ELNN864 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0015] In embodiments, the conjugated protein comprises D-Ile2-GHRH-ELNN648, wherein D-Ile2-GHRH-ELNN648 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 8 conjugated to the ELNN648 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 16, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to a cysteine in the ELNN sequence. In an embodiment, the ELNN648 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0016] In embodiments SEQ ID NO: 16 or SEQ ID NO: 23 are extender molecules.International Patent Application Attorney Docket No. 2920951-238977

[0017] In embodiments, the conjugated protein comprises D-Ile2-GHRH-ELNN432, wherein D-Ile2-GHRH-ELNN432 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 8 conjugated to the ELNN432 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 17, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to a cysteine in the ELNN sequence. In an embodiment, the ELNN432 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0018] In embodiments, the conjugated protein comprises D-Val2-GHRH-ELNN864, wherein D-Val2-GHRH-ELNN864 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 10 conjugated to the ELNN864 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 15, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to the cysteine at position 854 of the ELNN sequence. In an embodiment, the ELNN864 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0019] In embodiments, the conjugated protein comprises D-Val2-GHRH-ELNN648, wherein D-Val2-GHRH-ELNN648 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 10 conjugated to the ELNN648 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 16, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to a cysteine in the ELNN sequence. In an embodiment, the ELNN648 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0020] In embodiments, the conjugated protein comprises D-Val2-GHRH-ELNN432, wherein D-Val2-GHRH-ELNN432 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 10 conjugated to the ELNN432 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 17, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to a cysteine in the ELNN sequence. In an embodiment, the ELNN432 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0021] In embodiments, the conjugated protein comprises D-Thr2-GHRH-ELNN864, wherein D-Thr2-GHRH-ELNN864 comprises the GHRH amino acid sequence comprising at least about 95%International Patent Application Attorney Docket No. 2920951-238977 sequence identity to the amino acid sequence of SEQ ID NO: 12 conjugated to the ELNN864 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 15, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to the cysteine at position 854 of the ELNN sequence. In an embodiment, the ELNN864 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0022] In embodiments, the conjugated protein comprises D-Thr2-GHRH-ELNN648, wherein D-Thr2-GHRH-ELNN648 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 12 conjugated to the ELNN648 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 16, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to a cysteine in the ELNN sequence. In an embodiment, the ELNN648 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0023] In embodiments, the conjugated protein comprises D-Thr2-GHRH-ELNN432, wherein D-Thr2-GHRH-ELNN432 comprises the GHRH amino acid sequence comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 12 conjugated to the ELNN432 polypeptide comprising at least about 95% sequence identity to the amino acid sequence of SEQ ID NO: 17, wherein the lysine at position 30 of the GHRH sequence is conjugated via a linker to a cysteine in the ELNN sequence. In an embodiment, the ELNN432 polypeptide is conjugated to the GHRH polypeptide via maleimido-methylcyclohexane carboxylate activation through a thioester bond at on the cysteine residue.

[0024] In embodiments, a composition can comprise the isolated conjugated protein described herein. In embodiments, the composition can be a pharmaceutical composition. In embodiments, the composition can comprise a carrier. In embodiments, the carrier can be an excipient, lubricant, antioxidant, emulsifier, stabilizer, solvent, diluent, buffer, vehicle, or any combination thereof.

[0025] In embodiments, a kit can comprise the conjugated protein described herein and composition comprising the same and instructions for reconstitution and / or administration of the composition to a pregnant animal.

[0026] In embodiments, a method to decrease pre-weaning mortality and / or incidence of intrauterine growth restriction (IUGR) in an offspring from a mammal can comprise administering to the female animal an effective amount of the isolated conjugated protein described herein or the composition of described herein. In embodiments, the mammal can be female. In embodiments, the mammal can be pregnant.International Patent Application Attorney Docket No. 2920951-238977

[0027] In embodiments, a method of treating a pregnant mammal can comprise administering to the mammal an effective amount of the isolated conjugated protein described herein or the composition described herein. In embodiments, the treatment can decrease the pre-weaning mortality and / or incidence of IUGR in the offspring born from the pregnant mammal. In embodiments, the administration of the isolated conjugated protein can further result in at least one characteristic in the offspring, selected from the group consisting of: increased survivability, increased average birth weight, increased average BMI, increased average pre-weaning and weaning body weight, increased average rectal temperature between 2-24 hours after birth (RT), increased initial vitality score, increased average crown rump length (CRL), and decreased incidence of fostering, as compared to untreated mammals.

[0028] In embodiments, a method of increasing birth weight of a mammal can comprise administrating an effective amount of an isolated conjugated protein described herein or the composition described herein to a pregnant mammal.

[0029] In embodiments, the method can further comprise performing a pregnancy check on the animal before administering the isolated conjugated protein or composition.

[0030] In embodiments, the pregnancy test can comprise an ultrasound evaluation, blood test, visual inspection, or any combination thereof.

[0031] In embodiments, administration of the conjugated protein described herein and composition comprising the same increases serum IGF-1 concentration in the pregnant animal.

[0032] In embodiments, administration of the conjugated protein described herein and composition comprising the same to an animal increases serum IGF-1 concentration in the animal.

[0033] In embodiments, administration of the conjugated protein described herein and composition comprising the same to an animal increases the rate of gain in the animal.

[0034] In embodiments, administration of the conjugated protein described herein and composition comprising the same to an animal increases feed efficiency in the animal.

[0035] In embodiments, the dosage of the conjugated protein can be between about 0.1 mg per animal and 2.0 mg per kg of body weight. In embodiments, the dosage of the isolated conjugated protein can be between about 0.2 mg per animal and 1.0 mg per kg of body weight. In embodiments, the dosage of the isolated conjugated protein can be about 0.10 mg / kg, about 0.11 mg / kg, about 0.12 mg / kg, 0.13 mg / kg, 0.14 mg / kg, 0.15 mg / kg, 0.16 mg / kg, 0.17 mg / kg, 0.18 mg / kg, 0.19 mg / kg, 0.20 mg / kg, 0.21 mg / kg, 0.22 mg / kg, 0.23 mg / kg, 0.24 mg / kg, 0.25 mg / kg, 0.26 mg / kg, 0.27 mg / kg, 0.28 mg / kg, 0.29 mg / kg, 0.30 mg / kg, 0.40 mg / kg, about 0.41 mg / kg, about 0.42 mg / kg, 0.43 mg / kg, 0.44 mg / kg, 0.45 mg / kg, 0.46 mg / kg, 0.47 mg / kg, 0.48 mg / kg, 0.49 mg / kg, 0.50 mg / kg, about 0.51 mg / kg, about 0.52 mg / kg, 0.53 mg / kg, 0.54 mg / kg, 0.55 mg / kg,International Patent Application Attorney Docket No. 2920951-238977 0.56 mg / kg, 0.57 mg / kg, 0.58 mg / kg, 0.59 mg / kg, 0.60 mg / kg, about 0.61 mg / kg, about 0.62 mg / kg, 0.63 mg / kg, 0.64 mg / kg, 0.65 mg / kg, 0.66 mg / kg, 0.67 mg / kg, 0.68 mg / kg, 0.69 mg / kg, 0.70 mg / kg, about 0.71 mg / kg, about 0.72 mg / kg, 0.73 mg / kg, 0.74 mg / kg, 0.75 mg / kg, 0.76 mg / kg, 0.77 mg / kg, 0.78 mg / kg, 0.79 mg / kg, 0.80 mg / kg, about 0.81 mg / kg, about 0.82 mg / kg, 0.83 mg / kg, 0.84 mg / kg, 0.85 mg / kg, 0.86 mg / kg, 0.87 mg / kg, 0.88 mg / kg, 0.89 mg / kg, 0.90 mg / kg, about 0.91 mg / kg, about 0.92 mg / kg, 0.93 mg / kg, 0.94 mg / kg, 0.95 mg / kg, 0.96 mg / kg, 0.97 mg / kg, 0.98 mg / kg, 0.99 mg / kg, 1.0 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, or 2.0 mg / kg. In embodiments, the dosage of isolated conjugated protein can be 0.95 mg / kg weight of the animal.

[0036] In embodiments, the dosage of isolated conjugated protein can be between about 0.1 mg / kg and about 1.0 mg / kg weight of the animal. In embodiments, the dosage of isolated conjugated protein can be about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, or 1.0 mg / kg weight of the animal. In embodiments, the dosage of isolated conjugated protein can be about 0.1 mg / kg weight of the animal.

[0037] In embodiments, the isolated conjugated protein can be administered at between about 15 days of gestation to about 65 days of gestation. In embodiments, the isolated conjugated protein can be administered at between about 20 days of gestation to about 40 days of gestation, about 25 days of gestation to about 30 days of gestation, about 20 days of gestation to about 50 days of gestation, or about 25 days of gestation to about 35 days of gestation. The isolated conjugated protein can be administered at about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, about 28 days, about 29 days, about 30 days, about 31 days, about 32 days, about 33 days, about 34 days, about 35 days, about 36 days, about 37 days, about 38 days, about 39 days, about 40 days, about 41 days, about 42 days, about 43 days, about 44 days, about 45 days, about 46 days, about 47 days, about 48 days, about 49 days, about 50 days, about 51 days, about 52 days, about 53 days, about 54 days, about 55 days, about 56 days, about 57 days, about 58 days, about 59 days, about 60 days, about 61 days, about 62 days, about 63 days, about 64 days, or about 65 days of gestation.

[0038] In embodiments, the isolated conjugated protein can be administered at about 35 days of gestation.

[0039] In embodiments, the isolated conjugated protein can be administered at about 25 mg split into two separate doses and administered at about 35 days of gestation.International Patent Application Attorney Docket No. 2920951-238977

[0040] In embodiments, the isolated conjugated protein can be not administered at insemination of the animal.

[0041] In embodiments, the isolated conjugated protein can be administered before, during, and after insemination.

[0042] In embodiments, the isolated conjugated protein can be administered before insemination.

[0043] In embodiments, the isolated conjugated protein can be administered during insemination.

[0044] In embodiments, the isolated conjugated protein can be administered after insemination.

[0045] In embodiments, the isolated conjugated protein can be administered to a non-pregnant sow.

[0046] In embodiments, the isolated conjugated protein can be administered between about 1 and 30 days before insemination. In embodiments, the isolated conjugated protein can be administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or about 30 days before insemination.

[0047] In embodiments, the isolated conjugated protein can be administered between about 1 and about 24 hours before insemination. In embodiments, the isolated conjugated protein can be administered about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours before insemination.

[0048] In embodiments, the isolated conjugated protein increases ovulation, feed conversion, weight gain, or any combination thereof in the pig.

[0049] In embodiments, the isolated conjugated protein can be administered intramuscularly.

[0050] In embodiments, the isolated conjugated protein can be administered at least once during gestation. In embodiments, the isolated conjugated protein can be administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times during gestation.

[0051] In embodiments, the pregnant mammal can be a pig.

[0052] In embodiments, the pregnant mammal can be a sow.

[0053] In embodiments, the pregnant mammal is not a gilt.

[0054] In embodiments, use of the isolated conjugated protein described herein or the composition described herein for the manufacture of a medicament to administer to a pregnant mammal to decrease pre-weaning mortality and / or incidence of IUGR in a baby born from the pregnant animal as compared to untreated mammals.International Patent Application Attorney Docket No. 2920951-238977

[0055] In embodiments, a method of increasing feed efficiency (IFE) can comprise administrating an effective amount of an isolated conjugated protein described herein or the composition described herein to a mammal.

[0056] In embodiments, a method of increasing gain (ADG) can comprise administrating an effective amount of an isolated conjugated protein described herein or the composition described herein to a mammal.

[0057] In embodiments, the mammal can be a cow, sheep, goat, horse, pig, or llama.

[0058] In embodiments, an isolated nucleic acid can comprise a nucleotide sequence encoding the conjugated protein of described herein or the complement thereof.

[0059] In embodiments, an expression vector comprises the nucleic acid described herein.

[0060] In embodiments, the isolated host cell can comprise the nucleic acid of described herein. In embodiments, the host cell can be a eukaryotic host cell. In embodiments, the host cell can be a prokaryotic host cell.BRIEF DESCRIPTION OF THE DRAWINGS

[0061] FIG. 1 depicts the effect of treatment of 0.3 mg / kg D-Ala2-GHRH-ELNN864 at D25 and / or D65 on Serum IGF-1 Concentrations in pregnant sows.

[0062] FIG. 2 depicts the effect of treatment of 0.3 mg / kg D-Ala2-GHRH-ELNN864 at D25 ± 3 days gestation on pregnant sows compared to control (no treatment) on birth weight distribution of the piglets.

[0063] FIG. 3 depicts the effect of treatment of 0.1 and 0.3 mg / kg D-Ala2-GHRH-ELNN864 on pregnant sows compared to control (no treatment) on birth weight distribution of the piglets.

[0064] FIGs. 4A-B depicts the effect of treatment of 0.1, 0.2, and 0.3 mg / kg D-Ala2-GHRH-ELNN864 on pregnant sows compared to control (no treatment). FIG. 4A shows the effect on the number of light weight and heavy weight live piglets born per litter, and FIG. 4B shows the effect on the proportion of light weight and heavy weight live piglets born per litter.

[0065] FIG. 5 depicts the effect of treatment of 0.05, 0.1, 0.2, and 0.3 mg / kg D-Ala2-GHRH-ELNN864 on pregnant sows compared to control (no treatment) on piglet mortalities on or before D5 and at weaning.

[0066] FIG. 6A-B depicts the effect of treatment of a fixed dose of 25 mg / sow D-Ala2-GHRH-ELNN864 administered on D28 ± 3 days gestation to pregnant sow on weight distribution of the piglets. FIG. 6A shows the effect on the birth weight distribution of the piglets. FIG. 6B shows the effect on weaning weight distribution of the piglets.International Patent Application Attorney Docket No. 2920951-238977

[0067] FIG. 7A-B depicts the effect of treatment of a fixed dose of 25 mg / sow D-Ala2-GHRH-ELNN864 administered on D35 ± 3 days gestation to pregnant sow on weight distribution of the piglets. FIG. 7A shows the effect on the % birth weight distribution of the piglets. FIG. 7B shows the effect on % weaning weight distribution of the piglets.

[0068] FIG. 8 depicts the CRL measurement procedure.

[0069] FIG. 9 depicts the determination of IUGR by external signs relating to head morphology criteria.

[0070] FIG. 10 depicts the plasma IGF-1 after a single injection of 0.95 mg / kg of D-Ala2-GHRH-ELNN864 in heifers (body weight about 800 lbs.)

[0071] FIG. 11 depicts the plasma urea nitrogen after a single injection of 0.95 mg / kg of D-Ala2-GHRH-ELNN864 in heifers (body weight about 800 lbs.)

[0072] FIG. 12 depicts a BRRS study results measuring IGF-1 data: (•) Control; (■) Ile2-GHRH-ELNN864; (A) Ile2-GHRH-ELNN648; (X) Ile2-ELNN432; (*) D-Ala2-ELNN864.

[0073] FIG. 13 depicts a chart of the concentration of the GRF-XTEN concentration versus days for the four treatment groups.

[0074] FIG. 14 depicts a chart of serum IGF-1 concentration versus days for the four treatment groups and the saline control.DETAILED DESCRIPTION

[0075] The features described herein are merely illustrative, and they are not intended to represent the full scope of the invention or limit the scope of the invention. It should be appreciated that various modifications of the present description of the invention are possible without departing from the spirit of the invention.Definitions

[0076] “About,” as used herein, refers broadly to a range of plus or minus 5% of that value.

[0077] “Animal” as used herein, refers broadly to any species of the animal kingdom. It can refer more specifically to animals in their wild state, animals used as pets (birds, dogs, cats, horses), animals used for work (horses, cows, dogs) and animals which produce food (chickens, cows, fish), farm animals (pigs, horses, cows, sheep, chickens) or are themselves food (frogs, chickens, fish, crabs, lobsters, shrimp, mussels, scallops, goats, boars, cows, lambs, pigs, ostrich, emu, eel) and other animals well known to the art. Mammals are a subgenus of animal and can include but are not limited to farm animals (pigs, horses, cows, sheep).International Patent Application Attorney Docket No. 2920951-238977

[0078] “Effective amount” as used herein, refers broadly to the amount of the composition required to produce an effect in a animal which can be monitored using several endpoints known to those skilled in the art.

[0079] As used herein, the terms “ELNN polypeptide”, “ELNN”, “XTEN”, and “XTEN polypeptide” are synonymous, and refer to extended length polypeptides comprising non-naturally occurring, substantially non-repetitive sequences (e.g., polypeptide motifs) that are composed mainly of small hydrophilic amino acids, with the sequence having a low degree of or no secondary or tertiary structure under physiologic conditions. Such extended length polypeptides include unstructured hydrophilic polypeptides comprising repeating motifs of 6 natural amino acids (G, A, P, E, S, and / or T). In some embodiments, an ELNN polypeptide comprises multiple motifs of 6 natural amino acids (G, A, P, E, S, T), wherein the motifs are the same or comprise a combination of different motifs. ELNN polypeptides can confer certain desirable pharmacokinetic, physicochemical and pharmaceutical properties when linked to another therapeutic protein of the disclosure to create a conjugated protein. Such desirable properties include but are not limited to enhanced pharmacokinetic parameters and solubility characteristics. Examples of ELNN polypeptides are known in the art, and non-limiting descriptions relating to and examples of ELNN polypeptides (referred to as XTEN polypeptides) are available in Schellenberger et al., (2009) Nat Biotechnol 27(12): 1186-90; Brandl et al., (2020) Journal of Controlled Release 327:186-197; and Radon et al., (2021) Advanced Functional Materials 31, 2101633 (pages 1-33), the entire contents of each of which are incorporated herein by reference.

[0080] “ Growth hormone (GH)” as used herein, refers broadly to a hormone which relates to growth and acts as a chemical messenger to exert its action on a target cell.

[0081] “ Growth hormone releasing hormone or factor (GHRH or GRF)” as used herein, refers broadly to a hormone which facilitates or stimulates release of growth hormone.

[0082] “ Growth hormone releasing hormone (GRF or GHRH) analog” as used herein, refers broadly to a protein which contains amino acid mutations and / or deletions in the naturally occurring form of the amino acid sequence (with no synthetic dextro or cyclic amino acids), but not naturally occurring in the GHRH / GRF molecule, yet still retains its function to enhance synthesis and secretion of growth hormone.

[0083] “Isolated,” as used herein, refers broadly biological molecules that have been identified and separated and / or recovered from a component of its natural environment. In general, a polypeptide made by recombinant means and expressed in a host cell is considered to be “isolated.”

[0084] An “isolated” polynucleotide or polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least oneInternational Patent Application Attorney Docket No. 2920951-238977 contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal or extra-chromosomal location different from that of natural cells.

[0085] “Linked,” as used herein, refers broadly to the joining together of two or more chemical elements or components, by whatever means including chemical conjugation or recombinant means.

[0086] “Newborn,” as used herein, refers broadly to an animal immediately after birth.

[0087] “Offspring,” as used herein, refers broadly to a progeny of a parent, wherein the progeny is an unborn fetus or a newborn.

[0088] “Parenteral,” as used herein, refers broadly to a mechanism for introduction of material into an animal other than through the intestinal canal. Parenteral can include subcutaneous, intramuscular, intravenous, intrathecal, intraperitoneal, or others.

[0089] “Somatotroph,” as used herein, refers broadly to a cell which produces growth hormone.

[0090] “Effective dose regimen”, as used herein, refers broadly to a schedule for consecutively administered multiple doses (e.g., at least two or more) of a biologically active protein, either alone or as a part of a conjugated protein composition, wherein the doses are given in effective amounts to result in sustained beneficial effect on any symptom, aspect, measured parameter or characteristics in an animal (or any offspring or litter of the animal).

[0091] “Percent (%) sequence identity,” with respect to the polypeptide sequences identified herein, refers broadly to the percentage of amino acid residues in a query sequence that are identical with the amino acid residues of a second, reference polypeptide sequence or a portion thereof, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software including but not limited to as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Percent identity may be measured over the length of anInternational Patent Application Attorney Docket No. 2920951-238977 entire defined polypeptide sequence, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues.

[0092] Also herein, the recitations of numerical ranges by endpoints include all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0093] “Vector” as used herein, refers broadly to any vehicle which delivers a nucleic acid into a cell or organism. Examples include plasmids, viral vectors, liposomes, or cationic lipids. Liposomes and cationic lipids can be adjuvant (carriers) that can be complexed with other vectors to increase the uptake of plasmid or viral vectors by a target cell. The vector can comprise a promoter, a nucleotide sequence, which can encode a growth hormone releasing hormone or its analog, and a 3 ' untranslated region. The promoter, nucleotide sequence, and 3' untranslated region can be linked operably for expression in a eukaryotic cell.

[0094] IUGR determination: Methods for identification of IUGR piglets include various birth weight categorizations. Secondly, IUGR is associated with a long and thin body shape, which can be quantified, as in human neonates, by low ponderal index (PI) or body mass index (BMI). Perhaps the clearest external sign of IUGR relates to head morphology criteria as seen in FIG. 9. When fetal nutrient supply is limited, relatively more nutrients are directed toward growth of the brain (brain sparing) and heart as part of a fetal adaptive reaction to placental insufficiency.

[0095] A classification of severe (s-IUGR) is given if 2 or 3 of the characteristics are present, and of moderate (m-IUGR) if only one of the characteristics is present.

[0096] CRL measurement procedure (see FIG. 8): The piglet is held in a standard position by fixing the front and hind legs. A flexible measuring instrument is used to be able to follow the curve of the back. The supine length is measured from the crown of the head to the base of the tail. The length will be recorded up to a decimal of cm.

[0097] Initial Vitality Score is determined by the following (0-1-2):0 Unresponsive while processing and lies down on the spot when put back in farrowing pen and feels chilled.1 Unresponsive while processing or lies down on the spot when put back in farrowing pen or feels chilled.2 Normal = Responsive while processing and walk away when put back in farrowing pen and does not feel chilled.

[0098] “Abortion,” as used herein, refers broadly to premature (e.g., prior to day 109 of pregnancy) expulsion of dead or nonviable fetuses.International Patent Application Attorney Docket No. 2920951-238977

[0099] “Mummies” refers broadly to partially reabsorbed or decomposed fetuses expelled at birth.

[0100] “ Stillborn,” as used herein, refers broadly to fully-formed not reabsorbed animals at birth that have not taken a breath of air. In case of doubt, the lung flotation test indicates whether the piglet was stillborn or live born.

[0101] “Live born,” as used herein, refers broadly to the following:

[0102] All offspring that are alive when observed;

[0103] Offsprings that are found dead and have either moved away from the birthing area (e.g., a piglet that may have been crushed by the sow); and

[0104] Offsprings that are found dead or found dead in the birthing area directly behind the sow and have lungs that float in water.

[0105] “Retained Piglet,” as used herein, refers broadly, to a dead pig that is born after the litter has been processed.

[0106] “ Cross fostering,” as used herein, refers broadly, to removing some or all piglets from their birth sow to a foster sow, or exchanging piglets between sows depending on their size, vigor and gender, as well as physical characteristics of the sow’s udder. If performed correctly, grouping small piglets on a suitable sow, cross-fostering gives piglets enhanced survival prospects and can reduce the need for further management interventions for piglets that would otherwise suffer from remaining in a large litter.Intra-uterine growth restriction (IUGR)

[0107] Large litter sizes, while being a benefit to animal producers in terms of production efficiency, has also resulted in an associated increase in newborn mortality and morbidity. Offspring stillbirth and pre-weaning mortality increase with litter size. The reasons for this association between litter size and offspring mortality encompass a number of factors, including an increase of offspring birthweight variation within the larger litters resulting in increase of the proportion of low birth weight newborn mammals, a prolongation of farrowing and associated hypoxia in the offspring and increased competition for teat access and nutrients. Intra-uterine growth restriction (IUGR) leads to increased mortality in litters of hyperprolific female mammals. There exists a need in the art to address the problem of IUGR.

[0108] Some of the survival challenges experienced by IUGR offspring relate specifically to their smaller size and lower energy reserves. Low birth weight newborns display lower vitality and are less resistant to cold because of their greater surface area to volume ratio. When born wet with fetal fluids, into an environment where the temperature is typically 10-20 degrees below core body temperature, they rapidly lose heat. Since they are born with very limited energy reserves, thisInternational Patent Application Attorney Docket No. 2920951-238977 negative energy balance can only persist for a short time before becoming fatal. The problem is even greater for low birth weight offspring competing in a litter with larger siblings.

[0109] Newborn mammals that show IUGR characteristics in their weight or morphology also show other differences which indicate reduced maturity at birth, such as absolute and relative decreased liver, heart and digestive system weight, decreased glycogen reserves and more. Brains from low birth weight fetuses are less myelinated and have less dendritic development than the brains from normally grown littermates. That might contribute to the tendency towards a lower vitality score in IUGR offspring. Furthermore, low birth weight offspring show compromised muscle, cardiac and renal physiology.

[0110] Digestive organs are also affected by IUGR. In low birth weight newborns, the relative weight of the pancreas is reduced, and IUGR is associated with a reduction in the wall thickness of the stomach, small intestine and colon. The intestinal surface area for absorption is highly reduced, with the average number of villi per unit area and the height of villi being 15% to 20% lower.[OHl] Hormonal status, at birth and subsequently, is also affected by IUGR.

[0112] The most obvious consequence of IUGR is the increased mortality of afflicted offspring during the neonatal period. The relationship between birth weight and survival is well established. In addition, low birth weight newborns that survive show consistently lower postnatal growth rates. Growth restriction during fetal life is linked with lower growth efficiency and increased susceptibility to infections in postnatal life and IUGR may associate with an altered innate immune system.

[0113] Thus, one major consequence of intrauterine growth restriction is an increased perinatal mortality. Moreover, large litters result in offspring that are smaller and have less mature immune and digestive systems at weaning. Offspring exposed to IUGR also show lower postnatal growth velocity compared to normal weight littermates. IUGR offspring may be more susceptible to disease, as their growth is already compromised.Accordingly, IUGR is a significant economic and welfare problem in the modern animal husbandry industry. Thus, a current unmet need exists for a lower cost and easy-to-use composition and method to administer to pregnant mammals to reduce offspring mortality and the prevalence of IUGR offspring born to the pregnant mammals, optionally pigs.International Patent Application Attorney Docket No. 2920951-238977 Improved Feed Conversion Ration (FCR) and Average Daily Gain (ADG)

[0114] Feed conversion ratio (FCR) is the amount of feed an animal needs to gain a certain amount of weight. An improved FCR can result in less feed required per animal for the animals to reach market weight.

[0115] Average Daily Gain (ADG) can be defined as the average amount of weight a market animal will gain each day during the feeding period. An improved ADG can result in less time required per animal for the animals to reach market weight.Improved Newborn Survivability

[0116] Increased birth weight is an indicator of improved pre-weaning survival. For example, in pigs, this increase generally has a steep slope up to a birth weight of 1.15 kg, after which the survival rate increase flattened out. The GHRH analog conjugates described herein can be administered to pregnant mammals to increase offspring birth weight, and thus, offspring survival.Growth Hormone

[0117] Growth hormone (GH) is a hormone that participates in the regulation of mammalian growth and development. Growth hormone, also known as somatotrophin, represents a class of proteinaceous hormones produced and secreted by the somatotropic cells of the anterior pituitary. GH regulates the secretion of insulin-like growth factor (IGF-1), among other peptide hormones known collectively as somatomedins, which account for most of the biological activities.

[0118] Growth hormone releasing hormone (referred to hereinafter as “GHRH”, but also generally known as GRF) leads to release of GH into the plasma. GH binds to liver cell surface receptors and stimulates the expression of IGF-1. IGF-1 supports cellular division and muscular growth. GH and IGF-1 are unlikely to cross the placenta, but they likely affect nutrient transfer through the placenta. It has been observed that placental insufficiency is a major cause of intra-uterine growth restriction that influences birth weight) and the thermo-regulatory capabilities of newborn piglets.

[0119] Species-specific forms of GH have seen widespread use in domestic animals. The growth velocity and body composition of humans, farm animals, and companion animals appear to respond to GH replacement therapies under a broad spectrum of conditions.

[0120] However, GHRH generally comprises short segments of amino acids and tends to have a very short half-life. Chemical modifications to a therapeutic peptide can reduce its in vivo clearance rate and increase subsequent serum half-life. Thus, there remains a need for improved growth hormone compositions with increased half-life which can be administered less frequently, and / or be produced by a simpler process at a lower cost.International Patent Application Attorney Docket No. 2920951-238977Growth hormone releasing hormone (GHRH) Analogs

[0121] Embodiments of the GHRH analog may have a molecular weight below the threshold value for kidney filtration, which contributes to a short serum half-life of the GHRH analog. Chemical modifications to a therapeutic protein can reduce its in vivo clearance rate and increase subsequent serum half-life, with most approaches either linking the drug to bulking moieties, or enabling FcRn-mediated recycling.

[0122] Disclosed is a conjugated protein comprising a GHRH analog linked to at least one pharmacokinetic extender molecule. In embodiments, the extender molecule has no biological activity.Table 1— GHRH and GHRH ANALOGS1 2 3 4 5 6 7 8 9 10 Human TYR ALA ASP ALA ILE PHE THR ASN SER TYR Bovine TYR ALA ASP ALA ILE PHE THR ASN SER TYR Porcine TYR ALA ASP ALA ILE PHE THR ASN SER TYR GHRH ANALOG TYR X ASP ALA ILE PHE THR GLN SER TYR11 12 13 14 15 16 17 18 19 20 Human ARG LYS VAL LEU GLY GLN LEU SER ALA ARG Bovine ARG LYS VAL LEU GLY GLN LEU SER ALA ARG Porcine ARG LYS VAL LEU GLY GLN LEU SER ALA ARG GHRH ANALOG ARG LYS VAL LEU ALA GLN LYS SER ALA ARG21 22 23 24 25 26 27 28 29 30 Human LYS LEU LEU GLN ASP ILE MET SER ARG GLN Bovine LYS LEU LEU GLN ASP ILE MET ASN ARG GLN Porcine LYS LEU LEU GLN ASP ILE MET SER ARG GLN GHRH ANALOG LYS LEU LEU GLN ASP ILE LEU SER ARG LYS31 32 33 34 35 36 37 38 39 40 Human GLN GLY GLU SER ASN GLN GLU ARG GLY ALA Bovine GLN GLY GLU ARG ASN GLN GLU GLN GLY ALA Porcine GLN GLY GLU ARG ASN GLN GLU GLN GLY ALA GHRH ANALOG41 42 43 44Human ARG ALA ARG LEUBovine LYS VAL ARG LEU X=(D) Ala or(D)lle Porcine ARG VAL ARG LEUInternational Patent Application Attorney Docket No. 2920951-238977Human GHRH is SEQ ID NO: 1.Bovine GHRH is SEQ ID NO: 2.Porcine GHRH is SEQ ID NO: 3.GHRH Analog is SEQ ID NO: 4.GHRH Analog with D-Ala at position 2 and a terminal lysine is SEQ ID NO: 6.GHRH Analog with D-Ile at position 2 and a terminal lysine is SEQ ID NO: 8.

[0123] The pre-sequence of the GHRH analog can comprise:MIEGGRYIDAIFTQSYRKVLAQKSARKLLQDILSRK (SEQ ID NO: 13)MIEGGR (SEQ ID NO: 22) is a leader sequence to be cleaved off with Trypsin so that the N term is Met freeHe2reduces degradation by DPP-IV.Gin8avoids conversion N to D.Ala15enhances receptor binding.Leu27avoids oxidation of Met.Lys30Is for conjugation to XTEN via maleimido thioester linkage at Cystein854, XTEN can comprise the amino acid sequence of SEQ ID NO: 15(numbering is after removal of MIEGGR (SEQ ID NO: 15) leader sequence)

[0124] The conjugated protein can comprise (D-Ala2-GHRH-ELNN864): GHRH analog comprising SEQ ID NO: 6 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, wherein the amino acid sequence of SEQ ID NO: 6 comprises a D-Ala substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at Cysteine at position 854).

[0125] D-Ile2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, wherein the amino acid sequence of SEQ ID NO: 8 comprises a D-Isoleucine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at Cysteine at position 854.

[0126] D-Ile2-GHRH-ELNN648 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 8 comprises a D-IsoleucineInternational Patent Application Attorney Docket No. 2920951-238977 substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionallly via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine.

[0127] D-Ile2-GHRH-ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 8 comprises a D-Isoleucine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine.

[0128] Val2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, wherein the amino acid sequence of SEQ ID NO: 10 comprises a Valine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at Cysteine at position 854.

[0129] Val2-GHRH-ELNN648 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 10 comprises a D-Isoleucine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine.

[0130] Val2-GHRH-ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 10 comprises a D-Isoleucine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine.

[0131] Thr2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 12 comprises a threonine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at Cysteine at position 854.International Patent Application Attorney Docket No. 2920951-238977

[0132] Thr2-GHRH-ELNN648 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 12 comprises a threonine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0133] Thr2-GHRH-ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 12 comprises a threonine substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a terminal lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0134] D-Ala2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 6 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, wherein the amino acid sequence of SEQ ID NO: 6 comprises a D-Ala substitution at position 2 and a terminal lysine at position 30 and the ELNN polypeptide is conjugated to the GHRH analogue at a lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at Cysteine at position 854.

[0135] D-Ala2-2GHRH-2ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 6 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 6 comprises a D-Ala substitution at position 2 and the ELNN polypeptide is conjugated to the GHRH analogue at a lysine at position 30, optionally via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine.

[0136] In embodiments, the GHRH analog can comprise a porcine somatorelin analog (a recombinant version of growth hormone-releasing hormone (GHRH)). In embodiments, the GHRH analog can comprise a sequence comprising about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to the amino acid sequence SEQ ID NO: 3. In embodiments, the GHRH analog may comprise the amino acid sequence of SEQ ID NO: 3.

[0137] In embodiments, the GHRH analog may comprise an amino acid analog with a D-alanine substitution at position 2 of the GHRH analog, relative to SEQ ID NO: 5, which confers resistance to endopeptidase. In embodiments, the GHRH analog can comprise a sequence having at leastInternational Patent Application Attorney Docket No. 2920951-238977 about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to the amino acid sequence of SEQ ID NO: 5.

[0138] In embodiments, the GHRH analog may comprise an amino acid analog with a D-isoleucine substitution at position 2 of the GHRH analog, relative to SEQ ID NO: 7, which confers resistance to endopeptidase. In embodiments, the GHRH analog can comprise a sequence having at least about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to the amino acid sequence of SEQ ID NO: 7.

[0139] In embodiments, the GHRH analog may comprise an amino acid analog with a D-alanine substitution at position 2 of the GHRH analog, relative to SEQ ID NO: 6, which confers resistance to endopeptidase and a lysine linker at position 30. In embodiments, the GHRH analog can comprise a sequence having at least about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to the amino acid sequence of SEQ ID NO: 6.

[0140] The isolated protein can comprise a GHRH analog linked via a linker to at least one pharmacokinetic extender molecule. In embodiments, the extender molecule has no biological activity. In embodiments, the conjugated protein can comprise the formula, depicted in an N- to C-terminus orientation:[GHRH analog]-[linker]-[extender molecule],

[0141] The extender molecule can be a polyethylene glycol (PEG) moiety, natural and semisynthetic polysaccharides, including O- and N-linked oligosaccharides, dextran, hydroxyethyl starch (HES), polysialic acid and hyaluronic acid, as well as unstructured protein polymers such as homo-amino acid polymers, elastin-like polypeptides, extended length polypeptides, PAS (a linker comprising a mixture of proline, alanine and / or serine residues), or any combination thereof.

[0142] The GHRH analog in the conjugated protein may be linked to XTEN polypeptides (also referred to herein as ELNNs, ELNN polypeptides, and XTENs), examples of which are available in Schellenberger et al., (2009) Nat Biotechnol 27(12): 1186-90; Brandl et al., (2020) Journal of Controlled Release 327:186-197; and Radon et al., (2021) Advanced Functional Materials 31, 2101633 (pages 1-33), the entire contents of each of which are incorporated herein by reference.International Patent Application Attorney Docket No. 2920951-238977 The XTEN polypeptide increases in vivo half-life from minutes to days. The XTEN polypeptide, as compared to PEG, has a more precise molecular weight distribution, is recombinant DNA versus random chemical polymerization, and has extremely low hydrophobicity. The XTEN polypeptide may comprise 864 amino acids and comprise the amino acid sequence of SEQ ID NO: 15. The XTEN polypeptide may comprise 648 amino acids and comprise the amino acid sequence of SEQ ID NO: 16. The XTEN polypeptide may comprise 643248 amino acids and comprise the amino acid sequence of SEQ ID NO: 17.

[0143] An ELNN may comprise a non-repetitive sequence having an unstructured conformation. The sum of glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues constitutes more than about 90%, 95%, 96%, 97%, 98%, or 99% of the total amino acid residues of the ELNN. The isolated protein can comprise 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, or 72 non-repetitive ELNN sequences of about 12 amino acid residues, or cumulatively about 432, 444, 456, 468, 480, 492, 504, 516, 528, 540, 552, 564, 576, 588, 600, 612, 624, 636, 648, 660, 672, 684, 696, 708, 720, 732, 744, 756, 768, 780, 792, 804, 816, 828, 840, 852, or 864 amino acid residues, wherein more than about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% of the sequence consists of multiple units of two or more non-overlapping sequence motifs selected from the amino acid sequences of GSPAGSPTSTEE (SEQ ID NO: 18), GSEPATSGSETP (SEQ ID NO: 19), GTSESATPESGP (SEQ ID NO:20), and GTSTEPSEGSAP (SEQ ID NO: 21).

[0144] While standard cloning techniques theoretically could permit any number of amino acid residues to be incorporated in the ELNN, the ELNN may comprise 100, or 200, or 300, or 400, or 500, or 600, or 700, or 800, or 900, or 1000, or 2000, up to about 3000 amino acids residues. The ELNN may comprise 864 amino acid residues, or defined fractional sizes, including 3 / 4 of 864 (648 residues), 2 / 3 of 864 (576 residues), 1 / 2 of 864 (432 residues), 1 / 3 of 864 (288 residues), and 1 / 6 of 864 (144 residues). The ELNN may comprise 864 amino acid residues. The ELNN may comprise a sequence comprising more than about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% sequence identity to an amino acid sequence selected from SEQ ID NO: 15, 16, or 17. The ELNN can comprise the amino acid sequence of SEQ ID NO: 15, 16, or 17. The ELNN can comprise the amino acid sequence of SEQ ID NO: 15.International Patent Application Attorney Docket No. 2920951-238977

[0145] The conjugated protein can comprise a GHRH analog-(Y)-ELNN, comprising a growth hormone-releasing hormone (GHRH) analog linked to ELNN via optional linker (Y). The linker (Y) sequence may comprise from about 1 to about 50 amino acid residues that optionally comprises a cleavage sequence. The linker (Y) can be a lysine molecule, cysteine molecule, threonine molecule, serine molecule, or ornithine molecule. The linker (Y) can be a lysine molecule.

[0146] The extender molecule may comprise a polyethylene glycol (PEG) moiety, natural and semi-synthetic polysaccharides, including O- and N-linked oligosaccharides, dextran, hydroxyethyl starch (HES), polysialic acid and hyaluronic acid, unstructured protein polymers including but not limited to as homo-amino acid polymers, elastin-like polypeptides, ELNN and PAS, or any combination thereof.

[0147] The extender molecule can exploit recycling through the FcRn receptor. Two plasma proteins, serum albumin and IgG, have exceptionally long half-lives in circulation. When taken up by cells through nonspecific endocytosis, both proteins bind to the FcRn receptor in acidic endosomes and become protected from intracellular degradation. The protein-receptor complexes are recycled to the cell surface, where albumin and immunoglobulin molecules are released back into circulation at the neutral pH of the plasma. Several methods have been used to exploit the increased half-life of IgG or albumin for therapeutic payloads: (1) genetic fusion of the GHRH analog to the Fc domains of IgG or to the albumin polypeptide; (2) chemical conjugation of the payload to the albumin, IgG or Fc domain; (3) fusion or conjugation to mediator molecules which physically bind to IgG or albumin. Examples of mediators include but are not limited to IgG-binding peptides, fatty acids, albumin-binding peptides, and albumin-specific antibody fragments. Thus, the extender molecule can comprise a Fc domain, include but are not limited to as albumin and immunoglobulin fragments, that is fused to the GHRH analog.

[0148] The conjugated protein can exhibit enhanced pharmacokinetic properties compared to GHRH analog not linked to the extender molecule (for example, ELNN), wherein the enhanced properties include but are not limited to longer terminal half-life, larger area under the curve, increased time in which the blood concentration remains within the therapeutic window, increased time between consecutive doses, and decreased dose in moles over time. The terminal half-life of the conjugated protein administered to an animal can be increased two fold, or three-fold, or fourfold, or five-fold, or six-fold, or eight-fold, or ten-fold, or 20-fold, or 40-fold, or 60-fold, or 100-fold, or even higher as compared to GHRH analog not linked to ELNN and administered to an animal at a comparable dose. The enhanced pharmacokinetic property can be reflected by the fact that the blood concentrations that remain within the therapeutic window for the conjugated protein for a given period are two fold, or three-fold, or four-fold, or five-fold, or six-fold, or eight-fold,International Patent Application Attorney Docket No. 2920951-238977 or ten-fold longer, or 20-fold, or 40-fold, or 60-fold, or 100-fold or more compared to GHRH analog not linked to the extender molecule (for example, ELNN) and administered to an animal at a comparable dose. The increase in half-life and time spent within the therapeutic window permits less frequent dosing and decreased amounts of the conjugated protein (in moles equivalent) that are administered to an animal, compared to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN).

[0149] The resulting conjugated protein can retain at least a portion of the biological activity of the corresponding GHRH analog not linked to the extender molecule (for example, ELNN). In other cases, the GHRH analog component either becomes biologically active or has an increase in activity upon its release from the extender molecule (for example, ELNN) by cleavage of an optional cleavage sequence incorporated within spacer sequences into the GHRH analog-ELNN.

[0150] The extender molecule can comprise an ELNN, which is linked to the GHRH analog on an N- or C-terminus of the GHRH analog. The conjugated proteins can be designed to have different configurations, N- to C-terminus, of a GHRH analog, an ELNN, and optional linker sequences, including but not limited to ELNN-GHRH analog, GHRH analog-ELNN, ELNN-Y-GHRH analog, or GHRH analog-Y-ELNN. The choice of configuration can, as disclosed herein, confer particular pharmacokinetic, physico / chemical, and / or pharmacologic properties.

[0151] Administration of an effective dose of a conjugated protein discussed herein to an animal in need thereof can result in a gain in time of at least two-fold, or at least three-fold, or at least four-fold, or at least five-fold or more spent within a therapeutic window for the conjugated protein compared to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) of and administered at a comparable dose to an animal

[0152] The isolated conjugated protein can be characterized in that: (i) it has a longer half-life compared to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN); (ii) when a smaller molar amount of the conjugated protein is administered to an animal in comparison to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) administered to an animal under an otherwise equivalent dose regimen, the conjugated protein achieves a comparable therapeutic effect as the corresponding GHRH analog not linked to the extender molecule (for example, ELNN); (iii) when the conjugated protein is administered to an animal less frequently in comparison to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) administered to an animal using an otherwise equivalent molar amount, the conjugated protein achieves a comparable therapeutic effect as the corresponding GHRH analog not linked to the extender molecule (for example, ELNN); and / or (iv) when an accumulatively smaller molar amount of the conjugated protein is administered to anInternational Patent Application Attorney Docket No. 2920951-238977 animal in comparison to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) administered to an animal under an otherwise equivalent dose period, the conjugated protein achieves comparable therapeutic effect as the corresponding GHRH analog not linked to the extender molecule (for example, ELNN).

[0153] The conjugated protein described above can exhibit a biological activity of about 0.1%, about 0.1%, about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or about 100% of the biological activity compared to the GHRH analog not linked to the extender molecule (for example, ELNN). The conjugated proteins can bind the same receptors or ligands as the corresponding parental biologically active protein that is not covalently linked to the extender molecule (for example, ELNN).

[0154] The extender molecule can be linked via a Lys-MPA linkage (using maleimidoOpropionic acid) or a Lys-MCC linkage (using maleimido-methylcyclohexane carboxylate).Method for Producing Conjugated Protein

[0155] The half-life extender polypeptide can be expressed in E. coli. In embodiments, it accumulates in the cytosol as a soluble protein and can be isolated from whole cell paste. The extender is isolated, purified, and, and optionally digested by trypsin to remove N and C-terminal flanking regions. In embodiments, the extender is isolated from E. coli. by osmatic lysis of the cells. A cysteine residue, for example introduced at position 854 of the XTEN sequence, can be used as a conjugation site to the GHRH molecule. The cysteine residue is reduced by reductant to enable conjugation reaction via a maleimido-methylcyclohexane carboxylate group (MCC), thus producing the conjugated protein. This is subsequently purified to create the GHRH conjugate.Nucleic Acids, Vectors, Host Cells

[0156] Disclosed is an isolated nucleic acid, which can comprise a polynucleotide sequence selected from (a) a polynucleotide encoding the conjugated protein comprising a growth hormone-releasing hormone (GHRH) analog linked to a pharmacokinetic extender molecule described herein or (b) the complement of the polynucleotide of (a). Embodiments also provide expression vectors, which can comprise the nucleic acid of any of the features hereinabove described in this paragraph. The expression vector of the foregoing further can comprise a recombinant regulatory sequence operably linked to the polynucleotide sequence. The polynucleotide sequence of the expression vectors of the foregoing can be fused in frame to a polynucleotide encoding a secretion signal sequence, which can be a prokaryotic signal sequence.International Patent Application Attorney Docket No. 2920951-238977

[0157] The disclosure also provides a host cell, which can comprise an expression vector disclosed in the foregoing paragraph. The host cell can be a prokaryotic cell. The host cell can be E. coli. The host cell can be a eukaryotic cell.

[0158] The disclosure provides a composition, which can comprise the conjugated protein comprising a growth hormone-releasing hormone (GHRH) analog linked to a pharmacokinetic extender molecule described herein in any order and / or in any combination, and an acceptable carrier. The disclosure also provides kits, which can comprise packaging material and at least a first container comprising the composition of the foregoing aspects / embodiments / features in any order and / or in any combination, and a label identifying the composition and storage and handling conditions, and a sheet of instructions for the reconstitution and / or administration of the compositions to an animal.Dosage

[0159] The dosage of the conjugated protein can be between about 0.1 mg per animal and 2.0 mg per kg of body weight. The dosage of the isolated conjugated protein can be between about 0.2 mg per animal and 1.0 mg per kg of body weight. The dosage of the isolated conjugated protein can be about 0.10 mg / kg, about 0.11 mg / kg, about 0.12 mg / kg, 0.13 mg / kg, 0.14 mg / kg, 0.15 mg / kg, 0.16 mg / kg, 0.17 mg / kg, 0.18 mg / kg, 0.19 mg / kg, 0.20 mg / kg, 0.21 mg / kg, 0.22 mg / kg, 0.23 mg / kg, 0.24 mg / kg, 0.25 mg / kg, 0.26 mg / kg, 0.27 mg / kg, 0.28 mg / kg, 0.29 mg / kg, 0.30 mg / kg, 0.40 mg / kg, about 0.41 mg / kg, about 0.42 mg / kg, 0.43 mg / kg, 0.44 mg / kg, 0.45 mg / kg, 0.46 mg / kg, 0.47 mg / kg, 0.48 mg / kg, 0.49 mg / kg, 0.50 mg / kg, about 0.51 mg / kg, about 0.52 mg / kg, 0.53 mg / kg, 0.54 mg / kg, 0.55 mg / kg, 0.56 mg / kg, 0.57 mg / kg, 0.58 mg / kg, 0.59 mg / kg, 0.60 mg / kg, about 0.61 mg / kg, about 0.62 mg / kg, 0.63 mg / kg, 0.64 mg / kg, 0.65 mg / kg, 0.66 mg / kg, 0.67 mg / kg, 0.68 mg / kg, 0.69 mg / kg, 0.70 mg / kg, about 0.71 mg / kg, about 0.72 mg / kg, 0.73 mg / kg, 0.74 mg / kg, 0.75 mg / kg, 0.76 mg / kg, 0.77 mg / kg, 0.78 mg / kg, 0.79 mg / kg, 0.80 mg / kg, about 0.81 mg / kg, about 0.82 mg / kg, 0.83 mg / kg, 0.84 mg / kg, 0.85 mg / kg, 0.86 mg / kg, 0.87 mg / kg, 0.88 mg / kg, 0.89 mg / kg, 0.90 mg / kg, about 0.91 mg / kg, about 0.92 mg / kg, 0.93 mg / kg, 0.94 mg / kg, 0.95 mg / kg, 0.96 mg / kg, 0.97 mg / kg, 0.98 mg / kg, 0.99 mg / kg, 1.0 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, or 2.0 mg / kg. The dosage of isolated conjugated protein can be 0.95 mg / kg weight of the animal.International Patent Application Attorney Docket No. 2920951-238977 Routes of Administration

[0160] Examples of routes of administration include parenteral (e.g., intravenous, intradermal, subcutaneous, intraperitoneal, intramuscular), and topical (e.g., epicutaneous, inhalational, transmucosal) administration. Appropriate dosage forms for parenteral administration may include intravenous administration. Appropriate dosage forms for topical administration may include creams, ointments, and skin patch. The composition can be administered intramuscularly.Compositions

[0161] A composition can comprise the conjugated proteins described herein and a carrier, optionally a pharmaceutically acceptable carrier. As used herein “pharmaceutically acceptable carrier” includes, but is not limited to, saline, solvents, diluent, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols including but not limited to mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. The diluent can be benzyl alcohol.

[0162] The compositions described herein can be administered at an effective amount, wherein the administered effective amount can result in an increased terminal half-life gain for the conjugated protein compared to the corresponding GHRH analog of the conjugated protein not linked to the extender molecule (for example, ELNN) and administered at a comparable dose to an animal. The increase in terminal half-life can be at least three-fold longer than the corresponding GHRH analog not linked to the extender molecule (for example, ELNN), or alternatively, at least four-fold, or five-fold, or six-fold, or seven-fold, or eight-fold, or nine-fold, or at least 10-fold, or at least 20-fold, or 30-fold, or 50-fold, or 100-fold longer than the corresponding GHRH analog not linked to the extender molecule (for example, ELNN). The method of treatment can comprise (i) a smaller molar amount of (e.g., of about two-fold less, or about three-fold less, or about four-fold less, or about five-fold less, or about six-fold less, or about eight-fold less, or about 100 fold-less or greater) the conjugated protein is administered in comparison to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) under an otherwise same dose regimen, andInternational Patent Application Attorney Docket No. 2920951-238977 the conjugated protein achieves a comparable therapeutic effect as the corresponding GHRH analog not linked to the extender molecule (for example, ELNN); (ii) the conjugated protein is administered less frequently in comparison to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) under an otherwise same dose amount, and the conjugated protein achieves a comparable physiologic effect as the corresponding GHRH analog not linked to the extender molecule (for example, ELNN); or (iii) an accumulative smaller molar amount (e.g. about 5%, or about 10%, or about 20%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90% less) of the conjugated protein is administered in comparison to the corresponding GHRH analog not linked to the extender molecule (for example, ELNN) under the otherwise same dose regimen the conjugated protein achieves a comparable therapeutic effect as the corresponding GHRH analog not linked to the extender molecule (for example, ELNN). The accumulative smaller molar amount is measured for a period of one week, or about 14 days, or about 21 days, or about one month.Methods for Increased Feed Efficiency (IEE) and Rate of Gain (ADG)

[0163] The GHRH analog conjugated proteins described herein can be used in methods of increasing feed efficiency (IEE), rate of gain (ADG), or any combination thereof. The GHRH analog conjugated proteins described herein can be administered to an animal, for example cattle, to increase feed efficiency (IEE), rate of gain (ADG), or any combination thereof. The GHRH analog conjugated proteins described herein is a non-antibiotic, non-beta agonist, and non-steroidal agent. This is an advantage over existing products on the market.Methods of Reducing IUGR

[0164] Disclosed is a method of treating an animal, which can comprise administering the isolated conjugated protein or composition described above to an animal using one or more consecutive doses of the protein or composition administered using an effective dose regimen. The administration of the conjugated protein can result in improvement in at least one measured characteristic discussed herein using less frequent dosing or a lower total dosage in moles of the conjugated protein of the pharmaceutical composition compared to the corresponding biologically active protein component(s) not linked to the conjugated protein and administered to an animal using an effective regimen to an animal.

[0165] The composition can be administered to an animal that is pregnant. The administration can begin at DI 8-65 ±3 days after insemination, or D20-50 ± 3 days, or D25-40 ± 3 days, or D25-35 ± 3 days of gestation during the animal's pregnancy.International Patent Application Attorney Docket No. 2920951-238977

[0166] The present disclosure further provides use of the isolated conjugated protein or composition discussed herein comprising the conjugated protein of any of the foregoing aspects / embodiments / features in any order and / or in any combination in the manufacture / preparation of a medicament to administer to a pregnant animal for treating, improving, or increasing a characteristic in the offspring or litter of the pregnant animal, compared to a control offspring or litter.

[0167] The pre-weaning mortality and / or incidence of intrauterine growth restriction (IUGR) in a litter can be decreased by at least about 1-15%. The pre-weaning mortality and / or incidence of intrauterine growth restriction (IUGR) in a litter can be decreased by at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.

[0168] The characteristic in the offspring or litter can be further selected from the group consisting of: increased survivability, increased average birth weight, increased average BMI, increased average pre-weaning and weaning body weight, increased average rectal temperature between 2-24 hours after birth (RT), increased initial vitality score, increased average crown rump length (CRL), and decreased incidence of fostering, by at least between about 1-15%. These parameters can be decreases by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.

[0169] The characteristics of offspring, litter, or any combination thereof, that are improved can include, but are not limited to, improvement of a characteristic at birth. Examples of improved characteristics at birth include, but are not limited to, increased number of offspring bom alive, increased litter birth weight, increased offspring birth weight, reduced number of stillborn offspring, increased birth weight and average birth weight of fully formed offspring (stillborn and live), reduced number of mortality of offspring, reduced incidence of IUGR of offspring, increased average BMI of offspring, average rectal temperature of offspring, increased vitality score, or any combination thereof. Where the animal is a pig, the improvement can include increased crown rump length (CRL) of piglet, increased number of piglets weighing 2.5 pounds (about 1.13-1.15 kg) at birth. The improvement can include increased birth weight where the mother is a first- time mother. The treatment can reduce piglet pre-weaning mortality by about 0.5-1 piglet per litter and / or increases the piglet birth weight by an average of about 0.1kg to about 0.5 kg.

[0170] The characteristics of offspring or litter that are improved can include, but are not limited to, improvement of a characteristic afterbirth. Examples of improved characteristics afterbirth can include, but are not limited to, increased survival of offspring before weaning, increased weight of offspring at weaning, reduced number of mortality at weaning, increased average daily gain (ADG)International Patent Application Attorney Docket No. 2920951-238977 of live offspring, increased average offspring weaning weight, increased total litter weaning weight, decreased incidence of fostering, or any combination thereof. Where the animal is a pig, the improvement can include increasing the number of piglets weighing at least 5kg at weaning.

[0171] The method can improve characteristics of offspring or litter after weaning and before adulthood. Characteristics include, but are not limited to, ADG (average pounds gained by animal per day per period), increased average daily food intake (ADFI, average pounds consumed per animal per day), improved feed conversion ratio (ADFI ADG, measurement of feed efficiency), or combinations thereof. The increased average daily gain for an offspring born to an animal receiving the composition during pregnancy, lactation, or any combination thereof may be an increase of at least between about 0.5% and 15% of a control offspring. The increase can be about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15%.

[0172] The present disclosure provides a method of treating an animal, for example, a pregnant animal, which can comprise administering to the animal a physiologically-effective amount of the conjugated protein of any of the foregoing aspects / embodiments / features in any order and / or in any combination, wherein said administration results in an improvement or enhancement of at least one characteristic in an offspring or litter. The improvement can be relative to a control, e.g., the improvement is determined by comparing offspring of a mother receiving a conjugated protein or composition as described herein with offspring of a mother that did not receive a conjugated protein or composition. The administration of the effective amount of the GHRH analog-extender molecule (for example, GHRH analog-ELNN) conjugated protein can result in 1%, or 5%, or 6%, or 7%, or 8%, or 9%, or 10%, or 12%, or 15%, or 20%, or a range from about 1% to about 20%, increase in the at least one characteristic compared to the offspring or litter of an animal not treated.

[0173] The treatment can increase serum insulin-like growth factor (IGF) concentration in the pregnant animal, including but not limited to IGF-1 and / or IGF-2. IGF plays a role in regulation of normal physiology and a number of pathological states, including cancer, as well as cell proliferation and inhibition of cell death. IGF may affect different growth stages. Insulin-like growth factor 2 (IGF-2) is thought to be a primary growth factor required for early development while insulin-like growth factor 1 (IGF-1) expression is required for achieving maximal growth. Almost every cell in the human body is affected by IGF-1, especially cells in muscle, cartilage, bone, liver, kidney, nerves, skin, and lungs. IGF-1 can also regulate cell growth and development, especially in nerve cells, as well as DNA synthesis. The treatment can increase serum IGF-1 concentration between at least about 1% and 15% in the pregnant animal. The increase in serumInternational Patent Application Attorney Docket No. 2920951-238977 IGF-1 concentration can be at least about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% in the pregnant animal.

[0174] The methods described herein can result in improved weight gain. The weight gain can be at an interval of time after birth including during the offspring's nursing phase, during the phase between weaning and adulthood, and during adulthood. The weight of an animal can be measured as body weight. The increase in body weight can result from increased bone density, increased bone growth, increased muscle (e.g., increased number of muscle fibers, increased length of muscle fibers), increased adipose tissue, or any combination thereof. The increase in body weight can result from increased organ growth (e.g., internal organs, including, but not limited to, increased tissue of heart, liver, lungs, stomach, intestines), increased head growth (e.g., increased brain growth), increased skin growth, or any combination thereof. The increase in weight of an offspring, when measured using body weight, may be an increase of 0.25% of a control offspring resulting from an animal not administered the conjugated protein or composition, 0.5%, 1%, 2%, 2.5%, or 5%. For instance, when the offspring is a pig, the weight gain may be 0.5 pounds, 1 pound, 3 pounds, or 4 pounds greater than a control.EXAMPLES EXAMPLE 1GHRH ANALOGS

[0175] A study was performed to evaluate different GHRH analog constructs with substitutions at the second position from Isoleucine, Valine, Threonine and D-Alanine combined with three different ELNN sizes. This study was conducted to evaluate the activity of these long acting GHRH analogs in gilts. The levels of IGF 1 and blood urea nitrogen were used as indicators of activity.

[0176] Pigs (n = 60; 72.1 - 103.2 kg) were randomly assigned to receive one of twelve treatments by intramuscular injection on Day 0 (11 different long acting GHRH analog constructs and 1 control: TGOI: control (118mM Tris). TGO2: D-Ile2-GHRH-ELNN864; TGO3: D-Ile2-GHRH-ELNN648; TGO4: D-Ile2-GHRH-ELNN432; TG05: Val2-GHRH-ELNN864; TG06: Val2-GHRH-ELNN648; TG07: Val2-GHRH-ELNN432; TG08: Thr2-GHRH-ELNN864; TGO9: Thr2-GHRH-ELNN648; TG10: Thr2-GHRH-ELNN432; TG11: D-Ala2-GHRH-ELNN864; TG12: D-Ala2-2GHRH-2ELNN432.

[0177] D-Ile2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 15,International Patent Application Attorney Docket No. 2920951-238977 wherein the amino acid sequence of SEQ ID NO: 8 comprises a D-Isoleucine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at the cysteine at position 854.

[0178] D-Ile2-GHRH-ELNN648 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 8 comprises a D-Isoleucine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0179] D-Ile2-GHRH-ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 8 comprises a D-Isoleucine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0180] Val2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 15, wherein the amino acid sequence of SEQ ID NO: 10 comprises a Valine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at the cysteine at position 854.

[0181] Val2-GHRH-ELNN648 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 10 comprises a D-Isoleucine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0182] Val2-GHRH-ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 10 comprises a D-Isoleucine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.International Patent Application Attorney Docket No. 2920951-238977

[0183] Thr2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 12 comprises a threonine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at the cysteine at position 854.

[0184] Thr2-GHRH-ELNN648 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 12 comprises a threonine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0185] Thr2-GHRH-ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 12 comprises a threonine substitution at position 2 and the XTEN is conjugated to the GHRH analogue at a terminal lysine at position 30 via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0186] D-Ala2-GHRH-ELNN864 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 6 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 15, wherein the amino acid sequence of SEQ ID NO: 6 comprises a D-Ala substitution at position 2 and a terminal lysine at position 30 and the XTEN is conjugated to the GHRH analogue via maleimido-methylcyclohexane carboxylate activation through a thioester bond at the cysteine at position 854.

[0187] D-Ala2-2GHRH-2ELNN432 comprises a GHRH analog comprising the amino acid sequence of SEQ ID NO: 6 conjugated to XTEN comprising the amino acid sequence of SEQ ID NO: 16, wherein the amino acid sequence of SEQ ID NO: 6 comprises a D-Ala substitution at position 2 and the XTEN is conjugated to the GHRH analogue via maleimido-methylcyclohexane carboxylate activation through a thioester bond at a cysteine residue.

[0188] Blood samples for IGF-1 and BUN determination were collected at -4, 0, 3, 7, 10, 14, 21, 28, 35, 42, 49, 56, and 63 days after injection for each treatment. Bodyweights were also collected on Study Day -4, 0, 14, 28, 42, 56, and 63.International Patent Application Attorney Docket No. 2920951-238977 Table 2:Treatment Treat Total Duration of Group Treatment Dose ment # Study Day of pigs1 Control 118mM Tris, pH 7 Day 0 5 63 days 2 Ile2-GHRH-ELNN864 0.3 mg / kg Day 0 5 63 days 3 Ile2-GHRH-ELNN648 0.3 mg / kg Day 0 5 63 days 4 Ile2-GHRH-ELNN432 0.3 mg / kg Day 0 5 63 days 5 Val2-GHRH-ELNN864 0.3 mg / kg Day 0 5 63 days 6 Val2-GHRH-ELNN648 0.3 mg / kg Day 0 5 63 days 7 Val2-GHRH-ELNN432 0.3 mg / kg Day 0 5 63 days 8 Thr2-GHRH-ELNN864 0.3 mg / kg Day 0 5 63 days 9 Thr2-GHRH-ELNN648 0.3 mg / kg Day 0 5 63 days 10 Thr2-GHRH-ELNN432 0.3 mg / kg Day 0 5 63 days 11 D-Ala2-GHRH- 0.3 mg / kg Day 0 5 63 days ELNN86412 D-Ala2-2GHRH- 0.3 mg / kg Day 0 5 63 days2ELNN432

[0189] All GHRH analog constructs but the Thr2-GHRH-ELNN432 induced a significant increase in circulating levels of IGF-1. By day 28, the area under the curve for D-Ala2-GHRH-ELNN864 and D-Ala2-2GHRH-2ELNN432 were the only two construct that were significantly different from control. By day 42 only D-Ala-GHRH-ELNN864 remained significantly different. Circulating levels of Blood urea nitrogen (BUN =, mg / dL) decreased following GHRH analog-ELNN injection. Area under the Curve BUN for D-Ala2-GHRH-ELNN864 was the only one construct that was significantly different from control by day 28. By day 42 and day 63 all constructs were not significantly different from control.

[0190] The study was design to evaluate different GHRH analog constructs with substitutions at the second position from Isoleucine, Valine, Threonine and D-Alanine combined with three different ELNN sizes. The D-Ala2-GHRH-ELNN864 was the only construct that was clearly superior to all other constructs at increasing IGF1 levels and maintaining them elevated for theInternational Patent Application Attorney Docket No. 2920951-238977 longest time. Similar to IGF-1, D-Ala2-GHRH-ELNN864 significantly reduced BUN area under the curve.EXAMPLE 2GHRH ANALOG DOSES

[0191] This study was conducted to evaluate the effects of various doses of two long-acting GHRH analog constructs (D-Ala2-GHRH-ELNN864 and L-Ile2-GHRH-ELNN) administered to multiparous sows (IM) during early gestation on maternal serum levels of IGF-1, maternal body growth, and fetal growth (body and liver weights).

[0192] Sows (n = 99; 163.0 - 310.7 kg) were randomly assigned to receive one of five doses of D-Ala2-GHRH-ELNN864 (TG2-TG6) or one of five doses of L-Ile2-GHRH-ELNN (TG7-TG 11) by intramuscular injection on Day 0: TG 1) 0 mg / kg; TG2) 0.05 mg / kg; TG3) 0.10 mg / kg; TG4) 0.20 mg / kg; TGS) 0.30 mg / kg; TG6) 0.40 mg / kg; TG7) 0.30 mg / kg; TG8) 0.40 mg / kg; TG9) 0.50 mg / kg; TG10) 0.60 mg / kg; TG 11) 0.80 mg / kg. Blood samples for IGF-1 and BUN determination were collected on approximately Day 7, Day 14, Day 21, Day 28, Day 35, and Day 42 after IM injection.

[0193] IGF-1 Area Under the Curve (AUC): Area under the curve for IGF-1 were significantly higher when compared to control for both the D-Ala2-GHRH-ELNN864 and L-Ile-GHRH-ELNN864 constructs (p<0.0001). When comparing the two constructs, the D- Ala2-GHRH-ELNN864 construct had a significantly higher AUC at almost all dose than the L-Ile-GHRH-ELNN864 at all doses tested. Only the D-Ala2-GHRH-ELNN864 at 0.05 mg / kg dose, which was only significantly different to the L-Ile-GHRH-ELNN864 at 0.30 mg / kg (p=0. 0199). Circulating levels of IGF-1 (ng / ml) increased significantly following GHRH analog- ELNN injection. The D-ala2-GHRH-ELNN864 remained significantly higher than control thru week 5 whereas the L Ile-GHRH-ELNN864 was significantly different mostly 2 weeks only.EXAMPLE 3 PHARMACOKINETIC / PHARMACODYNAMIC OF GHRH ANALOGS

[0194] The objective of this study was to compare the pharmacokinetic / pharmacodynamic relationships of two GHRH analog-ELNN constructs comprising an ELNN length of either 864 or 648 amino acids. Concentrations of IGF-1 were used as a pharmacodynamic indicator of biological activity.

[0195] Growing barrows were randomly assigned to receive one of five treatments via intramuscular injection on Day 0. D-Ala2-GHRH -ELNN648 and D-Ala2-GHRH-ELNN864 wereInternational Patent Application Attorney Docket No. 2920951-238977 administered at 0.1 and 0.3 mg / kg of body weight and compared to saline control. Animals were weighed on the day prior to dosing and at the end of the study on Day 42. Blood samples for IGF-1 and GHRH analog-ELNN assay were collected on Day 0 prior to dosing and on Days 1, 3, 7, 14, 21, 28, 35 and 42.Table 3:AnimalsTreatment Treatment Dose (mg / kg Route / perGroup # Group BW) Frequency TreatmentTGI Control 0 IM / IX -Day 0 7SalineTG2 D-ala GHRH 0.1 IM / IX -Day 0 7ELNN 648TG3 D-ala GHRH 0.3 IM / IX -Day 0 7ELNN 648TG4 D-ala GHRH 0.1 IM / IX -Day 0 7ELNN 864TG5 D-ala GHRH 0.3 IM / IX -Day 0 7ELNN 864

[0196] Cmax was similar for the two constructs at an equivalent dose level. Cmax for the 0.1 mg / kg GHRH-ELNN 648 and 864 treatment groups was 1040 and 982 ng / ml, respectively and was 3080 and 3040 ng / ml for the 0.3 mg / kg GHRH-ELNN 648 and 864 groups, respectively. GHRH-ELNN 864 was detectable for a longer period of time than the GHRH-ELNN 648. AUCo-infwas higher for the GHRH-ELNN 864 treated groups compared to the same dose of GHRH-ELNN 648. AUCo-inf for the 0.1 and 0.3 mg / kg GHRH-ELNN 864 groups was 4310 and 12500 ng*day / ml, respectively, and was 3110 and 9950 ng*day / mL for the 0.1 and 0.3 mg / kg GHRH ELNN 648 groups, respectively. Cmax and AUCo-inf appear to increase linearly with increasing dose. Half-life for the GHRH-ELNN 864 treated groups was double that of the GHRH ELNN 648 groups, averaging 4.5 days for the 864 groups and 1.9 days for the 648 groups.

[0197] IGF-1 response was relatively consistent amongst the four treated groups. On Day 1, IGF-1 was significantly higher for TG3 (648 0.3 mg / kg) compared to saline controls (P<0.01). From Day 3 through Day 14, IGF-1 was significantly higher for all four treated groups compared to saline control (P0.001). On Day 21, IGF-1 continued to be higher for the two 0.3 mg / kg treatedInternational Patent Application Attorney Docket No. 2920951-238977 groups compared to control (PO.OOl) On Day 14, there was a differentiation between the two 0.3 mg / kg groups, with the GHRH-ELNN 648 group having significantly higher IGF-1 than the GHRH-ELNN 864 group (P<0.05). Emax was similar amongst the four treated groups and ranged from 440 to 472 ng / ml. The AUEC0-42 was similar across constructs of an equivalent dose, and slightly increased by the increased dose. AUEC0-42 was 10,400 and 10,900 ng*day / ml for the 0.1 mg / kg GHRH ELNN 648 and 864 constructs, respectively, and 12,600 and 12,400 ng*day / ml for the 0.3 mg / kg GHRH ELNN 648 and 864 constructs, respectively. Therefore, it appears the IGF-1 response was not notably dose responsive nor markedly better for one construct versus the other.

[0198] This study determined the pharmacokinetics and pharmacodynamics of two different constructs of GHRH analog-ELNN at two different doses. Cmax and AUC increased linearly with dose, however the pharmacodynamic IGF-1 response was relatively consistent amongst the treatment doses and constructs.EXAMPLE 4SERUMS MARKERS

[0199] Exogenous porcine somatotropin increases serum IGF-1 levels in gestating pigs and is believed to improve fetal growth and development which could correspond to increased survivability of the neonate. Hence, efforts to improve the well-being of newborn piglets can be advanced through the development of practices that elevate circulating IGF-1 in the gestating pig. This experiment examines the effects of GHRH analog-ELNN administered during gestation in gilts on Serum levels of IGF-1 and markers of placental transport and fetal growth and myogenesis to day 60 of gestation.

[0200] 36 female gilts were determined to be in good health, as determined by the study Investigator, based on physical examination conducted. Examples of exclusion criteria included preexisting conditions (e.g., enteric disease, respiratory disease, lameness, neurological disease, septicemia), unthrifty appearance, abnormal conformation, or history of treatment with any antimicrobial within 5 days of study enrollment.

[0201] The study ran from d 24 to d 60 of gestation. On d 24, each gilt was weighed, backfat depth measured via ultrasound, and pregnancy checked with real-time ultrasound. Gilts confirmed to be pregnant were randomized to one of the three treatment groups with day of insemination used as a blocking factor. Blocks were balanced on d 24 live weight. On 25 d post-first insemination (Study day 1) for each gilt, treatments were injected IM in the neck utilizing two injection sites if necessitated by volume of injection. Treatments consisted of TG01) saline (negative control, volume / kg to match volume administered to gilts in TG02), TG02) D-Ala2-GHRH-ELNN864 (1.25 mg / kg), and TG03) d-ala2-GHRH-ELNN864 (0.625 mg / kg).International Patent Application Attorney Docket No. 2920951-238977 Table 4:Treatment Compound / Animals / Planned Group Dose, mg / kg Frequency Route Treatment Necropsy Day TG01 Placebo Negative 1 x on Day 1 IM Day 36+2 Control, sterile saline (Day 25 of 12 (Day 60+2 of gestation) gestation) TG02 D-Ala2-GHRH- 1 x on Day 1 IM Day 36+2 ELNN864 , (Day 25 of 12 (Day 60+2 of 1.25 mg / kg gestation) gestation) TG03 d-ala2-GHRH-ELNN, 1 x on Day 1 IM Day 36+2 0.625 mg / kg (Day 25 of 12 (Day 60+2 of gestation) gestation)

[0202] Adverse events: An adverse event (AE) was defined as any observation in animals that was unfavorable and unintended and occurred after the use of an investigational veterinary product, whether or not considered to be product related. A serious adverse event was any adverse event which resulted in death, was life-threatening, resulted in persistent or significant disability / incapacity, a congenital anomaly or birth defect or that required professional treatment / intervention above and beyond routine preventive measures or common first aid. A non-serious AE was defined as any abnormal health observation occurring during the treatment phase that was not defined as a serious AE. All adverse events were non-serious and expected as shown in Table below:Table 5:Treatment Group Anorexia Anorexia Lame Lame (Number of (Gilt days) (Number of (Gilt days) gilts) gilts)TG01Control 2 5 0 0 TG02D-Ala2-GHRH- 2 5 1 6 ELNN8641.25 mg / kgInternational Patent Application Attorney Docket No. 2920951-238977 TG03D-Ala2-GHRH- 2 11 0 0 ELNN8640.625 mg / kgRESULTS

[0203] Gestating gilts were injected with three levels of D-Ala2-GHRH-ELNN864 (0 mg / kg, 0.625 mg / kg and 1.25 mg / kg) and blood IGF-1 levels were evaluated weekly for 36 d. Data indicated that there was a treatment x day interaction (P< 0.001) for serumIGF-1 levels. Therefore, treatment means were compared within day of IGF-1 analysis. Day 0 maternal serum IGF-1 levels did not differ (P > 0.10). D-Ala2-GHRH-ELNN864 at both the 0.625 mg / kg and 1.25 mg / kg doses increased (P < 0.05) d 8 serum IGF-1 levels above the d 8 IGF-1 levels of the control animals. On the remaining d of the experiment, serum IGF-1 levels of the gilts administered the 1.25 mg / kg dosage were greater (P < 0.05) than the serum IGF-1 levels of the gilts administered the 0.625 mg / kg dosage, which were greater (P < 0.05) than the serum levels of the controls. There were no differences (P > 0.10) in initial gilt body weights or ending weights. However, increasing dosage of D-Ala2-GHRH-ELNN864 increased (linear, P = 0.010) total gilt body weight gain over the study as well as increased (linear, P = 0.011) gain on a daily basis. No differences (P > 0.10) in last rib backfat depth were observed throughout the study. The number of live fetuses per litter tended to increase as dosage increased (linear, P = 0.094), but the number of non-viable (e.g., mummies, resorbing, recently dead) fetuses per litter did not differ (P > 0.10). Total litter weight linearly increased (P = 0.052) as dosage increased, however, treatment had no effect (P > 0.10) on the litter average fetal weight, standard deviation of fetal weights within each litter, litter average crownrump length, or standard deviation of crown-rump lengths within each litter. D-Ala2-GHRH-ELNN864 increased both bodyweight (linear, P = 0.038) and thoracic circumference (linear, P = 0.012) of the three fetuses analyzed per litter, but no differences (P > 0.10) in either crown-rump length or head circumference were observed. D-Ala2-GHRH-ELNN864 had no effect (P > 0.10) on fetal brain weight, but increased fetal liver weight, thereby decreasing the corresponding braindiver weight ratio (linear, P = 0.035 and 0.069, respectively). No differences (P > 0.10) in relative mRNA abundance of placental GLUT-1 transporter were observed. There were no (P > 0.10) treatment x muscle x fetal size or treatment x size interactions for any of the myogenic responses of the fetal litter subset. Trends for size x muscle interactions were observed for total primary muscle fiber number (P = 0.093) and the number of secondary fibers per primary fiber (PInternational Patent Application Attorney Docket No. 2920951-238977 = 0.059). Both whole muscle area and primary muscle fiber number in the muscle cross-sectional area increased (linear, P = 0.011 and 0.047, respectively) with increasing treatment dosage and also increased (linear, P < 0.05) with longer fetal crown-rump length sizes. The number of secondary muscle fibers per primary fiber was greater (P = 0.002) for longer fetal crown-rump sizes but was not affected by treatment. The average cross-sectional area of primary muscle fibers, average number of nuclei associated with each primary muscle fiber, and average number of Pax7+ nuclei associated with each primary fiber were all greater (P < 0.001) in the Longissimus Thoracis muscle than in the Longissimus Lumborum muscle.EXAMPLE 5Method for Producing Conjugated protein

[0204] The half-life extender XTEN864 (from Amunix Pharmaceuticals, Inc.) is expressed in E. coll. It accumulates in the cytosol as a soluble protein and can be isolated from whole cell paste. The extender is isolated, purified and digested by trypsin to remove N and C-terminal flanking regions. In embodiments, the extender is isolated from E. coll, by osmatic lysis of the cells. The cysteine residue, introduced at position 854 of the XTEN sequence, is the conjugation site to the GHRH molecule. The cysteine residue is reduced by reductant to enable conjugation reaction via a maleimido-methylcyclohexane carboxylate group (MCC), thus producing the conjugated protein. This is subsequently purified to create the final drug substance.EXAMPLE 6MATERNAL BLOOD IGF-1 CONCENTRATIONS AND PIGLET BIRTH WEIGHTS

[0205] This experiment examined the effect of administering an isolated D-Ala2-GHRH-ELNN864 to pigs during gestation on maternal blood IGF-1 concentrations and piglet birth weights.

[0206] 116 Pigs (2nd-6thparity) were confirmed to be pregnant via a real time transabdominal ultrasound on day 22 ± 3 days of gestation before treatment. A health status exam was performed just before treatment, and only sows having no “abnormal-significant” findings were enrolled in the study (sows / piglets that became ill, injured, or developed animal welfare concerns considered to interfere with the study objectives were removed from the study and not replaced). The 116 sows which gave birth to 1685 fully formed piglets.

[0207] 0.3 mg / kg isolated D-Ala2-GHRH-ELNN864 was administered IM in 1-2 doses to pregnant sows at D25, D65, or both days of gestation. As shown in table below, injections of the IVP (treatment) or placebo were given on days 25 and 65 of gestation:International Patent Application Attorney Docket No. 2920951-238977Table 6:Treatment Compound Frequency Animals / Group Dosage & Time of GroupID DosingSterile saline or buffer CP @ Days 25 and1 Placebo volume matched to 65 of gestation 28IVP volumeD-Ala2-GHRH-ELNN864 @ IVP @ Day 25 and2 0.3 mg / kg CP at Day 65 of 29gestationD-Ala2-GHRH-ELNN864 @ CP @ Day 25 and3 0.3 mg / kg IVP @ Day 65 of 30gestationD-Ala2-GHRH-ELNN864 @ IVP @ Days 25 & 654 0.3 mg / kg of gestation 29

[0208] Gilts (primiparous sows) were excluded from the analysis. At each site, there were 4 treatments denoted: “C+C” (control), “E+C” (early IVP administration at 25D), “C+L” (late IVP administration at 65D), and “E+L” (both early and late IVP administration).RESULTS

[0209] Piglet birth weight: there was a significant effect of the number of pigs born per litter (litter size) on the average piglet birth weight (P< .0001) with a larger litter size being associated with a smaller average piglet birth weight. There was an overall treatment effect (p = 0.0118) on piglet birth weight, with all treatments differing from control. Average piglet birth weights (kg) for control, early, late, and both early and late injections were 1.351, 1.507, 1.462, and 1.485, respectively, as seen in Tables below:Table 7:Type 3 Tests of Fixed EffectsEffect Num DE Den DE F Value Pr >FTrt 3 107 3.84 0.0118International Patent Application Attorney Docket No. 2920951-238977 Littersize 1 108 24.00 < 0.0001Table 8:ContrastsLabel Num DE Den DF F Value Pr >F 1(C+C) v 2(E+C) 1 106 9.78 0.0023 1(C+C) v 3(C+L) 1 105 5.13 0.0256 1(C+C) v 4(E+L) 1 106 7.18 0.0085Table 9:Least Squares MeansEffect Treatment Estimate Standard DF t Value Pr> [t] Errortrt 1(C+C) 1.3507 0.03544 105 38.11 <.0001 trt 2(E+C) 1.5073 0.03537 107 42.62 <.0001 trt 3(C+L) 1.4624 0.03430 105 42.64 <.0001 trt 4(E+L) 1.4851 0.03542 106 41.92 <.0001

[0210] Proportion of piglets born with birth weight above 1.15kg: Because piglet birth weight is a good predictor of piglet survivability in an analysis of the data was performed on the portion with weight above 1.15kg. The weight of approximately 1.15kg was found to be a clear break point when it comes down to pre-weaning survival changes. Below this weight, piglets on average had a 58% chance of survival; above this weight, the survival changes were 92%. There was an overall treatment effect (p = 0.0132) on the percent of piglet bom with birth weight above 1.15kg, with all treatments differing from control. Average of percent of piglets born with birth weight above 1.15kg for control, early, late, and both early and late injections were 70.76%, 84.97%, 80.04%, and 80.1%, respectively, as seen in Tables below.

[0211] Litter weight at birth: there was an overall treatment effect (p = 0.0212) on litter weight, with all treatments differing from control. Average litter weights (kg) for control, early, late, and both early and late injections were 19.69, 21.90, 21.41, and 21.5, respectively, as seen in Tables below.International Patent Application Attorney Docket No. 2920951-238977

[0212] Thus, administration of 0.3 mg / kg of the isolated D-Ala2-GHRH-ELNN864 to the sows is associated with a shift in the birth weight distribution of piglets (offspring) compared to control, leading to heavier piglets and heavier litters (FIG. 2).

[0213] Maternal blood levels of IGF-1 : there was a highly significant treatment x day interaction for circulating concentration IGF-1 (p< 0.0001) as seen FIG. 1. IGF-1 levels remained significantly higher than control in the groups that were treated with D-Ala2-GHRH-ELNN864 early (treatments 2 and 4) until day 65. Similarly, the groups that were treated with d-ala-2-GHRH-ELNN on day 65 (treatments 3 and 4) had significantly higher concentrations of serum IGF-1 until day 100 of gestation. Thus, the administration of the GHRH-ELNN were shown to result in an increase in serum IGF-1 concentration in the sows (FIG. 1). The IGF-1 profile of animals receiving two injections of GHRH analog-ELNN is shown to be similar to that of animals receiving one injection.

[0214] Maternal body weight gain: following each D-Ala2-GHRH-ELNN864 injection, sows transiently gained more weight than the sows in the control group. By weaning, only treatment 4, that received 2 D-Ala2-GHRH-ELNN864 injections, had maintained the weight gain advantage until weaning of their litters as seen in Table below.Table 10:Gain / TRT Gain from 25 to Gain from 65 to Gain from 25 to Gain from 25 to 65 Farrowing FRW Weaning TRT1 19.85 25.15 45 19.44 TRT2 26.60* 21.52 48.12 17.46 TRT3 17.41 37.23* 54.63* 22.96 TRT4 27.95* 31.77* 59.71* 25.53**: P<0.05

[0215] Thus, treatment with 0.3 mg / kg of D-Ala2-GHRH-ELNN864 during gestation, injected early (D25), late (D65), or both, significantly increased piglet birth weight, which has the potential to improve piglet health and survivability. Treatment did not affect piglet weight at weaning or piglet survivability, but the study was not powered to detect these effects. Treatment increased circulating concentrations of IGF-1 in the maternal pig up to eight-fold with concentrations remaining significantly higher for at least 35-40 days post-injection (FIG. 1). The treatment transiently increased sow body weight gain, with sows injected twice during injection maintaining their weight gain through to the weaning of their litters.International Patent Application Attorney Docket No. 2920951-238977 EXAMPLE 7DOSING DURING GESTATION

[0216] Another experiment was performed to determine the effect of different dosages of the conjugated protein D-Ala2-GHRH-ELNN864 (0.05 - 0.30 mg / kg body weight) during gestation to pregnant pigs on live piglet birth weight and offspring performance (survivability and / or mortality).

[0217] The female pigs (PIC genetics) were Parity 1 -Parity 6, and both gilts and sows were used. The pigs were confirmed pregnant via ultrasound on or before D25 ± 3 days of gestation. A total of 585 gilts and sows were randomized / allotted in the study based on 117 females per treatment and 5 treatment groups. The 585 gilts and sows were obtained from four breeding / farrowing groups. The number of gilts or sows representing each parity group was as follows (one group of 195 animals and three groups of 130 animals) to achieve the total animal numbers needed:Parity 1 (G = gilts): 110 bred gilts total in randomization (25 to 35 per farrowing Group Parity 2, 3, and 4 (Y = young sows): 295 total in randomization (60 to 105 per farrowing group)Parity 5, 6, and 7 (O = older sows): 180 total in randomization (30 to 65 per farrowing group.

[0218] The number of offspring from the gilts and sows assigned to the study was estimated to be approximately 8,000 assuming 13.4 piglets per litter and 585 litters.

[0219] The pigs were included only if they were in good health, as determined by the study Investigator, based on physical examination conducted within 3 days prior to IVP and CP administration. Only animals having no “significant abnormal” health findings were enrolled in the study. Any sow(s) that became ill, injured, or develop(s) health concerns prior to enrollment considered to interfere with the study objectives were excluded from the study. Examples of exclusion criteria include pre-existing conditions (e.g., enteric disease, respiratory disease, lameness, neurological disease, septicemia), unthrifty appearance, abnormal conformation, history of treatment with any antimicrobial within 5 days of study enrollment, or greater than parity 7 at time of allotment). In addition, animals may have been excluded if their temperament is deemed to be unsuitable for the study.

[0220] Five treatment dosages of the isolated D-Ala2-GHRH-ELNN864 were evaluated: 0, 0.05, 0.10, 0.20, and 0.30 mg per kg body weight administered IM one time to confirmed pregnant swine on day 25 (± 3 days) of gestation.International Patent Application Attorney Docket No. 2920951-238977 Table 11:Treatment Compound and Dose1, mg / kg Formulation Dose Route & Number of Group Concentration Volume Location* Animals (mL)2Treated Sterile saline or buffer placebo IM, left 1 0 mg / mL 3.1 to 7.2 118 (CP) neck LSN3377957 (IVP), 0.05 mg / kg IM, left 2 3.3 mg / mL 1.9 to 4.1 117 body wt. neck LSN3377957 (IVP), 0.05 mg / kg IM, left 3 3.3 mg / mL 3.8 to 8.5 116 body wt. neck LSN3377957 (IVP), 0.20 mg / kg IM, left 4 10.36 mg / mL 2.4 to 5.4 116 body wt. neck LSN3377957 (IVP), 0.30 mg / kg IM, left 5 10.36 mg / mL 3.3 to 7.0 116 body wt. neckSow assigned to LSN3377957(IVP), 0.10 mg / kg body wt., but IM, left Deviation33.3 mg / mL 10.9 1 received a dosage of 0.17 mg / kg neckbody wt.Total = 5841Control Product (CP) or Investigational Veterinary Product (IVP) administered on Day 25 (± 3 days) of gestation.2Dose volume varied based on body weight and formulation concentration. Treatment Group 1 was administered 0.025 mL / kg body weight.3Sow 27428 inadvertently was administered two doses (3.4mL + 7.5 mL of 3.3 mg / mL IVP instead of only 3.4 mL and was excluded from the data analysis: Deviation 3).Table 12:Parity Number of Animals per Number of Animals per Treatment in Actual Number of Group Farrowing Group1,2each Farrowing Group1Treated Animals 1 (G) 25-35 5-7 110 2, 3 and 4 60-105 12-21 295 (Y)5, 6 and 7 30 to 65 6 to 13 179 (O)Total 195 animals in first farrowing 38 or 39 animals per treatment in first 584 treated but 585 in group and 130 in the other farrowing group and 25 to or 27 in the randomization three farrowing groups other three farrowing groups1Number of animals differed between the farrowing groups based on the number of available animals for each parity group represented in a farrowing group.2Numbers of animals in a parity group differed within a farrowing group due to errors identified after randomization and or administration errors (see Deviation 3, 5, 6, 7, and 12) despite being a factor of 5 in the initial randomization to ensure each treatment is equally represented in each of the parity groups for a given farrowing group.International Patent Application Attorney Docket No. 2920951-238977 RESULTSSummary of farrowing:Table 13:Number of Sows Total Total NumberNumber that Farrowed by Number of Piglet Total Number of of Treatment Group of Live Mortalities on Piglet PreAnimals or (by Parity Pigs or before Day weaning Treatment Group Treated Group)1Bom25 of age2Mortalities2751 (Control) 118 937 114 146(14 G + 38 Y + 23 O)692 (0.05 mg / kg IVP) 117 870 88 124(12 G + 32 Y + 25 O)743 (0.10 mg / kg IVP) 116 930 73 117(14 G + 38 Y + 22 O)734 (0.20 mg / kg IVP) 116 902 93 124(14 G + 37 Y + 230)705 (0.30 mg / kg IVP) 116 871 71 108(17 G + 31 Y + 220)Live births and stillborn:Table 14:Treatment Number of Live BirthsGroup per Litter1Number of Live Births as a Proportion of Total Litter Size2With Without Without Gilts Gilts With Gilts Gilts Gilts Young Old1 (Control) 11.9 13.1 0.919 0.924 0.867 0.899 2 (0.05 mg / kg12.2 13.0 0.934 0.953 0.881 0.924 IVP)3 (0.10 mg / kg12.6 12.2 0.934 0.907 0.776* 0.853* IVP)4 (0.20 mg / kg12.3 12.3 0.972* 0.907 0.850 0.881 IVP)5 (0.30 mg / kg12.3 12.9 0.888 0.919 0.908 0.914 IVP)Treatment main Treatment x Parity Group Interaction0.876 0.548 <0.001 effect P value P = 0.002International Patent Application Attorney Docket No. 2920951-238977 Including Gilts

[0221] No effect was observed in the number of live births per litter when gilts were included in the analysis with gilts included (P=0.876; number of live births per litter ranged from 11.9 for TGI (Control) to 12.6 for TG3 (0.10 mg / kg)).Excluding Gilts

[0222] No effect was observed when gilts were excluded (P=0.548; number of live births per litter ranged from 12.2 for TG3 (0.10 mg / kg) to 13.1 for Control.). The absence of a treatment effect on the number of live born pigs per litter suggests that the IVP up to 0.30 mg / kg did not impact the number of pigs born alive. Although some treatment differences were observed in the number of live births as a proportion of total litter size, the only differences were among the intermediate treatment groups, so the responses did not appear to be a typical dose response (e.g., the Gilt administered the 0.20 mg / kg IVP dosage had the highest proportion and the Old parity group had the lowest proportion).Stillborn per litter:

[0223] Summary of number of stillborn, LS means:Table 15:Treatment Group Number of Stillborn per Litter1With Gilts Without Gilts Gilts Young Old1 (Control) 0.86 0.82 1.43 1.082 (0.05 mg / kg IVP) 0.42 0.53 1.32 0.843 (0.10 mg / kg IVP) 0.71 0.95 2.82* 1.63*4 (0.20 mg / kg IVP) 0.21* 1.08 1.70 1.365 (0.30 mg / kg IVP) 1.12 0.81 0.96 0.88P value Trt x Parity Group interaction P=0.004 Treatment main effect <0.001* indicates a significant difference (P<0.05) compared to Control.International Patent Application Attorney Docket No. 2920951-238977

[0224] Summary of number of stillborn per litter relative to number of fully formed pigs (live bom plus stillborn:Table 16:Proportion of Number of Stillborn per Litter relative to Number of Fully Formed Treatment Group Pigs (Live bom plus Stillborn)1With Gilts Without Gilts Gilts Young Old Young Old 1 (Control) 0.081 0.058 0.099 0.058 0.099 2 (0.05 mg / kg IVP) 0.038 0.039 0.094 0.039 0.094 3 (0.10 mg / kg IVP) 0.051 0.069 0.195* 0.069 0.195* 4 (0.20 mg / kg IVP) 0.017* 0.080 0.123 0.080 0.123 5 (0.30 mg / kg IVP) 0.091 0.061 0.066 0.061 0.066 Trt x Parity Group P value Trt x Parity Group interaction P<0.001interaction PO.033Including Gilts

[0225] With gilts included, there was a treatment effect (P = 0.04) and a treatment x Parity Group interaction (P=0.004) for the number of stillborn / litter, so each parity group was evaluated separately.

[0226] Among the gilts, TG4 (0.20 mg / kg; 0.214 stillborn) had fewer stillborn / litter (P=0.032) than TGI (Control; 0.857 stillborn). No effect was observed among the Young sows (P>0.156). Among the Old sows, TG3 (0.10 mg / kg; 2.82 stillborn) had more stillborn / litter compared to TGI (Control; 1.43 stillborn).

[0227] With Gilts included, there was a treatment x Parity Group interaction (P<0.001) for the proportion of stillborn relative to live plus stillborn, so each parity group was evaluated separately.

[0228] Among the gilts, TG4 (0.20 mg / kg; 0.017) had a lower (P=0.013) proportion of stillborn relative to live born + stillborn than TGI (Control; 0.081).

[0229] Among the Young sows, No effect was observed (P>0.157); range 0.039 to 0.080).

[0230] Among the Old sows, TG3 (0.10 mg / kg; 0.195) had a higher (P0.001) proportion of stillborn relative to live born + stillborn than TGI (Control; 0.099).Excluding Gilts

[0231] With Gilts excluded, there was a treatment effect (PO.OOl). The only treatment difference (P=0.012) observed in for the number of stillborn was between TG3 (0.10 mg / kg; 1.63 stillborn) and TGI (Control; 1.08 stillborn).International Patent Application Attorney Docket No. 2920951-238977

[0232] With Gilts excluded, there was a treatment effect (p < 0.01) and treatment x Parity Group interaction (P=0.033) for the proportion of stillborn relative to live plus stillborn, so each parity group was evaluated separately.

[0233] Among the Young sows, No effect was observed (P>0.157); range 0.039 to 0.080).

[0234] Among the Old sows, TG3 (0.10 mg / kg; 0.195) had a higher (P0.001) proportion of stillborn relative to live born + stillborn than TGI (Control; 0.099).

[0235] Although there were some treatment differences in both the number of stillborn per litter and the proportion of stillborn per litter relative to fully formed pigs, there did not appear to be a consistent effect with increasing dosage nor across the parity groups. The Old parity group treated with 0.10 mg / kg IVP (TG3) had both the highest number as well as proportion of stillborn per litter; however, Gilts receiving 0.20 mg. kg IVP (TG4) had the lowest number and proportion of stillborn per litter. The fact that the treatment differences were only observed among the intermediate dosages with opposite effects relative to control observed in gilts compared to older sows, suggests that may have been a result of something in particular with the Old parity group receiving 0.20 mg / kg IVP. This is further supported by the fact that no treatment or parity differences were observed in the number of live births per litter (P>0.548; Table 12-2) and that Old parity sows in all treatment groups had higher numbers of stillborn per litter (and highest proportions of stillborn) than Gilts or Young parity sows with the exception of TG5 in which Gilts were greater than the Old parity group. In addition, the data shows the number of stillborn per litter for the Control (TGI) Old parity sows ranged from 0 to 6 while the number of stillborn per litter for TG3 (0.10 mg / kg IVP ) ranged from 0 to 9 indicating the number of stillborn per litter can be quite variable within a treatment group-parity group combination.Pig mortality and survivability:Piglet mortality and survivability at 5 day of age:

[0236] The number of piglets alive at 5 days of age and the number of piglet mortalities on or before 5 days of age are summarized in Table below.International Patent Application Attorney Docket No. 2920951-238977 Table 17:Number of Live Piglets per Number of Piglet Mortalities per Treatment Group Litter at 5 Days of Age1Litter on or before 5 Days of Age2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 10.6 11.7 1.44 1.72 2 (0.05 mg / kg IVP) 11.0 11.6 1.19 1.36 3 (0.10 mg / kg IVP) 11.7 11.4 1.03 1.04* 4 (0.20 mg / kg IVP) 11.1 10.9 1.25 1.35 5 (0.30 mg / kg IVP) 11.3 11.9 1.01 1.05* Treatment main effect P value 0.492 0.631 0.195 0.012* indicates a significant difference (P<0.05) compared to Control.

[0237] The proportion of piglets alive at 5 days of age relative to the number of piglets born alive and the proportion of piglet mortalities on or before 5 days of age relative to the number of piglets born alive are summarized in Table below:Table 18:Proportion of Live Piglets per Litter at 5 Proportion of Piglet Mortalities per Treatment Group Days of Age1Litter on or before 5 Days of Age2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 0.881 0.871 0.119 0.129 2 (0.05 mg / kg IVP) 0.902 0.896 0.098 0.104 3 (0.10 mg / kg IVP) 0.919 0.916* 0.081 0.084* 4 (0.20 mg / kg IVP) 0.899 0.890 0.101 0.110 5 (0.30 mg / kg IVP) 0.918 0.919* 0.082 0.081*Treatment main Treatment main effect Treatment main effect Treatment main effect P value effect P= 0.085 P= 0.019 P= 0.082P= 0.019* indicates a significant difference (P<0.05) compared to Control.Including Gilts

[0238] No effect was observed for the number of piglets alive at 5 days of age (P=0.492), or the number of piglet mortalities that occurred on or be 5 days of age (P=0.195). No effect was observed for neither the proportion of piglets alive at 5 days of age relative to the number of live born piglets (P=0.085), or the proportion of piglets that died on or before 5 days of age (P=0.085).International Patent Application Attorney Docket No. 2920951-238977 Excluding Gilts

[0239] No effect was observed for the number of piglets surviving at Day 5 of age (P=0.631). However, TG3 (0.10 mg / kg IVP) and TG5 (0.30 mg / kg IVP) exhibited fewer piglet mortalities after 5 days of age than TGI (Control; P<0.004).

[0240] TG3 (0.10 mg / kg) and TG5 (0.30 mg / kg) each had higher (P<0.006) proportions of piglets surviving at Day 5 of age relative to the number of live born piglets than TGI (Control). As expected, based on the higher proportion of piglets surviving through 5 days of age, TG3 (0.10 mg / kg) and TG5 (0.30 mg / kg) each also had lower (P<0.006) proportions of piglet mortalities on or before Day 5 of age relative to the number of live born piglets than TGI (Control).Pre-weaning piglet mortality and number piglets weaned:

[0241] Table below shows the number of pre-weaning mortalities both as a count per litter and as a proportion of the number of live births. The proportion of pre-weaning mortalities relative to the number of live births was lower (P=0.002) in TG5 (30 mg / kg IVP) than in TGI (Control) when gilts were excluded, but no differences were observed in the Young sows or in the evaluation of the number of pre-weaning mortalities per litter (P>0.056).Table 19:Number of Pre-weaning Mortalities Per Proportion of Pre-weaning Mortalities Treatment Group Litter1Relative to Number of Live Births2With Gilts Without Gilts With Gilts Without Gilts Young Old 1 (Control) 1.95 2.13 0.162 0.128 0.196 2 (0.05 mg / kg IVP) 1.70 1.93 0.140 0.146 0.150 3 (0.10 mg / kg IVP) 1.69 1.61 0.133 0.090 0.184 4 (0.20 mg / kg IVP) 1.71 1.75 0.139 0.120 0.170 5 (0.30 mg / kg IVP) 1.57 1.43 0.28 0.117 0.104* Treatment main Treatment main Treatment main Trt x Parity Group P valueeffect P= 0.589 effect P= 0.065 effect P= 0.372 interaction P<0.028* indicates a significant difference (P<0.05) compared to Control.

[0242] The number of pigs weaned per litter (Table below) was higher among the gilts in TG3 (0.10 mg / kg IVP) and TG4 (0.20 mg / kg IVP), but No effect was observed in the Young or Old parity groups regardless of whether the gilts were included or exclude (P>0.057).International Patent Application Attorney Docket No. 2920951-238977 Table 20:Treatment Group Number of Pigs Weaned per Litter1With Gilts Without Gilts Gilts Young Old Young Old1 (Control) 7.43 10.50 9.23 10.50 9.23 2 (0.05 mg / kg IVP) 9.00 9.06 9.32 9.06 9.32 3 (0.10 mg / kg IVP) 10.70* 10.80 8.19 10.80 8.19 4 (0.20 mg / kg IVP) 9.86* 10.40 8.65 10.40 8.65 5 (0.30 mg / kg IVP) 7.71 9.45 10.80 9.45 10.80Trt x Parity Group interaction P value Trt x Parity Group interaction P=0.001P=0.007* indicates a significant difference (P<0.05) compared to Control.

[0243] With gilts included as well as gilts excluded, Young TG3 sows, TG2 Old sows, and TG5 Old sows had a higher proportions of pigs weaned relative the number of live pigs in the litter than their respective Controls (P<0.050; Table below).Table 21:Proportion of Number of Pigs Weaned per Litter Relative to Number of Live Pigs Treatment Group Bom1With Gilts Without Gilts Gilts Young Old Young Old1 (Control) 0.819 0.864 0.775 0.864 0.775 2 (0.05 mg / kg IVP) 0.871 0.829 0.844* 0.829 0.844* 3 (0.10 mg / kg IVP) 0.852 0.905* 0.785 0.905* 0.785 4 (0.20 mg / kg IVP) 0.857 0.876 0.812 0.876 0.812 5 (0.30 mg / kg IVP) 0.804 0.867 0.885* 0.867 0.885* Trt x Parity Group interaction P value Trt x Parity Group interaction P=0.003P=0.002* indicates a significant difference (P<0.05) compared to Control.Mortality: With Gilts included, No effect was observed in the proportion of piglets surviving through 5 days of age or piglets dying on or before 5 days of age (e.g., early mortalities), one of the primary variables. However, with Gilts excluded, the proportion of piglets alive at 5 days of age (survivability) was higher for TG3 (0.10 mg / kg IVP) and TG5 (0.30 mg / kg IVP) with TG2 and TG4 also having numerically improved survivability compared to Control. TG3 and TG5 also had fewer early mortalities compared to Control. With fewer early mortalities in TG3 and TG5,International Patent Application Attorney Docket No. 2920951-238977 the proportion of early mortalities relative to live bom pigs was also lower in TG3 and TG5 compared to TGI (Control). The treatment with the IVP appears to have resulted in lower early mortality rates among the treated group even though only TG3 and TG5 were significantly better than the TGI (Control).Piglet weights:

[0244] The average birth weight of live births per litter and the total weight of live births per litter are summarized in Table below:Table 22:Average Live Piglet Birth Total Litter Birth Weight for Live Treatment Group Weight per Litter, kg1Piglets, kg2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 1.33 1.32 15.9 17.5 2 (0.05 mg / kg IVP) 1.40 1.39 16.3 17.4 3 (0.10 mg / kg IVP) 1.41 1.45* 17.7 17.8 4 (0.20 mg / kg IVP) 1.41 1.46* 16.5 17.2 5 (0.30 mg / kg IVP) 1.42 1.46* 17.1 18.5 Treatment main effect P value 0.743 0.020 0.289 0.620* indicates a significant difference (P<0.05) compared to Control.Including Gilts

[0245] No effect was observedeffect was seen in the average weight of live births / litter (P=0.397) or the total weight of live births / litter (P=0.146).Excluding Gilts

[0246] The average weight of live birth weights (range 1.32 to 1.46 kg / pig) were greater (P<0.011) for TG3 (0.10 mg / kg), TG4 (0.20 mg / kg) and TG5 (0.30 mg / kg) compared to the Control (1.32 kg). There was no difference between TGI (Control; 1.32kg) and TG2 (0.05 mg / kg; 1.39 kg) (p = 0.159). No effect was observed in the total weight of live births / litter (P=0.516; range 17.2 to 18.5 kg).Birth weight of stillborn:

[0247] The average birth weight of stillborn piglets per litter and the total weight of stillborn piglet birth weights per litter are presented in Table below:International Patent Application Attorney Docket No. 2920951-238977 Table 23:Average Stillborn Piglet Birth Total Litter Weight for Stillborn Treatment Group Weight per Litter, kg1Piglets, kg2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 1.10 1.05 2.19 1.90 2 (0.05 mg / kg IVP) 1.26 1.23 1.79 1.97 3 (0.10 mg / kg IVP) 1.27 1.21 2.57 2.75 4 (0.20 mg / kg IVP) 1.30 1.20 2.23 2.59 5 (0.30 mg / kg IVP) 1.10 1.11 2.00 1.96 Treatment main effect P value 0.152 0.259 0.422 0.0625* indicates a significant difference (P<0.05) compared to Control.

[0248] No effect was observed for either the average birth weight of stillborn piglets or the total weight of all stillborn piglets per litter regardless of whether Gilts were included or excluded (P>0.062).Birthweight by weight classification:

[0249] Birth weights of the pigs bom alive were further classified as being either Light (<1.13 kg) or Heavy (> 1.13 kg) and additional statistical analyses were conducted to evaluate the number of these pigs per litter in table below:Table 24:Number of Piglets with a Birth Number of Piglets with a Birth Weight Treatment Group Weight < 1.13 kg1> 1.13 kg2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 3.86 4.01 8.08 9.22 2 (0.05 mg / kg IVP) 3.96 3.94 8.15 9.01 3 (0.10 mg / kg IVP) 3.21 2.90* 9.49* 9.60 4 (0.20 mg / kg IVP) 3.71 3.12* 8.46 9.11 5 (0.30 mg / kg IVP) 3.06* 2.87* 9.20* 10.00 Treatment main effect P value 0.022 <0.001 0.029 0.397* indicates a significant difference (P<0.05) compared to Control.International Patent Application Attorney Docket No. 2920951-238977 as well as the proportion of each weight classification relative to the live births per litter in Table below:Table 25:Proportion of Piglets with a Proportion of Piglets with a Birth Treatment Group Birth Weight < 1.13 kg1Weight > 1.13 kg2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 0.323 0.303 0.677 0.697 2 (0.05 mg / kg IVP) 0.327 0.304 0.673 0.696 3 (0.10 mg / kg IVP) 0.253* 0.232* 0.747* 0.768* 4 (0.20 mg / kg IVP) 0.305 0.255* 0.695 0.745* 5 (0.30 mg / kg IVP) 0.249* 0.222* 0.751* 0.778* Treatment main effect P value <0.001 <0.001 <0.001 <0.001* indicates a significant difference (P<0.05) compared to Control.Light Birth Weight Classification

[0250] Including Gilts - Piglets with birth weights <1.13 kg

[0251] Only TG5 (0.30 mg / kg) had fewer numbers of pigs with live birth weights of 1.13 kg or less (P=0.015) compared to TGI (Control). Only TG3 (0.10 mg / kg) and TG5 (0.30 mg / kg) had lower (P=0.002) proportions of the litter weighing of 1.13 kg or less at birth than TGI (Control).

[0252] Excluding Gilts - Piglets with birth weights <1.13 kg TG3, TG4, and TG5 all had fewer numbers of pigs with live birth weights of 1.13 kg or less (P<0.013) compared to TGI (Control). TG3, TG4, and TG5 all had lower proportions of pigs with live birth weights of 1.13 kg or less (P<0.044) compared to TGI (Control).Heavy Birth Weight Classification

[0253] Including Gilts - Piglets with birth weights >1.13 kg

[0254] TG3 (0.10 mg / kg) and TG5 (0.30 mg / kg) had greater numbers of live pigs with birth weights over 1.13 kg (P<0.039) compared to TGI (Control). TG3 (0.10 mg / kg) and TG5 (0.30 mg / kg) had higher (P=0.002) proportions of the litter weighing greater than 1.13 kg at birth than TGI (Control).

[0255] Excluding Gilts - Piglets with birth weights >1.13 kg

[0256] When gilts were excluded, no treatment differences compared to Control were observed in the number with live birth weights over 1.13 kg (P=0.397). TG3 (0.10 mg / kg), TG4 (0.20 mg / kg) and TG5 (0.30 mg / kg) all had higher (P<0.044) proportions of the piglets in a litter with weightsInternational Patent Application Attorney Docket No. 2920951-238977 greater than 1.13 kg at birth than TGI (Control). TG2 (0.05mg / kg) was not different (p = 0.970) from TGI (Control).Weaning weights and average daily gain from birth to weaning:

[0257] Weaning weights per pig and total per litter are summarized in Table below:Table 26:Average Piglet Weaning Weight,Treatment Group kg1Total Litter Weaning Weight, kg2With Gilts Without Gilts With Gilts Without Gilts 1 (Control) 5.59 5.59 52.6 58.6 2 (0.05 mg / kg IVP) 5.82 5.83 56.2 58.0 3 (0.10 mg / kg IVP) 5.62 5.90 57.5 59.0 4 (0.20 mg / kg IVP) 5.60 5.84 55.8 58.3 5 (0.30 mg / kg IVP) 5.52 5.70 53.8 60.4 Treatment main effect P value 0.601 0.557 0.621 0.976* indicates a significant difference (P<0.05) compared to Control.and the average daily gain (kg / day / animal) from birth to weaning are summarized in Table below:Table 27:Treatment Group Average Daily Gain from Birth to Weaning, kg / day / pig1With Gilts Without Gilts1 (Control) 0.208 0.2082 (0.05 mg / kg IVP) 0.215 0.2143 (0.10 mg / kg IVP) 0.204 0.2164 (0.20 mg / kg IVP) 0.199 0.2095 (0.30 mg / kg IVP) 0.197 0.203Treatment main effect P value 0.139 0.571* indicates a significant difference (P<0.05) compared to Control.

[0258] No effect was observed in the weaning weights of individual pigs or of the entire litter regardless of whether gilts were included or excluded (P>0.557). Similarly, no differences were observed in the average daily gain from birth to weaning regardless of whether gilts were included or excluded (P>0.139).International Patent Application Attorney Docket No. 2920951-238977 Weaning to end of nursery average daily gain:

[0259] The average daily gain (kg / day / animal) from weaning to the end of nursery are summarized in Table below:Table 28:Treatment Group Average Daily Gain from Birth thru Nursery, kg / day / pig1With Gilts Without Gilts1 (Control) 0.256 0.2422 (0.05 mg / kg IVP) 0.253 0.2773 (0.10 mg / kg IVP) 0.264 0.2784 (0.20 mg / kg IVP) 0.235 02565 (0.30 mg / kg IVP) 0.240 0.255Treatment main effect P value 0.736 0.671* indicates a significant difference (P<0.05) compared to Control.

[0260] No differences were observed in the average daily gain from weaning through nursery regardless of whether gilts were included or excluded (P>0.671). However, results for the average daily gain from weaning through nursery should be interpreted with extreme caution for several reasons. One reason is because the piglets that were weighed at the end of the nursery period did not represent all farrowing groups. Another reason is that while the group of pigs sent to the nursery were sent at the same time and were primarily from one farrowing group, pigs from earlier farrowing groups were also included because these older pigs were slow growing pigs or “fall offs” which had been transferred to another sow during lactation to aid in their growth and remained in the farrowing rooms until a majority of the later farrowing group reached their normal weaning age. Thus, the ending nursery weights included weights of pigs that may have been 1 to 2 weeks older than most pigs because the study site had identified them as slow growing pigs, and no attempt was made to equalize the number of these slow growing pigs across treatment groups or parity groups. In addition, because the pigs were transferred to a commercial swine nursery farm along with other non-study weaned pigs, some of the pigs sent to the nursery may not have been found on the end of nursery weigh date (approximately 655 pigs had end of nursery weights recorded).Piglet weights:

[0261] When gilts were included in the various weight analyses, few treatment differences were observed. This may have been in part due to the lower number of gilts assigned to the study compared to the Younger sows (Parity 2, 3, and 4) and Older sows (Parity 5, 6, and 7). However,International Patent Application Attorney Docket No. 2920951-238977 when the analyses only included the Young and Old sow parity groups, a consistent and modest increase of approximately 0.14 kg / pig in average piglet birth weight was observed for the IVP for the dosages of 0.10 mg / kg up to 0.30 mg / kg (TG3, TG, and TG5) even though the total litter birth weights did not differ between the treatment groups. The evaluation of the different birth weight classifications (e.g., <1.13 kg / pig and >1.13 kg / pig) indicated that treatment with at least 0.10 mg / kg IVP reduced the number light birth weight pigs as well as the proportion of the litter represented by light birth weight pigs.

[0262] Treatment of the sow with the IVP had little impact on the total litter birth weight, total litter weaning weight or average piglet weaning weights. However, this study was not powered to detect differences in litter birth weights or weaning weights. It is possible that larger study evaluating fewer dosages may detect any impact on the total litter weight or weaning weights.Blood results:

[0263] The isolated D-Ala2-GHRH-ELNN864 concentrations were dose dependent and decreased in a similar manner for all treatment groups. The treatment with the isolated D-Ala2-GHRH-ELNN864 resulted in a similar IGF-1 concentrations at 7 days post treatment with TG2 (0.05 mg / kg) declining more rapidly than the other three treatment groups. These results demonstrated that the isolated D-Ala2-GHRH-ELNN864 administered was active based on the IGF-1 concentrations with the higher doses having more sustained elevations in IGF-1 as well the isolated D-Ala2-GHRH-ELNN864.Summary:

[0264] This study was intended to evaluate the efficacy of different dosages of the isolated D-Ala2-GHRH-ELNN864 administered to pregnant sows primarily based on live piglet birth weights and piglet mortality at 5 days of age. As that Gilts (parity 1 sows) increased the variability of the evaluations, the following summary will focus on just the Young and Old Parity groups.

[0265] With Gilts excluded, it was demonstrated that the treatment did not impact the number of live piglets born; however, TG3, TG4, and TG5, had on average heavier piglets at birth compared to Control (FIG. 3). As shown in FIG. 3, while dosages of 0.1 mg / kg and 0.3 mg / kg resulted in a shift in birth weight distribution of piglets vs. control similar to Example 1, no difference in shift is seen between O.lmg / kg and 0.3 mg / kg isolated D-Ala2-GHRH-ELNN864.

[0266] TG3, TG4 and TG5 had greater proportions of piglets per litter above 1.13 kg compared to Control. Conversely, TG3, TG4, and TG5 had fewer light weight piglets (e.g., <1.13 kg) born per litter and a lower proportion of light weigh piglets than the Control (FIG. 4A). Compared toInternational Patent Application Attorney Docket No. 2920951-238977 Controls, in sows treated with 0.1, 0.2, and 0.3 mg / kg GHRH analog-ELNN, the proportions of live light weight pigs bom in a litter (< 2.5 lbs (~1.13kg)) was lower and normal / heavy weight live pigs (> 2.5 lb) was greater (FIG. 4B). TG3 had a lower proportion of live births (and a higher number and proportion of stillborn among Older sows) relative to the total litter size than Control which was most likely due to a higher incidence of stillborn in TG3 among the Older sows compared to Control; However, TG2 and TG5 had numerically lower number of stillborn than Control. The absence of a dose response suggests that the number of stillborn per litter in TG3 was likely due to conditions other than the treatment or dose.

[0267] The proportion of mortalities in a litter as well as the number of mortalities in a litter prior to Day 5 of age was lower in TG3 and TG5 than Control (FIG. 5). Only the old sows of TG5 had a lower proportion of preweaning mortalities than Control with numerically lower proportions of preweaning mortalities observed in all treatment groups except the young sows of TG2. While there were no significant treatment differences in the number of preweaning mortalities or the number of piglets weaned per litter, TG2, TG3, TG4, and TG5 all had numerically lower preweaning mortalities per litter. Thus, compared to Controls, the number of piglet deaths was lower through Day 5 of age and to weaning for sows treated with 0.1 and 0.3 mg / kg GHRH analog-Y-ELNN (FIG. 5).

[0268] When evaluating the piglets weaned, TG3 had a higher proportion of piglets weaned than Control among the Young sows while among the older sows TG2 and TG5 had higher proportions of piglets weaned than Control.

[0269] Piglet weights at weaning and average daily gain from birth to weaning were not different for the treated groups compared to Control. However, the Control group had numerically lower weaning weights than TG3.

[0270] Evaluation of weight gains from weaning through nursery did not differ between treatment groups, but interpretation of the weight gains during the nursery phase should be cautiously interpreted because the group of pigs sent to the nursery included pigs from other farrowing groups as well as not all pigs from a single farrowing group.

[0271] Table below provides a general summary of the results for the three primary variables and other variables that were considered when determining the lowest effective dose (excluding gilts):International Patent Application Attorney Docket No. 2920951-238977 Table 29:Treatment GroupsTG2 TG3 TG4 TG5 Variable Description (0.05 mg / kg) (0.10 mg / kg) (0.20 mg / kg) (0.30 mg / kg) f Live piglet birth weight NST T* T* T* f Proportion live pigs at 5 days of ageNST T* NST T* relative to live birthsf Proportion of mortalities on or before 5NST 1* NST 1 days of age relative to live birthsNumber of live births NST NST NST NST Number of stillborn NST T* NST NST Proportion of stillborn relative to fully NST Young NST Young NST Young NST Young formed pigs NST Old T*01d NST Old NST Old Proportion of live births relative to totalNST 1* NST 1* litter sizeNumber of piglet mortalities on or before 5NST 1* NST 1* days of ageNumber of preweaning mortalities NST NST NST NST NST Young NST Young NST Young NST Young Number of weaned pigsNST Old NST Old NST Old NST Old Proportion of preweaning mortalities NST Young NST Young NST Young NST Young relative to live births NST Old NST Old NST Old l* Old Proportion of pigs weaned relative to live NST Young T* Young NST Young NST Young births T* 01d NST Old NST Old T*01d Number of light (<1.13 kg) birth weightNST 1* 1* 1* PigsProportion of light (<1.13 kg) birth weightNST 1* 1* 1* pigs relative to live birthsNumber of heavy (>1.13 kg) birth weightNST NST NST NSTPigsProportion of heavy (>1.13 kg) birth weightNST T* T* T* pigs relative to live birthsf Indicates a primary variable;T* indicates significantly higher than Control1 * indicates significantly lower than ControlNST = Not significantly different from Control, but numerically lower than Control;NST = Not significantly different from Control, but numerically higher than Control;International Patent Application Attorney Docket No. 2920951-238977

[0272] Three related variables showed significant treatment differences from Control in an undesirable direction. These three variables (Number of stillborn, Proportion of stillborn relative to fully formed pigs, and Proportion of live births relative to total litter size) were all related to the number of stillborn observed in the TG3 group, but the effect was not considered to be related to the dose since TG2 and TG5 had numerically desirable results for each of these three variables.

[0273] This study demonstrated that due to an increased variability, inclusion of gilts in the evaluation creates issues on evaluating the efficacy, so separate studies should be considered. The number of gilts included is low and variation in gilts is high, so this experiment was not the right design to demonstrate efficacy for gilts.

[0274] Treatment of sows, excluding gilts, with the isolated D-Ala2-GHRH-ELNN864 was effective in increasing the live piglet birth weight as well as reducing piglet mortality that occurs by 5 days of age. Doses of 0.10 mg per kg of sow or higher demonstrated more consistent improvements.EXAMPLE 825 mg DOSAGE

[0275] This experiment was to determine the effectiveness of a fixed dose of 25 mg of isolated D-Ala2-GHRH-ELNN864 administered on D28 of gestation to pregnant sows as measured by live piglet birth weight and offspring performance.

[0276] The sows were parity 2-parity 6, and were confirmed to be pregnant via ultrasound on D28 of gestation (± 3 days). The sows were confirmed to be in good health, as determined by the dispenser, based on physical examination conducted within 3 days prior to IVP administration. Only animals having no “significant abnormal” health findings were enrolled in the study. Any sow(s) that becomes ill, injured, or develop(s) health concerns prior to enrollment considered to interfere with the study objectives were excluded from the study. Examples of exclusion criteria included pre-existing conditions (e.g., enteric disease, respiratory disease, lameness, neurological disease, septicemia), unthrifty appearance, abnormal conformation, history of treatment with any antimicrobial within 5 days of study enrollment, bred gilts, or greater than parity 6 at time of allotment. In addition, animals may be excluded if their temperament was deemed to be unsuitable for the study.

[0277] A total of 232 sows (ACMC genetics) were used in the study, 117 and 115 in the Control and Test article group, respectively. A total of 218 from 232 sows farrowed. The 232 sows were obtained from five breeding / farrowing groups (51, 58, 57, 53 and 13 females in group 1, 2, 3, 4 and 5, respectively). Within each of the breeding / farrowing groups the number of sowsInternational Patent Application Attorney Docket No. 2920951-238977 representing each parity group (Parity 2 to 6) in the study depended on the demography of that group. In total, 52, 48, 50, 45 and 37 females of parity 2, 3, 4, 5 and 6, respectively, were included. The sows were further divided into two age groups, Y and O: Parity 2 and 3 sows represented the younger sows (Y) and Parity 4, 5 and 6 sows represented the older sows (O). Offspring: During the study, the number of offspring from the sows assigned to the study were 2930 born alive (3265 total born); 13.44 born alive piglets per litter and 218 litters.

[0278] A fixed dose of the isolated D-Ala2-GHRH-ELNN864 of 25 mg / sow was administered IM one time on D28 + / - 3 days gestation. The treated group was evaluated compared to no treatment.Table 30:Treatment Compound and Formulation Dose Volume Route & Number of Group Dose1, mg / kg Concentration2(mL)2Location* Animals1 No Treatment NA NA NA 1174.3 ml / sowbased onLSN3377957 (IVP),2 5.8 mg / ml formulation IM, left neck 11525.00 mg / sowconcentration of5.8 mg / mlTotal = 232Primary Continuous Variables

[0279] Live Piglet Average Birth Weight was not different between Treated (1.189 kg) and Control (1.158 kg) group (p = 0.2956)Primary Discrete Variables

[0280] Piglet Survivability at Day 5 was significantly better in Treated group (86.1%) compared to Control group (81.8%) (p = 0.0019). There was a Parity effect (p < 0.0001) but no Parity x Treatment effect (p = 0.7180) with higher survival rates in the Younger sows (87.0%) compared to the Older sows (80.7%).

[0281] Also Piglet Survivability at Weaning was significantly better in Treated group (78.1%) compared to Control group (74.5%)(p = 0.0231). There was a Parity effect (p < 0.0001) but no Parity x Treatment effect (p = 0.8734) with higher survival rates in the Younger sows (79.9%) compared to the Older sows (72.4%).International Patent Application Attorney Docket No. 2920951-238977 Secondary Continuous Variables

[0282] Live Piglet Litter Birth Weight was not different between Treated group (15.881 kg) and Control group (15.514 kg) (p = 0.4581). There tended to be a parity effect (p = 0.0939) where the litters of the Younger sows were heavier than those of the Older sows.

[0283] Stillborn Piglets Litter Birth Weight was not different between Treated group (1.292 kg) and Control group (1.066kg) (p = 0.3364). There was a parity effect (p = 0.0004) where the total dead born weight of the litters of the Younger sows (0.755 kg) were lower than those of the Older sows (1.602kg).

[0284] Stillborn Piglet Average Birth Weight was not different between Treated group (0.797 kg) and Control group (0.957 kg) (p = 0.7096). There tended to be a parity x treatment effect (p = 0.0583) but not significant within both age parity groups.

[0285] Total Litter Birth Weight of Fully Formed Piglets was not different between Treated group (17.173 kg) and Control group (16.580 kg) (p = 0.2640).

[0286] Average Birth Weight of Fully Formed Piglets was not different between Treated group (1.172 kg) and Control group (1.148 kg) (p = 0.4210).

[0287] Total Litter Weaning Weight was not different between Treated group (66.439kg) and Control group (63.245kg) (p = 0.2909).

[0288] Average Piglet Weaning Weight per Litter was not different between Treated group (6.317kg) and Control group (6.306kg) (p = 0.9426). There tended to be a parity effect (p = 0.0533) with Older sows weaning heavier pigs than Younger sows.

[0289] Average Daily Gain (ADG) of Live Piglets (Birth to Weaning by birth sow) was not different between Treated group (0.201kg / animal / day) and Control group (0.201kg / animal / day) (p = 0.9371). There was a parity effect (p = 0.0457) with piglets from Older sows having higher ADG (0.206 kg / animal / day) compared to piglets from Younger sows (0.196kg / animal / day).

[0290] Average Rectal Temperature was significantly higher in Treated group (38.491°C) compared to Control group (38.281°C) (p = 0.0282). There was a parity effect (p = 0.0069) where the total Rectal Temperature of the piglets of the Younger sows (38.515°C) was higher than those of the piglets of the Older sows (38.256°C). There was no treatment x parity effect.Secondary Discrete VariablesDiscrete variables evaluated as counts- Younger and Older sows

[0291] Number of Total Born per litter was not different between Treated group (14.91) and Control group (14.93) (p = 0.9651).International Patent Application Attorney Docket No. 2920951-238977

[0292] Number of Piglets Born Alive per litter was not different between Treated group (13.39) and Control group (13.53) (p = 0.7881).

[0293] Number of Piglets Born Alive < 1.13kg per litter was significantly lower for Treated group (5.81) compared to Control group (6.57) (p = 0.0274). There was a parity effect (p = 0.0129) where Younger sows (5.77) had less piglets < 1.13kg than the Older sows (6.62). There was no treatment x parity effect.

[0294] Number of Piglets Born Alive > 1.13kg per litter was not different between Treated group (7.53) compared to Control group (7.05) (p = 0.1922). There was a parity effect (p = 0.0071) where Younger sows (7.80) had more piglets > 1.13kg than the Older sows (6.80). There was no treatment x parity effect.

[0295] Number of Stillborn Piglets per litter was not different between Treated group (1.19) compared to Control group (1.04) (p = 0.3201). There was a parity effect (p < 0.0001) where the number of stillborn piglets of the Younger sows (0.74) was lower than for the piglets of the Older sows (1.66).

[0296] Number of Survivability on Day 5 per litter was not different between Treated group (11.49) compared to Control group (11.11) (p = 0.4043). There was a parity effect (p = 0.0336) where survivability of the piglets of the Younger sows (11.80) was higher than those of the piglets of the Older sows (10.82). There was no treatment x parity effect.

[0297] Number of Piglets Weaned per litter was not different between Treated group (10.42) and Control group (10.12) (p = 0.4824). There was a parity effect (p = 0.0096) where survivability of the piglets of the Younger sows (10.85) was higher than those of the piglets of the Older sows (9.71). There was no treatment x parity effect.

[0298] Number of Mortality at Weaning per litter was significantly lower for Treated group (2.92) compared to Control group (3.47) (p = 0.0272). There was a parity effect (p < 0.0001) where Mortality of the piglets of the Younger sows (2.73) was lower than those of the piglets of the Older sows (3.71). There was no treatment x parity effect.

[0299] Number of dead piglets < 1.13kg until Weaning per litter was significantly lower for Treated group (2.14) compared to Control group (2.72) (p = 0.0081). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (2.01) was lower than those of the piglets of the Older sows (2.88). There was no treatment x parity effect.

[0300] Number of dead piglets > 1.13kg until Weaning per litter was not different between Treated group (0.78) and Control group (0.75) (p = 0.8115).

[0301] Number of crushed piglets until Weaning per litter was not different between Treated group (1.15) and Control group (1.16) (p = 0.9202). Also when divided up into two groups, < or >International Patent Application Attorney Docket No. 2920951-238977 1.13kg and < or > 37.74°C RT there was no difference between Treated and Control group. For piglets < 1.13kg and piglets > 37.74°C RT there tented to be a parity effect (p = 0.0998) and (p = 0.0505) always with lower numbers for the Younger sows. Number of piglets crushed that had an empty stomach and signs of emaciation was not different, nor for the piglets < 1.13 kg (p = 0.6030) nor for the piglets > 1.13 kg (p = 0.3558). Number of piglets crushed with empty stomach and signs of emaciation was not different between treatment and control both for pigs with RT < 37.74°C (p = 0.3226). Number of piglets crushed with empty stomachs and emaciation <1.13 kg irrespective whether the RT was < or > 37.74 °C was not different between treatment and control (p = 0.5526 for < 37.74°C and p = 0.8404 for > 37.74°C).

[0302] Number of piglets that starved until Weaning per litter was significantly lower for Treated group (0.52) compared to Control group (0.74) (p = 0.0447). There was a parity effect (p = 0.0046) where the number of these piglets of the Younger sows (0.48) was lower than those of the piglets of the Older sows (0.80). There was no treatment x parity effect.

[0303] Number of piglets <1.13 kg that starved until Weaning per litter tended to be lower for Treated group (0.44) compared to Control group (0.64) (p = 0.0516). There was a parity effect (p = 0.0015) where the number of these piglets of the Younger sows (0.39) was lower than those of the piglets of the Older sows (0.73). There was no treatment x parity effect.

[0304] Number of piglets >1.13 kg that starved until Weaning per litter was not different between Treated group (0.08) and Control group (0.09) (p = 0.6735).

[0305] Number of piglets that died and had signs of emaciation per litter was significantly lower for Treated group (1.86) compared to Control group (2.65) (p = 0.0002). There was a parity effect (p = 0.0002) where the number of these piglets of the Younger sows (1.86) was lower than those of the piglets of the Older sows (2.66). There was no treatment x parity effect.

[0306] Number of piglets <1.13 kg that died and had signs of emaciation per litter was significantly lower for Treated group (1.66) compared to Control group (2.38) (p = 0.0004). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (1.64) was lower than those of the piglets of the Older sows (2.42). There was no treatment x parity effect.

[0307] Number of piglets >1.13 kg that died and had signs of emaciation per litter not different between Treated group (0.20) and Control group (0.27) (p = 0.3150).

[0308] Number of piglets that died within 2 days and had empty stomachs per litter was significantly lower for Treated group (1.07) compared to Control group (1.49) (p = 0.0078). There tended to be a parity effect (p = 0.0867) where the number of these piglets of the Younger sows (1.14) was lower than those of the piglets of the Older sows (1.41). There was no treatment x parity effect.International Patent Application Attorney Docket No. 2920951-238977

[0309] Number of piglets <1.13 kg that died within 2 days and had empty stomachs per litter was significantly lower for Treated group (0.93) compared to Control group (1.37) (p = 0.0035). There tended to be a parity effect (p = 0.0824) where the number of these piglets of the Younger sows (1.01) was lower than those of the piglets of the Older sows (1.27). There was no treatment x parity effect.

[0310] Number of piglets >1.13 kg that died within 2 days and had empty stomachs per litter was not different between Treated group (0.14) and Control group (0.12) (p = 0.6984).

[0311] Number of piglets with Rectal Temperature < 37.74°C per litter was significantly lower for Treated group (2.05) compared to Control group (2.82) (p = 0.0006). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (2.22) was lower than those of the piglets of the Older sows (3.56). There was no treatment x parity effect.

[0312] Number of piglets with Rectal Temperature > 37.74°C per litter was not different between Treated group (11.31) and Control group (10.71) (p = 0.1891). There was a parity effect (p = 0.0087) where the number of these piglets of the Younger sows (1162) was higher than those of the piglets of the Older sows (10.42). There was no treatment x parity effect.

[0313] Number of piglets that died with Rectal Temperature < 37.74°C per litter was significantly lower for Treated group (1.51) compared to Control group (1.98) (p = 0.0113). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (1.40) was lower than those of the piglets of the Older sows (2.14). There was no treatment x parity effect.

[0314] Number of piglets that died with Rectal Temperature > 37.74°C per litter was not different between Treated group (1.41) and Control group (1.47) (p = 0.6799).

[0315] Number of piglets that died because of starvation with Rectal Temperature < 37.74° per litter not different between Treated group (0.15) and Control group (0.19) (p = 0.5459). There was a parity effect (p = 0.0050) where the number of these piglets of the Younger sows (0.10) was lower than those of the piglets of the Older sows (0.29). As there was a near treatment x parity effect (p = 0.1009). the treatment effect was calculated per parity showing that there was a treatment effect for the Older sows (p = 0.0211) with less of these piglets dying from starvation in the treated group (0.19) compared to the Control group (0.44).

[0316] Number of piglets that died because of starvation with Rectal Temperature > 37.74° per litter was not different between Treated group (0.36) and Control group (0.51) (p = 0.1113).

[0317] Number of piglets that died with signs of emaciation and Rectal Temperature < 37.74°C per litter was significantly lower for Treated group (1.08) compared to Control group (1.59) (p = 0.0020). There was a parity effect (p < 0.0001) where the number of these piglets ofInternational Patent Application Attorney Docket No. 2920951-238977 the Younger sows (1.01) was lower than those of the piglets of the Older sows (1.70). There was no treatment x parity effect.

[0318] Number of piglets that died with signs of emaciation and Rectal Temperature > 37.74°C per litter was not different between Treated group (0.64) compared to Control group (0.84) (p = 0.1312).

[0319] Number of piglets that died within 2 days and had empty stomachs and Rectal Temperature < 37.74°C per litter was significantly lower for Treated group (0.86) compared to Control group (1.21) (p = 0.0142). There tended to be a parity effect (p = 0.0674) where the number of these piglets of the Younger sows (0.90) was lower than those of the piglets of the Older sows (1.16). There was no treatment x parity effect (p = 0.1977) although the difference was attributable to the Young sows only with 0.69 piglets for treated versus 1.17 piglets for control (p = 0.0177) and not the older sows with 1.07 piglets for treated versus 1.26 piglets for control (p = 0.2395).

[0320] Number of piglets that died within 2 days and had empty stomachs and Rectal Temperature > 37.74°C per litter was not different between Treated group (0.21) and Control group (0.28) (p = 0.2698).

[0321] Number of dead piglets with signs of low viability relative to Live Births per Litter was significantly lower for Treated group (0.58) compared to Control group (1.05) (p = 0.0004). There was a parity effect (p = 0.0018) where the number of these piglets of the Younger sows (0.61) was lower than those of the piglets of the Older sows (1.01). There was no treatment x parity effect (p = 0.5341).

[0322] Number of dead piglets with signs of low viability < 1.13 kg relative to Live Births per Litter was significantly lower for Treated group (0.58) compared to Control group (1.02) (p = 0.0007). There was a parity effect (p = 0.0017) where the number of these piglets of the Younger sows (0.59) was lower than those of the piglets of the Older sows (0.99). There was no treatment x parity effect (p = 0.6629).

[0323] Number of dead piglets with signs of low viability and RT < 37.74°C relative to Live Births per Litter was significantly lower for Treated group (0.41) compared to Control group (0.78) (p = 0.0011). There was a parity effect (p < 0.0002) where the number of these piglets of the Younger sows (0.39) was lower than those of the piglets of the Older sows (0.82). There was no treatment x parity effect (p = 0.6192).

[0324] Number of dead piglets with signs of low viability and RT > 37.74°C relative to Live Births per litter was not different between Treated group (0.17) and Control group (0.25) (p = 0.2055).

[0325] Number of piglets with signs of low viability with empty stomach and signs of emaciation (< 1.13 kg) relative to Live Births per Litter was significantly lower for Treated group (0.44)International Patent Application Attorney Docket No. 2920951-238977 compared to Control group (0.81) (p = 0.0011). There was a parity effect (p = 0.0097) where the number of these piglets of the Younger sows (0.47) was lower than those of the piglets of the Older sows (0.76). There was no treatment x parity effect (p = 0.6005).

[0326] Number of piglets with signs of low viability with empty stomach and signs of emaciation and a RT < 37.74 C relative to Live Births was significantly lower for Treated group (0.32) compared to Control group (0.64) (p = 0.0025). There was a parity effect (p = 0.0008) where the number of these piglets of the Younger sows (0.31) was lower than those of the piglets of the Older sows (0.66). There was no treatment x parity effect (p = 0.4282).

[0327] Number of piglets with signs of low viability with empty stomach and signs of emaciation and a RT > 37.74 C relative to Live Births with RT collected was not different between Treated group (0.09) and Control group (0.16) (p = 0.1446).

[0328] Number of piglets signs of low viability + empty stomach + emaciation < 1.13 kg and < 37.74 C) relative to Live Births with RT taken was significantly lower for Treated group (0.32) compared to Control group (0.63) (p = 0.0028). There was a parity effect (p = 0.0009) where the number of these piglets of the Younger sows (0.31) was lower than those of the piglets of the Older sows (0.66). There was no treatment x parity effect (p = 0.4041).

[0329] Number of piglets signs of low viability + empty stomach + emaciation. (< 1.13 kg and > 37.74 C) relative to Live Births with RT taken was not different between Treated group (0.09) and Control group (0.16) (p = 0.1446).

[0330] Discrete variables evaluated as proportions- Younger and Older sows

[0331] Number of Piglets Born Alive per litter as a proportion of total piglets born was not different between Treated group (90.8%) compared to Control group (91.1%) (p = 0.7257).

[0332] Number of Piglets Born Alive < 1.13kg per litter as a proportion of total piglets born alive was significantly lower for Treated group (43.6%) compared to Control group (48.2%) (p = 0.0124). There was a parity effect (p = 0.0003) where Younger sows (42.5%) had less piglets < 1.13kg than the Older sows (49.3%). There was no treatment x parity effect.

[0333] Number of Piglets Born Alive > 1.13kg per litter as a proportion of total piglets born alive was significantly higher in Treated group (56.4%) compared to Control group (51.8%) (p = 0.0124). There was a parity effect (p = 0.0003) where Younger sows (57.5%) had more piglets > 1.13kg than the Older sows (50.7%). There was no treatment x parity effect.

[0334] Number of Stillborn Piglets per litter as a proportion of total piglets born was not different between Treated group (8.1%) compared to Control group (7.0%) (p = 0.2713). There was a parity effect (p < 0.0001) where the number of stillborn piglets of the Younger sows (5.1%) was lower than for the piglets of the Older sows (10.8%). There was no parity x treatment effectInternational Patent Application Attorney Docket No. 2920951-238977 (p = 0.1542) but there was a difference between treatment (12.7%) and control in the older sows (9.2%) (p = 0.0170).

[0335] Piglet survivability at Day 5 per litter as a proportion of total piglets born alive was significantly higher for Treated group (86.1%) compared to Control group (81.8%) (p = 0.0019). There was a parity effect (p < 0.0001) where survivability of the piglets of the Younger sows (87.0%) was higher than those of the piglets of the Older sows (80.7%). There was no treatment x parity effect.

[0336] Piglet survivability at weaning per litter as a proportion of total piglets born alive was significantly higher for Treated group (78.1%) compared to Control group (74.58%) (p = 0.0231). There was a parity effect (p < 0.0001) where survivability of the piglets of the Younger sows (79.9%) was higher than those of the piglets of the Older sows (72.4%). There was no treatment x parity effect.

[0337] Piglet mortality at Weaning per litter as a proportion of total piglets born alive was significantly lower for Treated group (21.9%) compared to Control group (25.5%) (p = 0.0231). There was a parity effect (p < 0.0001) where Mortality of the piglets of the Younger sows (20.1%) was lower than those of the piglets of the Older sows (27.6%). There was no treatment x parity effect.

[0338] Number of dead piglets < 1.13kg until Weaning per litter as a proportion of total piglets born alive was significantly lower for Treated group (16.0%) compared to Control group (20.0%) (p = 0.067). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (14.8%) was lower than those of the piglets of the Older sows (21.5%). There was no treatment x parity effect.

[0339] Number of dead piglets > 1.13kg until Weaning per litter as a proportion of total piglets born alive was not different between Treated group (5.8%) and Control group (5.5%) (p = 0.7159).

[0340] Number of crushed piglets until Weaning per litter as a proportion of total piglets born alive was not different between Treated group (8.6%) and Control group (8.5%%) (p = 0.9653). Also when divided up into two groups, < or > 1.13kg and < or > 37.74°C RT. there was no difference between Treated and Control group. Number of piglets crushed that had empty stomach and signs of emaciation was not different, nor for the piglets < 1.13 kg (p = 0.5445) nor for the piglets > 1.13 kg (p = 0.3444). Number of piglets crushed with empty stomach and signs of emaciation was not different between treatment and control both for pigs with RT < 37.74°C (p = 0.2827) and > 37.74°C (p = 0.9365). Number of piglets crushed with empty stomach and emaciation <1.13 kg irrespective whether the RT was < or > 37.74 °C was not different between treatment and control (p = 0.5030 for < 37.74°C and p = 0.8165 for > 37.74°C).International Patent Application Attorney Docket No. 2920951-238977

[0341] Number of piglets that starved until Weaning per litter as a proportion of total piglets born alive was significantly lower for Treated group (3.9%) compared to Control group (5.5%) (p = 0.0494). There was a parity effect (p = 0.0029) where the number of these piglets of the Younger sows (3.5%) was lower than those of the piglets of the Older sows (6.0%). There was no treatment x parity effect.

[0342] Number of piglets <1.13 kg that starved until Weaning per litter as a proportion of total piglets born alive tended to be lower for Treated group (3.3%) compared to Control group (4.7%) (p = 0.0566). There was a parity effect (p = 0.0010) where the number of these piglets of the Younger sows (2.8%) was lower than those of the piglets of the Older sows (5.4%). There was no treatment x parity effect.

[0343] Number of piglets >1.13 kg that starved until Weaning per litter as a proportion of total piglets bom alive was not different between Treated group (0.6%) and Control group (0.7%) (p = 0.7005).

[0344] Number of piglets that died and had signs of emaciation per litter as a proportion of total piglets born alive was significantly lower for Treated group (14.0%) compared to Control group (19.4%) (p = 0.0002). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (13.7%) was lower than those of the piglets of the Older sows (19.8%). There was no treatment x parity effect.

[0345] Number of piglets <1.13 kg that died and had signs of emaciation per litter as a proportion of total piglets born alive was significantly lower for Treated group (12.5%) compared to Control group (17.5%) (p = 0.0003). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (12.1%) was lower than those of the piglets of the Older sows (18.0%). There was no treatment x parity effect.

[0346] Number of piglets >1.13 kg that died and had signs of emaciation per litter as a proportion of total piglets bom alive was not different between Treated group (1.5%) and Control group (1.9%) (p = 0.3419).

[0347] Number of piglets that died within 2 days and had empty stomachs per litter as a proportion of total piglets born alive was significantly lower for Treated group (8.0%) compared to Control group (10.9%) (p = 0.0083). There tended to be a parity effect (p = 0.0586) where the number of these piglets of the Younger sows (8.4%) was lower than those of the piglets of the Older sows (10.5%). There was no treatment x parity effect

[0348] Number of piglets <1.13 kg that died within 2 days and had empty stomachs per litter as a proportion of total piglets bom alive was significantly lower for Treated group (7.0%) compared to Control group (10.1%) (p = 0.0037). There tended to be a parity effect (p = 0.0573) where theInternational Patent Application Attorney Docket No. 2920951-238977 number of these piglets of the Younger sows (7.4%) was lower than those of the piglets of the Older sows (9.5%). There was no treatment x parity effect

[0349] Number of piglets >1.13 kg that died within 2 days and had empty stomachs per litter as a proportion of total piglets born alive was not different between Treated group (1.0%) and Control group (0.90%) (p = 0.6624).

[0350] Number of piglets with RT < 37.74°C per litter as a proportion of total piglets born alive was significantly lower for Treated group (15.4%) compared to Control group (20.8%) (p = 0.0002). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (14.5%) was lower than those of the piglets of the Older sows (22.0%). There was no treatment x parity effect (p = 0.2672) but the difference between treated (18.2%) and Control (26.4%) was primarily seen in the Older sows (p <0.0001) and tended to be different in the younger sows (p = 0.0988) with 12.9% in treated and 16.2% in control.

[0351] Number of piglets RT > 37.74°C per litter as a proportion of total piglets born alive was significantly higher for Treated group (84.6%) compared to Control group (79.2%) (p = 0.0002). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (85.5%) was lower than those of the piglets of the Older sows (78.0%). There was no treatment x parity effect (p = 0.1530) but the difference between treated (81.8%) and Control (73.6%) was primarily seen in the Older sows (p <0.0001) and tended to be different in the younger sows (p=0.0988) with 87.1% in treated and 83.8% in control.

[0352] Number of piglets that died with RT < 37.74°C per litter as a proportion of total piglets born alive was significantly lower for Treated group (11.3%) compared to Control group (14.6%) (p = 0.0105). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (10.3%) was lower than those of the piglets of the Older sows (15.9%). There was no treatment x parity effect.

[0353] Number of piglets that died with RT > 37.74°C per litter as a proportion of total piglets born alive was not different between Treated group (10.5%) and Control group (10.8%) (p = 0.7917).

[0354] Number of piglets that died because of starvation with RT < 37.74°C per litter as a proportion of total piglets born alive was not different between Treated group (1.1%) and Control group (1.4%) (p = 0.5665). There was a parity effect (p = 0.0042) where the number of these piglets of the Younger sows (0.7%) was lower than those of the piglets of the Older sows (2.1%). As there was a near treatment x parity effect (p = 0.0913). the treatment effect was calculated per parity showing that there was a treatment effect for the Older sows (p = 0.0207) withInternational Patent Application Attorney Docket No. 2920951-238977 less of these piglets dying from starvation in the treated group (1.4%) compared to the Control group (3.2%).

[0355] Number of piglets that died because of starvation with RT > 37.74°C per litter as a proportion of total piglets born alive was not different between Treated group (2.7%) and Control group (3.8%) (p = 0.1257).

[0356] Number of piglets that died with signs of emaciation and RT < 37.74°C per litter as a proportion of total piglets born alive was significantly lower for Treated group (8.1%) compared to Control group (11.7%) (p = 0.0019). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (7.4%) was lower than those of the piglets of the Older sows (12.7%). There was no treatment x parity effect

[0357] Number of piglets that died with signs of emaciation and RT > 37.74°C per litter as a proportion of total piglets born alive was not different between Treated group (4.8%) compared to Control group (6.0%) (p = 0.1510).

[0358] Number of piglets that died within 2 days and had empty stomachs and RT < 37.74°C per litter as a proportion of total piglets born alive was significantly lower for Treated group (6.4%) compared to Control group (8.9%) (p = 0.0160). There was a parity effect (p = 0.0473) where the number of these piglets of the Younger sows (6.6%) was lower than those of the piglets of the Older sows (8.6%). There was no treatment x parity effect (p = 0.2146) although the difference was attributable to the Young sows only with 5.2% for treated versus 8.5% piglets for control (p = 0.0200) and not the older sows with 8.0%for treated versus 9.3%piglets for control (p = 0.3412).

[0359] Number of piglets that died within 2 days and had empty stomachs and RT > 37.74°C per litter as a proportion of total piglets born alive was not different between Treated group (1.5%) and Control group (2.1%) (p = 0.2940).

[0360] Number of dead piglets with signs of low viability per litter as a proportion of total piglets born alive was significantly lower for Treated group (4.4%) compared to Control group (7.7%) (p = 0.0004). There was a parity effect (p = 0.0010) where the number of these piglets of the Younger sows (4.5%) was lower than those of the piglets of the Older sows (7.5%). There was no treatment x parity effect (p = 0.6028).

[0361] Number of dead piglets with signs of low viability < 1.13 kg per litter as a proportion of total piglets born alive was significantly lower for Treated group (4.4%) compared to Control group (7.5%) (p = 0.0007). There was a parity effect (p = 0.0009) where the number of these piglets of the Younger sows (4.3%) was lower than those of the piglets of the Older sows (7.4%). There was no treatment x parity effect (p = 0.7408).International Patent Application Attorney Docket No. 2920951-238977

[0362] Number of dead piglets with signs of low viability and RT < 37.74°C a per litter s a proportion of total piglets born alive was significantly lower for Treated group (3.0%) compared to Control group (5.7%) (p = 0.0012). There was a parity effect (p < 0.0001) where the number of these piglets of the Younger sows (2.8%) was lower than those of the piglets of the Older sows (6.1%). There was no treatment x parity effect (p = 0.6977).

[0363] Number of dead piglets with signs of low viability and RT > 37.74°C per litter as a proportion of total piglets born alive was not different between Treated group (1.3%) and Control group (1.8%) (p = 0.2234).

[0364] Number of piglets with signs of low viability with empty stomach and signs of emaciation (< 1.13 kg) per litter as a proportion of total piglets born alive was significantly lower for Treated group (3.3%) compared to Control group (5.9%) (p = 0.0012). There was a parity effect (p = 0.0066) where the number of these piglets of the Younger sows (3.4%) was lower than those of the piglets of the Older sows (5.7%). There was no treatment x parity effect (p = 0.6571).

[0365] Number of piglets with signs of low viability with empty stomach and signs of emaciation and a RT < 37.74 per litter as a proportion of total piglets born alive was significantly lower for Treated group (2.4%) compared to Control group (4.70%) (p = 0.0026). There was a parity effect (p = 0.0005) where the number of these piglets of the Younger sows (2.3%) was lower than those of the piglets of the Older sows (5.0%). There was no treatment x parity effect (p = 0.4702).

[0366] Number of piglets with signs of low viability with empty stomach and signs of emaciation and a RT > 37.74 C per litter as a proportion of total piglets bom alive was not different between Treated group (0.7%) and Control group (1.2%) (p = 0.1554).

[0367] Number of piglets signs of low viability + empty stomach + emaciation < 1.13 kg and < 37.74 C) per litter as a proportion of total piglets born alive was significantly lower for Treated group (2.4%) compared to Control group (4.7%) (p = 0.0031). There was a parity effect (p = 0.0006) where the number of these piglets of the Younger sows (2.3%) was lower than those of the piglets of the Older sows (4.9%). There was no treatment x parity effect (p = 0.4433).

[0368] Number of piglets signs of low viability + empty stomach + emaciation. (< 1.13 kg and > 37.74 C) per litter as a proportion of total piglets born alive was not different between Treated group (0.7%) and Control group (1.2%) (p = 0.1554). A number of exploratory analysis where performed to further understand the impact of the treatment using the thresholds for birth weight and for rectal temperature.

[0369] Live average birth weight was not different between treatment and control for piglets with a birth weight of < or > 1.13 kg nor for piglets with a rectal temperature of < or > 37.74°C.International Patent Application Attorney Docket No. 2920951-238977

[0370] Survivability until Day 5 was significantly higher for treated piglets (74.6%) compared to control pigs (68.1%) (p = 0.0119) in the < 1.13 kg group but there was no difference in the > 1.13 kg group (p = 0.5996).

[0371] Survivability until Day 5 tended to be higher for treated piglets (95.3%) compared to control pigs (93.5%) (p = 0.0616) in the > 37.74°C group but there was no difference in the < 37.74°C group (p = 0.8549).

[0372] Survivability until weaning tended to be higher for treated piglets (64.8%) compared to control pigs (59.6%) (p = 0.0594) in the < 1.13 kg group but there was no difference in the > 1.13 kg group (p = 0.5204).

[0373] Survivability until weaning tended to be higher for treated piglets (89.1%) compared to control pigs (86.4%) (p = 0.0511) in the > 37.74°C group but there was no difference in the < 37.74°C group (p = 0.3073).

[0374] Average rectal temperature was significantly higher for treated piglets (38.19°C) compared to control pigs (37.91°C) (p = 0.0398) in the < 1.13 kg group and was significantly higher for treated piglets (38.74°C) compared to control pigs (38.57°C) (p = 0.0309) in the > 1.13 kg group.TABLE 31All Piglets < 1,13 kg Piglets > 1,13 kg RT < 37,740C RT > 37,740C PRIMARY CONTINUOUS VARIABLESTreated Control p Treated Control p Treated Control p Treated Control p Treated Control p value value value value value LIVE PIGLETS AVERAGE BIRTH1,189 1,158 0,2956 0,91 0,90 0,4370 1,38 1,36 0,3541 0,81 0,85 0,4974 1,24 1,22 0,5051WEIGHT (kg)All Piglets < 1,13 kg Piglets > 1,13 kg RT < 37,740C RT > 37,740C PRIMARY DISCRETE VARIABLESTreated Control p Treated Control p Treated Control p Treated Control p Treated Control p value value value value value SURVIVABILITY UNTIL DAY 5 (%) 86,1 81,8 0,0019 74,60 68,10 0,0119 95,10 94,50 0,5996 35,80 36,60 0,8549 95,30 93,50 0,0616 SURVIVABILITY UNTIL WEANING78,1 74,5 0,0231 64,80 59,60 0,0594 90,80 89,90 0,5204 26,90 31,20 0,3073 89,10 86,40 0,0511(5)All Piglets < 1,13 kg Piglets > 1,13 kg RT < 37,740C RT > 37,740C SECONDARY CONTINUOUS VARIABLESTreated Control p Treated Control p Treated Control p Treated Control P Treated Control P value value value value value LITTER BIRTH WEIGHT LIVE BORN15,88 15,51 0,4581PIGLETS (kg)STILLBORN PER LITTER WEIGHT (kg) 1,29 1,07 0,3364TOTAL LITTER WEANING WEIGHT66,44 63,25 0,2909(kg)PIGLETS AVERAGE WEANING6,32 6,31 0,9426WEIGHT (kg)AVERAGE RECTAL TEMPERATURE38,49 38,28 0,0282 38,19 37,91 0,0398 38,74 38,57 0,0309(°C)TABLE 32SECONDARY DISCRETE VARIABLES AS All Piglets < 1,13 kg Piglets > 1,13 kg RT < 37,740C RT > 37,740C PROPORTION OF TOTAL BORN ALIVE(%) Treated Control p Treated Control p Treated Control p Treated Control p Treated Control p value value value value value LIVE BORN 90,8 91,1 0,7257 43,6 48,2 0,0124 56,4 51,8 0,0124 15,4 20,8 0,0002 84,6 79,2 0,0002 STILLBORN 8,1 7,0 0,2713SURVIVABILITY UNTIL DAY 5 86,1 81,8 0,0019SURVIVABILITY UNTIL WEANING 78,1 74,5 0,0231MORTALITY UNTIL WEANING 21,9 25,5 0,0231 16,0 20,0 0,0067 5,8 5,5 0,7159 11,3 14,6 0,0105 10,5 10,8 0,7917 NUMBER OF PIGS CRUSHED 8,6 8,5 0,9653DEAD PIGLETS DUE TO STARVATION 3,9 5,5 0,0494 3,3 4,7 0,0566 0,6 0,7 0,7005 1,1 1,4 0,5665 2,7 3,8 0,1257 DEAD PIGLETS WITH EMACIATION14,0 19,4 0,0002 12,5 17,5 0,0003 1,5 1,9 0,3419 8,1 11,7 0,0019 4,8 6,0 0,1510 SIGNS DEAD PIGS FIRST 2 DAYS WITH EMPTY8,0 10,9 0,0083 7,0 10,1 0,0037 1,0 0,9 0,6624 6,4 8,9 0,0160 1,5 2,1 0,2940 STOMACH DEAD PIGS WITH LOW VIABILITY 4,4 7,7 0,0004 4,4 7,5 0,0007 3,0 5,7 0,0012 1,3 1,8 0,2234 LOW VIABILITY + EMACIATION +3,3 5,9 0,0012 2,4 4,7 0,0026 0,7 1,2 0,1554 EMPTY STOMACH LOW VIABILITY + EMACIATION +2,4 4,7 0,0031EMPTY STOMACH AND RT < 37,740CLOW VIABILITY + EMACIATION +0,7 1,3 0,154EMPTY STOMACH AND RT > 37,7404CInternational Patent Application Attorney Docket No. 2920951-238977

[0375] As seen in table below, an increase in survivability is seen until day 5 and until weaning. Table 33:allprimary continuous variablestreated control p value1live piglets average birth weight (kg) 1.189 1.158 0.2956allprimary discrete variablestreated control p value survivability until day 5 (proportion) 0.861 0.818 0.0019 survivabilty until weaning (proportion) 0.781 0.745 0.0231'A difference with a p-value below 0.05 is considered statistically relevant.

[0376] A weight analysis (of birth weight and weaning weight) distribution is seen FIG. 6A and 6B.

[0377] As seen in the Table below, there is no parity effect. The mortality on day 5 and at weaning is lower for treated vs. controlled, the treated also had less light weight live piglets and higher average rectal temperature vs. controlled.Table 34:TRT2*Control Treated Control Treated Variable Control Treated P- Parity p- Diff Diff value1young young old old valueProportionmortality day 18.2 13.9 0.019 0.7180 15.3 11.1 4.2 21.7 17.1 4.65Proportionmortality 25.5 21.9 0.0231 0.8734 21.9 18.4 3.5 29.5 25.8 3.7 weaningProportion48.2 43.6 0.0124 0.3012 45.8 39.3 6.5 50.7 47.9 2.8 BA < 1.13 kgAveragerectal 38.28 38.496 0.0282 0.4138 38.45 38.58 0.13 38.11 38.4 0.29 temperature_ m _Young = P2 and P3, Old = P4, P5 and P6Abbreviation TRT = Treatment; BA = Bom live; SB = Stillborn; CRL = Crown Rump Length; BMI = Body Mass Index; RT = Rectal Temperature'A difference with a p-value below 0.05 is considered statistically relevant.2A p-value below 0.05 is considered a statistically relevant Treatment by Parity effect (P-value TRT*Parity effect: When significant, it indicates there is difference in effect of treatment between the Young (P2 and P3) and Old (P4, P5 and P6) sows).International Patent Application Attorney Docket No. 2920951-238977

[0378] The Table below also shows that the treated sows had better viability of the piglets.Table 35:secondary discrete variables as proportion of total bom treated control p value1live born 0.908 0.911 0,7257 stillborn 0.081 0.070 0,2713 secondary discrete variables as proportion of life bom treated control p value survivability until day 5 0.861 0.818 0,0019 survivabilty until weaning 0.781 0.745 0,0231 mortality until weaning 0.219 0.25 0,0231 number of pigs crushed 0.086 0.085 0,9653 dead piglets due to starvation 0.039 0.055 0,0494 dead piglets with emaciation signs 0.140 0.194 0,0002 dead pigs first 2 days with empty stomach 0.080 0.109 0,0083 dead pigs with low viability 0.044 0.077 0,0004'A difference with a p-value below 0.05 is considered statistically relevant.

[0379] The following table demonstrates that results are driven by differences in < 1.13 kg segment of the live born piglets.Table 36:piglets < 1.13 kg piglets > 1.13 kg primary discrete variables as proportionstreated control p value treated control p value survivability until day 5 (%) 0.746 0.681 0.0119 0.951 0.945 0.5996 survivabilty until weaning (%) 0.648 0.596 0.0594 0.908 0.899 0.5204 piglets < 1.13 kg piglets > 1.13 kg secondary continuous variablestreated control p value treated control p value average rectal temperature (°c) 38.19 37.91 0.0398 38.74 38.57 0.0309 piglets < 1.13 kg piglets > 1,13 kg secondary discrete variables as counts per littertreated control p value treated control p value live bom 5.81 6,57 0.0274 7.53 7.05 0.1922 mortality until weaning 2.14 2,72 0.0081 0.78 0.75 0.8115 dead pilgets due to starvation 0.44 0,64 0.0516 0.08 0.09 0.6735 dead pilgets with emaciation signs 1.66 2,28 0.0004 0.20 0.27 0.3150 dead pigs first 2 days with empty stomach 0.93 1,37 0.0035 0.14 0.12 0.6984International Patent Application Attorney Docket No. 2920951-238977 dead pigs with low viability 0.58 1,02 0.0007 na na na piglets < 1.13 kg piglets > 1.13 kg secondary discrete variables as proportionstreated control p value treated control p value live bom of total bom 0.436 0.482 0.0124 0.564 0.518 0.0124 mortality until weaning of bom alive 0.160 0.200 0.0067 0.058 0.055 0.7159 dead piglets due to starvation of bom alive 0.033 0.047 0.0566 0.006 0.007 0.7005 dead piglets with emaciation signs of bom alive 0.125 0.175 0.0003 0.015 0.019 0.3419 dead pigs first 2 days with empty stomach of bom0.070 0.101 0.0037 0.010 0.009 0.6624 alivedead pigs with low viability of bom alive 0.044 0.075 0.0007 na na naA difference with a p-value below 0.05 is considered statistically relevant.Summary:

[0380] Although the average birth weight of the piglets was not different between treatment and control, the proportion of low birth weight piglets (< 1.13kg) decreased and the proportion of normal birth weight piglets (> 1.13kg) increased in litters from treated sows compared to litters from control sows. As the mortality rate of low birth weight piglets was higher compared to the normal birth weight piglets, the disproportion contributes to an increase in survivability of the piglets from treated sows. However, the mortality of < 1.13kg pigs was higher in the piglet from control sows compared to those of the treated sows, while there was no difference between both groups for piglets > 1.13 kg. This demonstrates that additional effects of the treatment lead to an improved survivability.

[0381] Rectal temperature during the first day of life was higher in the piglets of treated sows compared to the piglets of the control sows. A logistic piecewise linear mixed model was used to investigate the effect of rectal temperature on pre-weaning mortality. A breaking point of 37.74°C was estimated. The proportion of piglets having rectal temperatures equal or below 37.74°C was lower and the proportion of piglets above 37.74°C was higher for the piglets from treated sows compared to piglets from control sows. The mortality rate below the threshold temperature was lower for the treated group and not different for the pigs with a rectal temperature above the threshold. This resulted in more piglets from treated sows surviving compared to the control sows.

[0382] As a consequence, less piglets from the treated sows died because of incapability to nurse. This was reflected in a decrease of the number of piglets that died within 48 hours with empty stomachs, a decrease of piglets that starved, had signs of emaciation at death and that had low viability. The differences are driven by the groups of piglets with low birth weight and / or low rectalInternational Patent Application Attorney Docket No. 2920951-238977 temperature and there is no difference for piglets with a good birth weight and / or adequate rectal temperature.

[0383] In conclusion, the effectiveness of a fixed dose of 25 mg of GHRH-ELNN administered on day 28 of confirmed gestation by intramuscular injection was confirmed. Main

[0384] drivers of the increased survivability are a decrease in number of low weight piglets and an increase of thermo-regulatory capabilities of the piglets from treated sows. This leads to less piglets being incapable of nursing with death as the ultimate consequence.EXAMPLE 9PRE- WEANING MORTALITY AND IUGR

[0385] Another experiment was performed to study administration of GHRH analog-ELNN (isolated D-ala2-GHRH-ELNN864 (porcine somatorelin analogue injection)) on reduction of preweaning mortality and IUGR (based on head morphology criteria).

[0386] The sows (Danbred genetics) were confirmed to be pregnant via ultrasound on Day 35 of gestation (±3 days). The female pigs were Parity 2, Parity 4, Parity 5, or Parity 6 sows, where Parity 2 represents sows that were pregnant with their second litter at the time of treatment administration. No gilts were used. A total of 258 sows were originally included in the study from 3 breeding / farrowing groups. There was an outbreak of PRRS (Porcine Reproductive and Respiratory Syndrome) virus on the farm, which resulted in a high number of sows not giving birth (e.g., aborted or found non-pregnant), and thus, another farrowing group was included. The final total of sows was about 170 pigs treated vs. 165 non-treated sows (335 pregnant sows), and 128 treated vs. 129 non-treated litters. The number of offspring from the sows assigned to the study and that gave birth was 4515 piglets bom alive from 257 litters or 17.57 piglets per litter.

[0387] The isolated D-Ala2-GHRH-ELNN864 was at 12.5 mg / mL after reconstitution. A single fixed dose of 25 mg / sow was administered on D35 ± 3 days gestation to sows as an intramuscular injection (IM) in the neck with 2mL. The treatment window was broadened from 25 days to 35 days (+ / - 3 days) of gestation. The treated pregnant sows were compared to non-treated pregnant sows.International Patent Application Attorney Docket No. 2920951-238977 Table 37:Treatment Compound Formulation Dose Volume Route and Number of Group and Dose1Concentration2(ml)2Location* Animals mg / kg1 No treatment NA NA NA 165 2 GHRH-ELNN 12.5 mg / ml 2 ml / based on IM, 170(IVP), formulation left neck25 mg / sow concentrationof 12.5 mg / mlTotal = 335investigational Veterinary Product (IVP) administered on Day 35 (± 3 days) of gestation.2Formulation concentration represents the targeted concentration. Analyzed compound concentrations were used to calculate dose volume.

[0388] This study utilizes 335 confirmed pregnant female pigs in four farrowing groups representing sows of different ages but at a single physiological stage (35 ± 3 days of pregnancy) at the time of treatment. Numbers of sows per parity may have differed within a farrowing group, with a maximum difference of one sow per parity between the treatment groups. The sows were further divided into two parity groups: Parity 2 and 3 sows (Y; younger sows) and Parity 4, 5 and 6 sows (O; older sows).

[0389] The study began on day 35 (± 3 days) of gestation (Study Day 0). Sows are confirmed as pregnant via ultrasound and all sows were weighed and blood samples were taken, and treatment was administered on the same D 35 (± 3 days) of gestation.

[0390] On day 42 (± 3 days) of gestation (Study Day 7), the second blood sample was taken from the same sows. At 7 days post injection, blood concentrations of IGF- 1 and the compound (GHRH analog-ELNN) were expected to be elevated as compared to Day 0 before treatment and to the blood concentrations of the control animals on both Day 0 and Day 7. On day 110 (± 3 days) of gestation, the sows were moved from the gestation pens to the farrowing rooms. On day 115 (± 3 days) of gestation, the sows were expected to farrow. On day 143, after 25 to 31 days of lactation, the batch of piglets was weaned from the sows and the sows were assessed for re-breeding suitability.

[0391] For the litter following treatment, offspring from all farrowing groups were studied through weaning (approximately 28 days post-farrowing). The piglets born in the subsequent litter wereInternational Patent Application Attorney Docket No. 2920951-238977 studied on their day of birth only. During the entire period from day 35 of gestation (Study Day 0) to weaning, daily health observations were made.

[0392] The following cycle, data of the sows kept for re-breeding were captured:1. Date of breeding2. Date of repeat breeding3. Pregnancy confirmation by ultrasound4. Farrowing date, numbers Born Alive, Stillborn, and Mummified5. Date and reason of culling if prior to the day of farrowing

[0393] Within one day of farrowing, the following data were collected and recorded on the Sow:Gender of the offspring (live and stillborn)Birth weights (live, stillborn)Birth Status of offspring (e.g., live, stillborn, and mummies)Crown Rump Length (CRL) (live, and stillborn)Rectal Temperature (RT) of piglets between 2 and 24 hours after birth (live).Morphological evaluationInitial Vitality ScorePrimary discrete variables:

[0394] It was determined that primary variables (e.g., mortality and incidence of IUGR) are all significantly improved across parities. The proportion of piglet mortality at day 5 and at weaning relative to born alive (BA) was lower in the Treated versus the Control group. The number and proportion of piglets classified as IUGR (e.g, piglets observed as having one or more signs of IUGR include but are not limited to steep dolphin-like forehead, bulging eyes, and / or wrinkles perpendicular to the mouth) was lower in Treated compared to Control group. No Treatment by Parity (TRT*Parity) interaction was observed (P>0.1771) for any of the primary discrete variables, demonstrating that the treatment was effective across the parities that were in scope. The results of the primary variables are shown in Table below:Table 38:p-value p-value primary discrete variables control treated treatment TRT*parity effect1effect2number litters 108 103proportion mortality at day 5 to BA 0.1522 0.1235 0.0122 0.2775International Patent Application Attorney Docket No. 2920951-238977 Proportion mortality at weaning to0.1987 0.1600 0.0023 0.1771 BAproportion IUGR piglets to BA 0.2347 0.1979 0.0072 0.3968 additional analysisproportion IUGR piglets to BA+SB0.2567 0.2109 0.0006 0.2648 (stillborn)1 A difference with a p-value below 0.05 is considered statistically relevant.2 A p-value below 0.05 is considered a statistically relevant Treatment by Parity effect (P-value TRT*Parity effect: When significant, it indicates there is difference in effect of treatment between the Young (P2 and P3) and Old (P4, P5 and P6) sows).Secondary discrete variables:

[0395] It can be seen from Tables below that secondary variables are also significantly improved by the isolated D-Ala2-GHRH-ELNN864 treatments compared to control, and the treatment positively affects the development in utero of the piglets. Variables including but are not limited to the proportion of light weight piglets, birth weight, proportion of piglets where rectal temperature could be measured, proportion of piglets crushed, proportion of piglets with a weaning weight above 5 kg and proportion of piglets fostering, CRL and BMI all support the positive effect of the treatment. The proportion of mortality of IUGR piglets was not different between treatments but the number of IUGR piglets dying was lower for the treated group.

[0396] The secondary discrete variables were calculated as proportions and as number per litter as shown in tables below. First the proportions are shown followed by the number per litter.Secondary discrete variables, proportions:

[0397] As seen in Table below, while the proportion of piglets born alive, stillborn, and mummified was not different between Control and Treated group, the proportion of piglets lower or equal to, or higher than 1.13 kg was different, with a lower proportion of piglets with a lower weight and a higher proportion of piglets in the higher weight in the Treated group.

[0398] The proportion of IUGR piglets on fully formed piglets (=born alive + stillborn) was lower in the Treated group and the proportion of IUGR stillborn piglets relative to total stillborn piglets was also lower in the treated group. The proportion of IUGR piglet mortality relative to total born alive tended (p < 0.10) to be lower in the Treated group but there was no difference in proportion of IUGR piglet mortality relative to IUGR piglets born. This suggests the lower IUGR mortalityInternational Patent Application Attorney Docket No. 2920951-238977 trend in treated group was driven by a difference in incidence of IUGR rather than a difference between IUGR piglets from Treated versus Control litters.

[0399] While the proportion of IUGR piglets on born alive with a birth weight greater than 1.13 kg was not different between Treated and Control group, the proportion of IUGR piglets born alive with a birth weight lower than or equal to 1.13 kg was lower in the Treated group.

[0400] The proportion of mortality of piglets born alive < 1.13kg was numerically lower (p=0.0548) and was different for the piglets > 1.13kg with a lower proportion dying in the Treated group compared to the Control group.

[0401] Rectal Temperature (RT) of the piglets bom alive was measured between 2 and 24 hours after birth. However, a number of low viable piglets died before RT measurement and were reported as not reported. The proportion of non-reported RT and of crushed piglets was lower in the Treated group while the proportion of piglets with a normal vitality score tended to be higher in the Treated group.

[0402] The proportion of piglets weaned with a weight of more than 5kg was higher in the Treated group, while the proportion of fostered piglets (e.g., piglets that were not weaned by their biological mother) was lower in the Treated group.Table 39:p-value Control Treated p-value1TRI Parity Effect2Proportion BA to Total Bom (TB) 0.8587 0.8643 0.5980 0.3759 Proportion B A < 1.13 kg to BA 0.3880 0.3194 <0.0001 0.0003 Proportion BA > 1.13 kg to BA 0.6120 0.6806 <0.0001 0.0003 Proportion Stillborn (SB) piglets to TB 0.1214 0.1065 0.1324 0.9731 Proportion mummified to Total Bom 0.0190 0.0257 0.1373 0.2041 Proportion IUGR piglets to BA+SB 0.2567 0.2109 0.0006 0.2648 Proportion of IUGR piglets to SB 0.4169 0.3158 0.0263 0.2828 Proportion IUGR mortality to BA 0.1022 0.0859 0.0902 0.0689 Proportion IUGR mortality to BA IUGR 0.4374 0.4349 0.9429 0.1117 Proportion of IUGR > 1.3 kg BA to BA 0.0253 0.0242 0.8259 0.0985 Proportion of IUGR < 1.3 kg BA to BA 0.2091 0.1724 0.0051 0.1121 Proportion mortality > 1.3 kg BA to BA 0.0642 0.0454 0.0126 0.5229 Proportion mortality < 1.3 kg BA to BA 0.1345 0.1136 0.0548 0.0513 Proportion of RT not recorded to BA 0.0446 0.0318 0.0451 0.6170 Proportion crushed piglets to BA 0.0781 0.0547 0.0049 0.4235 Proportion empty stomach to BA 0.0569 0.0499 0.3407 0.4228 Proportion starvation to BA 0.0014 0.0035 0.2264 0.3221International Patent Application Attorney Docket No. 2920951-238977 Proportion normal vitality score to BA 0.9162 0.9318 0.0768 0.0288 Proportion of piglets >5kg at weaning to0.6778 0.7281 0.0026 <0.0001 weaned pigletsProportion of fostered piglets to BA 0.5128 0.4762 0.0258 0.0026

[0403] For those variables with a treatment effect and a treatment by parity effect, the results of the variables per parity group are shown in Table below. For these secondary variables (calculated as proportions), the treatment effect was driven by the differences between the young parity sows. Table 40:Control Treated p-value Control Treated p-value Variable Y Y Y1o O O1Proportion BA < 1.13 kg 0.3866 0.2661 <0.0001 0.3895 0.3780 0.6002 Proportion BA > 1.13 kg 0.6134 0.7339 <0.0001 0.6105 0.6220 0.6002 Proportion of piglets >5kg at0.6493 0.7674 <0.0001 0.7050 0.6848 0.3813 weaningProportion of fostered piglets 0.5463 0.4600 0.0003 0.4792 0.4924 0.55721A difference with a p- value below 0.05 is considered statistically relevant.Secondary discrete variables, number per litter:

[0404] The secondary discrete numeric variables are shown in Table below. The numbers are calculated as numbers per litter. The number of born alive, stillborn, and mummified were not different between the control and treated group. The number of fully formed piglets (born alive + stillborn) was higher in the Control group. The number of stillborn piglets with IUGR was higher in the Control group.

[0405] The number of piglets dying within 5 days was lower (0.74 piglets per litter lower) in the Treated group as was the number of piglets dying up to weaning (0.86 piglets per litter lower) in the Treated group. There was no treatment by parity effect.

[0406] The number of IUGR piglets in the born alive was lower (0.86 piglets per litter lower) in the treated group as was the number of IUGR piglets on fully formed piglets (1.12 piglets per litter lower) in the Treated group. Also, the number of IUGR piglets that died was lower in the Treated group. In other words, per litter, there is a pre-weaning mortality decrease of 0.86 piglets (0.82 taking into account litter size), a decrease of 0.86 (0.82) IUGR piglets on BA and 1.26 (1.19) IUGR on BA +SB piglets.

[0407] There were less piglets born alive with a birth weight < 1.13 Kg in the Treated group. There were less piglets that died in the treated group in both those with < and > 1.13 kg birth weight.International Patent Application Attorney Docket No. 2920951-238977 There were less piglets with no rectal temperature taken and less piglets that were fostered in the Treated group.Table 41:p-value2TRT*Parity Variable Control Treated p-value1Effect Number TB piglets 21.54 20.31 0.0531 0.5017 Number BA piglets 18.43 17.52 0.1242 0.3188 Number SB piglets 2.60 2.15 0.0417 0.7652 Number of SB IUGR piglets 1.09 0.68 0.0031 0.2882 Number of MM piglets 0.41 0.52 0.2388 0.2504 Number BA+SB (fully formed piglets) 21.13 19.75 0.0294 0.3641 Number Mortality at Day 5 2.80 2.16 0.0038 0.1581 Number Mortality at Weaning 3.66 2.80 0.0007 0.0939 Number of piglets Weaned 14.75 14.69 0.9173 0.6956 Number IUGR piglets BA 4.32 3.46 0.0020 0.1964 Number IUGR piglets BA+SB 5.41 4.15 <0.0001 0.1272 Number IUGR piglets < 1.13 kg BA 3.85 3.01 0.0014 0.0528 Number IUGR piglets > 1.13 kg BA 0.47 0.42 0.6484 0.1396 Number Mortality IUGR piglets 1.88 1.50 0.0365 0.0412 Number of piglets BA < 1.13 kg 7.15 5.56 <0.0001 0.0003 Number of piglets BA > 1.13 kg 11.28 11.84 0.2319 0.2403 Number mortality piglets < 1.13 kg on BA 2.48 1.99 0.0189 0.0286 Number mortality piglets > 1.13 kg on BA 1.18 0.80 0.0056 0.6931 Number piglets with not recorded RT 0.82 0.56 0.0241 0.4922 Number dead with Empty stomach 1.05 0.87 0.2020 0.5838 Number dead to starvation 0.03 0.06 0.2543 0.3449 Number with normal initial Vitality 16.88 16.28 0.2880 0.9929 Number piglets > 5kg at weaning 9.98 10.65 0.1307 0.0525 Number fostered 9.43 8.34 0.0088 0.0049Abbreviations TRT = Treatment; TB = Total Bom; BA = Bom Live; SB = Stillborn; IUGR = Intra Uterine Growth Restriction; MM = Mummified; RT = Rectal Temperature1A difference with a p- value below 0.05 is considered statistically relevant.2A p-value below 0.05 is considered a statistically relevant Treatment by Parity effect.

[0408] For those variables with also a treatment by parity effect, the results of the variables per parity group are shown in Table below. The numbers are calculated as numbers per litter. For these secondary variables, the treatment effect was driven by the differences in the young parity sows.Table 42:International Patent Application Attorney Docket No. 2920951-238977 Control Treated p-value Control Treated p-value Variable Y Y Y1O O O1Number Mortality IUGR piglets 1.84 1.17 0.0074 1.93 1.93 0.9681 Number of piglets BA < 1.13 kg 7.16 4.54 <0.0001 7.14 6.80 0.5123 Number of mortality piglets < 1.13 kg 2.45 1.60 0.0030 2.51 2.47 0.9002 Number fostered 10.12 7.85 0.0002 8.78 8.86 0.8838Abbreviations IUGR = Intra Uterine Growth Restriction; BA = Bom Live.1A difference with a p- value below 0.05 is considered statistically relevant.Secondary continuous variables:

[0409] The secondary continuous variables are represented in their appropriate unit of measure and shown in Table below. The average individual birth weight of the piglets born alive, stillborn, and fully formed (BA+SB) was higher in the Treated group. The Crown rump length of the piglets born alive and for the stillborn was higher for the Treated group. The BMI of the bom alive tended to be higher and the BMI of the stillborn was higher in the Treated group. All these are compared to the Control group.Table 43:p-value2TRT*Parity Variable Control Treated p-value1Effect Average BW (kg) BA 1.23 1.32 0.0008 0.0516 Total litter BW (kg) BA 22.55 22.68 0.8411 0.7839 Average BW (kg) SB 0.95 1.07 0.0049 0.4305 Average BW (kg) BA+SB 1.20 1.29 0.0004 0.0705 Total litter B W (kg) BA+SB 25.1 25.03 0.9070 0.6930 Average Weaning Weight (kg) 5.74 5.88 0.1069 0.0280 Total litter Weaning Weight (kg) 84.81 87.42 0.3740 0.3945 Average Daily gain (g / day) 193.0 195.9 0.4031 0.0200 Sow weight at treatment (kg) 225.87 225.50 0.8752 0.5472 Average CRL BA (cm) 21.25 21.74 0.0011 0.1307 Average CRL SB (cm) 21.78 22.45 0.0453 0.5300 Average BMI BA 26.74 27.37 0.0603 0.1037 Average BMI SB 19.45 20.62 0.0100 0.7280 Average RT (°C) 38.26 38.35 0.2396 0.3535Abbreviations TRT = Treatment; BA = Bom Live; SB = Stillborn; CRL = Crown Rump length; BMI = Body Mass Index; RT = Rectal Temperature1A difference with a p- value below 0.05 is considered statistically relevant.2A p-value below 0.05 is considered a statistically relevant Treatment by Parity effect.International Patent Application Attorney Docket No. 2920951-238977

[0410] The following Table (and FIG. 7A and 7B) demonstrates the distribution of weaning weight of treated vs. control, and as it can be seen, treatment group has a higher % with higher weaning weight (and lower % with lower weaning weight) compared to control.Table 44:weaning weight treatment control% < 4 kg 10 15% > 4 - 4.99 kg 17 17% > 5 kg 73 68Safety of the sows:

[0411] As the treatment is administered to healthy sows the safety for the sow is of high importance. The safety for sows was first evaluated for the period from treatment to weaning of the litter following treatment. There were no health observations and adverse events in the sows that can be attributed to the treatment. They occurred long after treatment and / or had similar frequencies of occurrence in the Control group. A subset of sows that were weighed at treatment in Batch 1 and then in Batch 4 showed no difference in weight increase between treated and control sows between two cycles.Table 45:ae reason control treatment abortion 15 16 Empty / not pregnant 11 11 accident 1 4 Clostridium 1 2 lame 0 3 prolapse 1 0 respiratory 0 1 septicemia 1 1 total 30 (18.2%) 3 (22.4%)

[0412] As seen in Table above, 3 treated sows were removed before the end of the 28-day withdrawal period = 2 deaths because of Clostridium and 1 had an accident, could not stand andInternational Patent Application Attorney Docket No. 2920951-238977 was euthanized. No dystocia, one prolapse (control sow). Difference of 8 sows due to diverse causes that seem unrelated to the treatment based on:Type of cause with > 1 sow difference (3 more accidents and 3 more lameness in T) Moment of occurrence (average 70 days after treatment).

[0413] The sows were also reassessed for their suitability for rebreeding: At weaning, all sows were assessed by the farmer for their suitability to stay in the breeding herd or to be culled. There were 4 sows from the Control group and 5 sows from the Treated group that were not retained in the breeding herd. All except one sow was from the old parity group.Sow assessment suitable for rebreeding at weaning:C sows = 96.90%T sows = 96.09%Sows bred within 10 days:C sows = 91.18%T sows = 92.71%

[0414] A comparison between the weight of the P3 shows the Control sows (n=35) gained average 6.6 kg (from 221.6 to 228.3 kg), while the Treated sows (n=28) gained a similar 6.2 kg (from 220.0 to 226.2 kg). Ten sows from the Control group and 12 sows from the Treated group died or were culled during the next cycle. Of the retained sows 92 / 98 (93.88%) of the Control group were bred withing 10 days after weaning while this was 88 / 91 (96.70%) for the Treated group. From each group, 1 sow returned to estrus following insemination. 89 / 98 (90.82%) sows were found pregnant in the Control group and 85 / 91 (93.41%) for the Treated group. 87 / 98 (88.78%) of the Control group that were retained and bred within 10 days after weaning gave birth while this was 78 / 91 (85.71%) for the Treated group.

[0415] As shown in Table below of secondary discrete variables proportions of sows, none of these variables were different between Control and Treated group.Table 46:Variable Control Treated P-value1Proportion of sows retained for breeding0.1020 0.1319 0.6509 that died or were culledProportion of sows bred within 10 days0.9388 0.9670 0.4999 after weaningProportion of sows returned in estrus after0.0102 0.0110 1.0000 first inseminationProportion of sows with positive ultrasonic0.9082 0.9341 0.5960 pregnancy testInternational Patent Application Attorney Docket No. 2920951-238977 Proportion of sows giving birth when bred0.8878 0.8571 0.6627 within 10 days after weaning1A difference with a p- value below 0.05 is considered statistically relevant.

[0416] The results of the litters of the follow up cycle are shown in Table below of secondary discrete variables numbers per litter and proportions. Litter size was not impacted. The number of stillborn piglets was higher in the Treated group litters, resulting on different proportions of piglets born alive and piglet stillborn between both groups.Table 47:Variable Control Treated P-value1Number Total Bom 20.86 20.76 0.8872 Number Bom Alive 17.99 17.47 0.4283 Number Stillborn 2.51 3.03 0.0491 Number mummified 0.26 0.27 0.9193 Proportion BA 0.8657 0.8416 0.0471 Proportion SB 0.1210 0.1458 0.0348 Proportion MM 0.0120 0.0125 0.90661A difference with a p- value below 0.05 is considered statistically relevant.

[0417] However, the treated cycle did not show an increased number of stillborn and even a numeric decrease of stillborn per litter (as seen in Table below).Table 48:P-value SECONDARY DISCRETE VARIABLES CONTROL TREATEDTreatment effect Proportion Stillborn piglets 0.1214 0.1065 0.1324 Proportion mummified 0.0190 0.0257 0.1373

[0418] The primary objectives of the study were to evaluate the effect of a fixed dose of 25 mg of GHRH analog-ELNN administered to a batch of pregnant sows at 35 ± 3 days of gestation on piglet mortality up to 5 days of age and from birth to weaning (e.g., pre-weaning mortality) and on IUGR as determined by morphological IUGR criteria of the head. This study demonstrates a statistical and clinically relevant decrease of the number and proportion of IUGR piglets leading to a decrease of number and proportion of piglet mortality from birth to 5 days and up to weaning. For the primary parameters, there was no treatment by parity effect, demonstrating that the treatment wasInternational Patent Application Attorney Docket No. 2920951-238977 effective across the parities that were in scope. While in previous studies, dosing was performed between 25 and 30 days of gestation, in this study the sows were treated at approximately 35 days of gestation with a successful outcome.

[0419] Analysis of the secondary parameters further support the findings that the treatment positively affects the development in utero of the piglets. Variables including but are not limited to the proportion of light weight piglets, birth weight, proportion of piglets where rectal temperature could be measured, proportion of piglets crushed, proportion of piglets with a weaning weight above 5 kg and proportion of piglets fostering, CRL (crown rump length) and BMI all support the positive effect of the treatment. For some secondary variables, a Treatment by Parity effect was found, with better responses in the young sows. For the secondary variables recorded at birth, there was no Treatment by Parity effect found in the previous experiment. The variables calculated at weaning may be impacted by the fostering policies followed at the farm. Fostering had to happen within treatment, but there were no constraints for choice of parity. Therefore, caution is needed for the interpretation on the impact on parity. The proportion of mortality of IUGR piglets was not different between treatments but the number of IUGR piglets dying was lower for the treated group.

[0420] As the treatment is administered to healthy sows the safety for the sow is of high importance. The safety for sows was first evaluated for the period from treatment to weaning of the litter following treatment. There were no health observations and adverse events in the sows that can be attributed to the treatment. They occurred long after treatment and / or had similar frequencies of occurrence in the Control group.

[0421] A second evaluation was performed from weaning until birth of the next litter. During the follow-up cycle, the only difference was found in the proportion of stillborn piglets and the proportion of born alive between sows that in the previous cycle were control sows versus sows that in the previous cycle were treated. The relevance of this can be questioned as in the previous treatment cycle, the number and proportion of stillborn was not different and even numerically lower in the litters of those sows that were treated compared to the control sows in these same batches.

[0422] Thus, treatment of a fixed dose of 25 mg of GHRH analog-ELNN administered to pregnant sows at 35 ± 3 days of gestation resulted in a statistical and clinically relevant decrease of the number and proportion of IUGR piglets leading to a decrease of the number and proportion of piglet mortality from birth to 5 days and from birth to weaning. The treatment was effective across the parities that were in scope. Furthermore, the treatment was safe for the sows and the piglets.International Patent Application Attorney Docket No. 2920951-238977 EXAMPLE 10FEED EFFICIENCY AND RATE OF GAIN STUDY

[0423] The GHRH analog conjugated proteins described herein was used on a group of cattle, 5 heifers per group, with a starting bodyweight of about 800 lbs. The cattle were treated via injection with either 0 or 0.95 of a d-Ala2-GHRH-XTEN864 GHRH analog conjugated protein described herein. FIGs. 10 and 11.

[0424] An increase in plasma IGF-1 was observed through 28 days post-injection. A decrease in plasma urea nitrogen was observed 21 days post-injection. A 39% increase in ADG was observed through 63 days post-injection. A 34% improvement / gain was observed through 64 days postinjection.Table 49 IEE and ADG in Cattle StudyGain (LBS) Feed / gainDay 63 Day 91 Day 63 Day 91Control 186.8 296.9 8.32 7.16Treated 258.8 365.3 5.45 5.85Difference 72.0 68.4 2.87 1.31% Change 38.5 23.0 34.4 18.3P- Value .017 .059 .027 .071

[0425] The administration of the d-Ala2-GHRH-XTEN864 GHRH analog conjugated protein described herein resulted in a greater than 70 pounds of gain over 60 days in the treated cattle.EXAMPLE 11BIRTH WEIGHT ANALYSIS AND STUDY

[0426] 1683 piglets from 3 farms were followed from birth to slaughter or moment of death. 71% of the mortality occurred the first 5 days of life. As birth weight increased, the probability for pre weaning survival increased This increase had a very steep slope up to a birth weight of 1.15 kg, after which the survival rate increase flattened out. Survivability increased in 2 steps: (1) UnderInternational Patent Application Attorney Docket No. 2920951-238977 1.15 kg (20% of total) had a 51% chance of survival; (2) Pigs above 1.15 kg had an 87% chance of survival.Table 50:Birth Weight, kg25th 75th Prewean Piglets Average Minimum percentile Median percentile Maximum Mortality StudyBergman 2,205 1.54 0.45 1.27 1.54 1.77 2.72 9.6% Elanco 1,863 1.47 0.43 1.23 1.49 1.72 2.58 15.2%Combined 4,068 1.51 0.43 1.27 1.52 1.77 2.72 12.2%

[0427] Birth weight is a good predictor for survival chances of piglets independent of farm and litter size. There is a breaking point weight under which the survival chances are very low. In this dataset, the breaking point was 1.15 kg with 20% of the pigs at very high risk.Table 51:Predicted Prewean Mortality by Birth WeightBirth PredictedWeight, Preweankg Mortality0.5 83.8%0.6 74.6%0.7 62.6%0.8 48.8%0.9 35.2%1.0 23.7%1.1 15.0%1.2 11.3%1.3 10.3%1.4 9.5%1.5 8.6%1.6 7.9%1.7 7.2%1.8 6.6%1.9 6.0%2.0 5.5%2.1 5.0%2.2 4.5%2.3 4.1%

[0428] The GHRH -XTEN conjugate described herein was administered to pregnant sows during gestation. The GHRH -XTEN conjugate described herein increased survivability at Day 5 and until weaning by 0.5 pigs / litter / sow. The GHRH -XTEN conjugate described herein increased birth weight and weaning weight of piglets. The IGF-1 (ng / mL) was measured over 70 days. The D-Ala-XTEN construct showed the highest increase in IGF-1 levels.

Claims

1. International Patent Application Attorney Docket No. 2920951-238977 CLAIMS1. A conjugated protein comprising a growth hormone-releasing hormone (GHRH), or an analogue thereof, linked to a pharmacokinetic extender molecule, wherein the GHRH analog sequence comprises an amino acid sequence comprising at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.

2. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

3. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 2.

4. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 3.

5. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 4.

6. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 5.

7. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 6.

8. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 7.International Patent Application Attorney Docket No. 2920951-238977 9. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 8.

10. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 9.

11. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 10.

12. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 4.

13. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 11.

14. The conjugated protein of claim 1, wherein the GHRH analog comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to the amino acid sequence of SEQ ID NO: 12.

15. The conjugated protein of any one of claims 1-14, wherein the pharmacokinetic extender molecule comprises an extended length polypeptide (ELNN) comprising between about 400 to 3000 amino acids residues.

16. The conjugated protein of any one of claims 1-15, wherein the ELNN comprises an amino acid sequence comprising at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% sequence identity to an amino acid sequence of SEQ ID NO: 15, 16, 17.

17. The conjugated protein of claim 16, wherein the ELNN comprises an amino acid sequence comprising at least 90% sequence identity to an amino acid sequence of SEQ ID NO: 15.International Patent Application Attorney Docket No. 2920951-238977 18. The conjugated protein of any one of claims 1-17, wherein the GHRH analog is linked to the ELNN via a linker.

19. The conjugated protein of claim 18, wherein the linker is a lysine, cysteine, threonine, serine, ornithine, or any combination thereof.

20. The conjugated protein of claim 19, wherein the linker is a lysine.

21. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises a D-alanine substitution at position 2 of the GHRH comprising the amino acid sequence of SEQ ID NO: 6.

22. The conjugated protein of any one of claims 1-21, wherein the conjugated protein comprises a D-isoleucine substitution at position 2 of the GHRH comprising the amino acid sequence of SEQ ID NO: 8.

23. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises D-Ala2-GHRH-ELNN864 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 6 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, optionally wherein the amino acid sequence of SEQ ID NO: 6 is conjugated to the ELNN polypeptide at a lysine at residue 30.

24. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises D-Ala2-2GHRH-2ELNN432 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 6 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, optionally wherein the amino acid sequence of SEQ ID NO: 6 is conjugated to the ELNN polypeptide at a lysine at residue 30.

25. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises D-Ile2-GHRH-ELNN864 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, optionally wherein the amino acid sequence of SEQ ID NO: 8 is conjugated to the ELNN polypeptide at a lysine at residue 30.

26. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises D-Ile2-GHRH-ELNN648 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, optionally wherein the amino acid sequence of SEQ ID NO: 8 is conjugated to the ELNN polypeptide at a lysine at residue 30.

27. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises D-Ile2-GHRH-ELNN432 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 8 conjugated to an ELNN polypeptide comprising the amino acid sequence ofInternational Patent Application Attorney Docket No. 2920951-238977 SEQ ID NO: 17, optionally wherein the amino acid sequence of SEQ ID NO: 8 is conjugated to the ELNN polypeptide at a lysine at residue 30.

28. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises Val2-GHRH-ELNN864 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 15, optionally wherein the amino acid sequence of SEQ ID NO: 10 is conjugated to the ELNN polypeptide at a lysine at residue 30.

29. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises Val2-GHRH-ELNN648 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, optionally wherein the amino acid sequence of SEQ ID NO: 10 is conjugated to the ELNN polypeptide at a lysine at residue 30.

30. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises Val2-GHRH-ELNN432 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 10 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 17, optionally wherein the amino acid sequence of SEQ ID NO: 10 is conjugated to the ELNN polypeptide at a lysine at residue 30.

31. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises Thr2-GHRH-ELNN864 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, optionally wherein the amino acid sequence of SEQ ID NO: 12 is conjugated to the ELNN polypeptide at a lysine at residue 30.

32. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises Thr2-GHRH-ELNN648 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 16, optionally wherein the amino acid sequence of SEQ ID NO: 12 is conjugated to the ELNN polypeptide at a lysine at residue 30.

33. The conjugated protein of any one of claims 1-20, wherein the conjugated protein comprises Thr2-GHRH-ELNN432 comprising a GHRH analog comprising the amino acid sequence of SEQ ID NO: 12 conjugated to an ELNN polypeptide comprising the amino acid sequence of SEQ ID NO: 17, wherein the amino acid sequence of SEQ ID NO: 17 is conjugated to the ELNN polypeptide at a lysine at residue 30.

34. The conjugated protein of any one of claims 1-33, wherein the ELNN polypeptide is conjugated to the GHRH analogue at the lysine at position 30 via maleimido-International Patent Application Attorney Docket No. 2920951-238977 methylcyclohexane carboxylate activation through a thioester bond at Cysteine on the ELNN polypeptide.

35. A composition comprising the conjugated protein of any one of claims 1-34.

36. The composition of claim 35, wherein the composition is a pharmaceutical composition.

37. The composition of claim 35 or 36, wherein the composition comprises a carrier.

38. The composition of claim 37, wherein the carrier is an excipient, lubricant, antioxidant, emulsifier, stabilizer, solvent, diluent, buffer, vehicle, or any combination thereof.

39. A method to decrease pre-weaning mortality of an offspring of a female mammal, incidence of intrauterine growth restriction (IUGR) in an offspring from a female mammal, and / or birth weight of an offspring from a female mammal comprising administering to the female animal an effective amount of the conjugated protein of any one of claims 1-35 or the composition of any one of claims 35-38.

40. The method of claim 39, wherein the animal is a mammal.

41. The method of claim 40, wherein the mammal is pregnant.

42. A method of treating a pregnant animal comprising administering to the animal an effective amount of the conjugated protein of any one of claims 1-35 or the composition of any one of claims 35-38.

43. The method of any one of claims 39-42, wherein the treatment decreases pre-weaning mortality and / or incidence of IUGR in the offspring bom from the pregnant animal.

44. The method of any one of claims 39-43, wherein the administration of the isolated conjugated protein further results in at least one characteristic in the offspring, selected from the group consisting of: increased survivability, increased average birth weight, increased average BMI, increased average pre-weaning and weaning body weight, increased average rectal temperature between 2-24 hours after birth (RT), increased initial vitality score, increased average crown rump length (CRL), and decreased incidence of fostering, as compared to untreated animals.

45. The method of any one of claims 39-44, wherein the method further comprises performing a pregnancy check on the animal before administering the isolated conjugated protein or composition.

46. The method of claim 45, wherein the pregnancy test comprises an ultrasound evaluation, blood test, visual inspection, or any combination thereof.

47. The method of any one of claims 39-46, wherein the treatment increases serum IGF-1 concentration in the pregnant animal.International Patent Application Attorney Docket No. 2920951-238977 48. The method of any one of claims 39-47, wherein the dosage of isolated conjugated protein is between about 0.1 mg / kg and about 1.0 mg / kg weight of the animal.

49. The method of any one of claims 39-48, wherein the dosage of isolated conjugated protein is about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, or 1.0 mg / kg weight of the animal.

50. The method of any one of claims 39-49, wherein the dosage of isolated conjugated protein is about 0.95 mg / kg weight of the animal.

51. The method of any one of claims 39-50, wherein the isolated conjugated protein is administered at between about 15 days of gestation to about 65 days of gestation.

52. The method of any one of claims 39-51, wherein the isolated conjugated protein is administered at between about 20 days of gestation to about 40 days of gestation, about 25 days of gestation to about 30 days of gestation, about 20 days of gestation to about 50 days of gestation, or about 25 days of gestation to about 35 days of gestation.

53. The method of any one of claims 39-52, wherein the isolated conjugated protein is administered at about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days, about 28 days, about 29 days, about 30 days, about 31 days, about 32 days, about 33 days, about 34 days, about 35 days, about 36 days, about 37 days, about 38 days, about 39 days, about 40 days, about 41 days, about 42 days, about 43 days, about 44 days, about 45 days, about 46 days, about 47 days, about 48 days, about 49 days, about 50 days, about 51 days, about 52 days, about 53 days, about 54 days, about 55 days, about 56 days, about 57 days, about 58 days, about 59 days, about 60 days, about 61 days, about 62 days, about 63 days, about 64 days, or about 65 days of gestation.

54. The method of any one of claims 39-53, wherein the isolated conjugated protein is administered at about 35 days of gestation.

55. The method of any one of claims 39-54, wherein the isolated conjugated protein is administered at about 25 mg split into two separate doses and administered at about 35 days of gestation.

56. The method of any one of claims 39-55, wherein the isolated conjugated protein is not administered at insemination of the animal.

57. The method of any one of claims 39-56, wherein the isolated conjugated protein is administered before, during, and after insemination.International Patent Application Attorney Docket No. 2920951-238977 58. The method of any one of claims 39-57, wherein the isolated conjugated protein is administered before insemination.

59. The method of any one of claims 39-58, wherein the isolated conjugated protein is administered during insemination.

60. The method of any one of claims 39-59, wherein the isolated conjugated protein is administered after insemination.

61. The method of any one of claims 39-60, wherein the isolated conjugated protein is administered to a non-pregnant female animal.

62. The method of any one of claims 39-61, wherein the isolated conjugated protein is administered between about 1 and 30 days before insemination.

63. The method of any one of claims 39-62, wherein the isolated conjugated protein is administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or about 30 days before insemination.

64. The method of any one of claims 39-63, wherein the isolated conjugated protein is administered between about 1 and about 24 hours before insemination.

65. The method of any one of claims 39-64, wherein the isolated conjugated protein is administered about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours before insemination.

66. The method of any one of claims 39-65, wherein the isolated conjugated protein increases ovulation, feed conversion, weight gain, or any combination thereof in the animal.

67. The method of any one of claims 39-66, wherein the isolated conjugated protein is administered intramuscularly.

68. The method of any one of claims 39-67, wherein the isolated conjugated protein is administered at least once during gestation.

69. The method of any one of claims 39-68, wherein the isolated conjugated protein is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times during gestation.

70. The method of any one of claims 39-69, wherein the animal is a mammal.

71. The method of any one of claims 39-70, wherein the pregnant animal is a pig.

72. The method of any one of claims 39-71, wherein the pregnant animal is a sow.

73. The method of any one of claims 39-72, wherein the pregnant animal is not a gilt.International Patent Application Attorney Docket No. 2920951-238977 74. A method for increasing feed efficiency comprising administering an effective amount of the conjugated protein of any one of claims 1-34 or the composition of any one of claims 35-38 to an animal.

75. A method for increasing the rate of weight gain comprising administering an effective amount of the conjugated protein of any one of claims 1-35 or the composition of any one of claims 35-38 to an animal.

76. The method of claims 74 or 75, wherein the dosage of isolated conjugated protein is between about 0.1 mg / kg and about 1.0 mg / kg weight of the animal.

77. The method of any one of claims 74-76, wherein the dosage of isolated conjugated protein is about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, or 1.0 mg / kg weight of the animal.

78. The method of any one of claims 74-77, wherein the dosage of isolated conjugated protein is about 0.95 mg / kg weight of the animal.

79. The method of any one of claims 74-78, wherein the administration is parenteral, optionally intravenous, intradermal, subcutaneous, intraperitoneal, intramuscular, or any combination thereof.

80. The method of any one of claims 74-79, wherein the administration is intravenous administration.

81. The method of any one of claims 74-80, wherein the administration is intramuscular inj ection.

82. The method of any one of claims 74-81, wherein the mammal is a cow, sheep, goat, pig, horse, llama, or alpaca.

83. The method of any one of claims 74-82, wherein the administration of the conjugate or composition increases serum IGF-1 in the animal.

84. The method of any one of claims 74-83, wherein the animal is a mammal.

85. The method of any one of claims 74-84, wherein the animal is a pig.

86. The method of any one of claims 74-84, wherein the animal is a cow.

87. The method of claim 86, wherein the animal is heifer.

88. Use of the conjugated protein of any one of claims 1-34 or the composition of claim 35-38 for the manufacture of a medicament to administer to a pregnant animal to decrease pre-weaning mortality, incidence of IUGR in an offspring from the pregnant animal, and / or increase birth weight of an offspring from the pregnant animal as compared to untreated animals.

89. The use of claim 88, wherein a pregnancy check on the animal is performed, optionally by ultrasound evaluation, before administration of the medicament.International Patent Application Attorney Docket No. 2920951-238977 90. The use of claim 88 or 89, wherein administration of the medicament further results in at least one of the following characteristics in the baby selected from the group consisting of increased survivability, increased average birth weight, increased average BMI, increased average preweaning and weaning body weight, increased average rectal temperature between 2-24 hours after birth (RT), increased initial vitality score, increased average crown rump length (CRL), and decreased incidence of fostering as compared to untreated animals.

91. The use of any one of claims 88-90, wherein the average birth weight of the offspring is at least 1 kg.

92. The use of any one of claims 88-91, wherein administration of the medicament increases serum IGF-1 concentration in the pregnant animal.

93. The use of any one of claims 88-92, wherein the medicament is administered at a range from about 20 mg per animal to about 75 mg per animal.

94. The use of any one of claims 88-93, wherein the medicament is administered at a range from about 20 mg per animal to about 30 mg per animal.

95. The use of any one of claims 88-94, wherein the medicament is administered at about 25 mg per animal.

96. The use of any one of claims 88-95, wherein the medicament is administered in at least 0.067 mg / kg weight of the animal.

97. The use of any one of claims 88-96, wherein the medicament is administered at a range from about 0.1 mg / kg weight of the animal to about 0.3 mg / kg weight of the animal.

98. The use of any one of claims 88-97, wherein the medicament is administered at about 0.1 mg / kg weight of the animal.

99. The use of any one of claims 88-98, wherein the medicament is administered between about 18 days of gestation and about 65 days of gestation.

100. The use of any one of claims 88-99, wherein the medicament is administered at between about 20 days of gestation and about 40 days of gestation.

101. The use of any one of claims 88-100, wherein the medicament is administered between about 25 days of gestation and about 40 days of gestation.

102. The use of any one of claims 88-101, wherein the medicament is administered between about 25 days of gestation and 35 days of gestation.

103. The use of any one of claims 88-102, wherein the medicament is not administered at insemination of the animal.

104. The use of any one of claims 88-103, wherein the medicament is formulated to be administered intramuscularly.International Patent Application Attorney Docket No. 2920951-238977 105. The use of any one of claims 88-104, wherein the medicament is administered in at least one dose.

106. The use of any one of claims 88-105, wherein the medicament is formulated to be administered in one dose.

107. The use of any one of claims 88-106, wherein the animal is a mammal.

108. The use of any one of claims 88-107, wherein the animal is a pig.

109. The use of claim 108, wherein the medicament is formulated to be administered to a pregnant Pig- 110. The use of claim 108, wherein the medicament is formulated to be administered to a pregnant sow.

111. An isolated nucleic acid comprising a nucleotide sequence encoding the conjugated protein of any one of claims 1-35 and / or the complement thereof.

112. An expression vector comprising the nucleic acid of claim 111.

113. An isolated host cell comprising the expression vector of claim 112.

114. The host cell of claim 113, wherein the host cell is a eukaryotic host cell.

115. The host cell of claim 113, wherein the host cell is a prokaryotic host cell.